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PREFACE
Fabry disease is a rare X-linked progressive multisystem disorder that belongs to the group of lysosomal storage disorders (LSDs). Signs and symptoms of Fabry disease may be first noted in childhood, such as acroparesthesia, heat intolerance, the in-
ability to sweat and micro-albuminuria. However, because physicians often do not attribute 
these signs and symptoms to Fabry disease, patients may not be diagnosed until adulthood, 
when cerebrovascular disease, cardiac hypertrophy and progressive kidney disease can oc-
cur. Fabry disease manifests itself not only in males but also in heterozygotes. Heterozy-
gous females show a more variable and in general a more attenuated course. Nonetheless, 
the mean life expectancy is significantly shortened in both sexes albeit more prominent in 
males than in females. 
The name “Fabry disease” originates from the 19th century. In Fabry patients, angiokera-
tomas, which are small purplish skin lesions, progressively appear on the skin and were 
first described in 1898 by two independently working physicians, William Anderson and 
Johannes Fabry (Figure 1.1.) 1.
Figure 1.1. Johannes Fabry. “Ein beitrag zur Kenntniss der Purpura haemorrhagica nodularis”
(Purpura papulosa haemorrhagica Hebrae) 1898.
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In the late 1950s and early 1960s, de Duve and colleagues identified the lysosome as a 
cellular organelle responsible for intracellular digestion and recycling of macromolecules. 
This was the scientific breakthrough that would lead to the understanding of the physiolog-
ical basis of the LSDs. Pompe disease was the first disease to be identified as a LSDs in 1963 
2.The deficiency of α-Galactosidase was first shown to be the enzymatic defect in Fabry 
disease in 1967 by Brady and colleagues using radiolabelled globotriaosylceramide (Gb-3), 
which is accumulated in Fabry disease 3. Subsequently, Kint from the Ghent University dem-
onstrated that α-Galactosidase could act on the synthetic substrates (p-nitrophenyl–α-d-
galactoside and 4-methylumbelliferyl–α-d-galactoside) and was specific for the α-anomeric 
galactosidic linkage 4. This breakthrough eventually facilitated the diagnosis of Fabry dis-
ease.
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INTRODUCTION
In inborn errors of metabolism (IEMs), a defect in a protein that functions as enzyme, co-factor or transport protein leads to the accumulation or the deficiency of a metabolite. Most of these deficiencies concern one single protein. They can be classified according 
to the general type of metabolism or the specific cellular organelle that is involved. Classes 
of IEMs concern the metabolism of amino acids, organic acids, carbohydrates, fatty acids, 
metals, or are due to deficiencies in lysosomal or peroxisomal enzymes. Most IEMs are very 
rare, but as a group, they are common. The symptoms of IEMS are extremely diverse, and 
can be almost any presenting complaint, especially in children, ranging from growth failure 
and skin rashes to immunodeficiency, vomiting and hyperventilation. Owing primarily to 
advances in diagnostic technology, a rapidly growing list of IEM presenting in adulthood 
is emerging. Some of these, e.g. Scheie disease, are caused by are milder variants of the 
same enzyme deficiency that commonly causes death in childhood. Others, such as clas-
sical hemochromatosis, almost never present in childhood. Fabry disease belongs to the 
sphingolipidoses, which are a group of LSDs, where a defective activity of a lysosomal pro-
tein results in intra-lysosomal accumulation of undegraded metabolites. 
In the first part of this chapter, a short introduction to the IEMs is presented with more 
details on the sphingolipidoses.
Metabolism
In all cells of living organisms, a set of chemical reactions, called “metabolism” enables 
growth, reproduction, maintenance of structure, and response to the environment. The 
term metabolism is derived from the Greek “μεταβολη”, which means “change”: a chemi-
cal reaction takes place where substance 1 is being transformed into substance 2, because 
substance 1 has to be degraded or because substance 2 has to be generated. In multicel-
lular organisms,  enzymes mediate a significant number of these chemical reactions. These 
are large biological molecules that catalyse or increase the rate of the chemical reaction. In 
case of IEMs, changes in the genes that encode for an enzyme disable the chemical reac-
tion, resulting either in the accumulation of substance 1 or in a deficiency of substance 2. 
(Figure 1.2.)
Inborn errors of metabolism: from black urine to gene alterations
Alkaptonuria or “black urine disease” is a key example of how IEMs shaped our current 
understanding of these rare diseases 5. It was the first IEM described in 1902 by Sir Archibald 
Garod. This disease was much later fully described as the result of a defect in the hepatic en-
zyme homogentisate 1,2 –deoxygenase (encoded by the HGD gene) which participates in 
the degradation of the amino-acid tyrosine. As a result, a toxic tyrosine degradation product 
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homogentisic acid or alkapton accumulates and is excreted in the urine in large quantities. 
This causes damage to cartilage (resulting in osteoarthritis, especially causing low back pain 
at young age) and heart valves and precipitates as kidney stones. Homogentisic acid, when 
exposed to air, colours black staining the sclera and urine of these patients.
Since 1902, hundreds of IEM have been described and can be classified according to the 
concerning defective metabolic pathway or cellular organelle ,
Presentation is usually in the neonatal period but can occur at any time, even in adult-
hood. In older children and adolescents, an IEM should be considered in case of subtle 
neurologic or psychiatric abnormalities. Many of these patients who have been diagnosed 
with “birth injury”, atypical psychiatric disorders or medical diseases like multiple sclerosis, 
migraine or stroke may actually have an undiagnosed IEM. 
As other IEMs, Fabry disease presents with a myriad of symptoms that frequently present 
in other diseases but not directly point to an IEM. For this reason, Fabry disease has been 
called “the new great imposter” 6. Even psychosis or schizophrenia in adults with typical 
auditory hallucinations or catatonia can result from IEMs such as Wilson’s disease, Niemann-
Pick disease, ureum cycle disorders or acute intermittent porphyria 7. Inherited metabolic 
disorders can remain undiagnosed or are misdiagnosed for a number of reasons. Most im-
portant is the fact that many physicians are unfamiliar with the symptoms or syndromes 
of these rare conditions that are excellent keys to the diagnosis. Consequently they do not 
perform comprehensive examinations but discard signs and symptoms as non-specific or 
attributable to other conditions. For example, exercise intolerance or fatigue in Fabry dis-
ease is frequently attributed to psychological factors, and stroke at young age to a family 
history of presumed classical atherosclerotic disease. 
IEMs individually are very rare but collectively they represent a relatively common group 
of diseases. In a study in British Columbia 8, the overall minimum incidence of the metabolic 
diseases surveyed in children is 40 cases per 100 000 live births, but this is probably an 
underestimation as not all metabolic diseases have been surveyed; the data do not include 
Figure 1.2. Inborn errors of metabolism: a mutation in the gene that codes for an enzyme results in the accu-
mulation of substance 1 or the deficiency of substance 2.
Fabry disease among the sphingolipidosis and inborn errors of metabolism
13
diseases of collagen, such as osteogenesis imperfecta; disorders of metal metabolism, such 
as Menkes or Wilson’s disease; diseases of porphyrin metabolism or any of the blood lipid 
diseases, such as hypercholesterolemia (other than the LSDs involving glycolipids). As a 
consequence, we argue that the actual overall incidence is probably much higher. 
The lysosome is the stomach of the cell
An important part of IEMs takes origin in lysosomal enzymes. The lysosome is a cyto-
plasmic organelle described by the Belgian Christian De Duve 9who was awarded with the 
Noble price for this landmark discovery in 1974 (Figure 1.3.) 10. Lysosomes are present in all 
eukaryotic cell types except in erythrocytes and can be described as the recycling centres of 
the cell where macromolecules are degraded for (re) utilisation 11. This process is achieved 
in a stepwise manner by removal of terminal residues by a series of lysosomal enzymes, 
usually hydrolases. The released monomeric units are either transported or diffuse out of 
the lysosome 12.
Figure 1.3. The endo-lysosomal pathway. 
Lysosomes receive substances for degradation via endocytosis: this is invagination and pinching-off of 
membrane-bound vesicles from the plasma membrane. Through a series of vesicle fusion and fission events 
involving protein sorting, early endosomes gradually transform into late endosomes, a process called endo-
somal maturation. mRNA transscrips from genes for lysosomal proteins are translated by ribosomes on the 
rough endoplasmatic reticulum. The nascent peptide chains are translocated into the rough endoplasmatic 
reticulum where they are modified and transported to Golgi. In Golgi, a smal molecule, mannose-6-phosphate 
is added to the peptides. This molecule makes it possible for the peptides to leave the Golgi Apparatus and 
are ready for traficking to the lysosome. The lysosome matures, as it becomes more acidic by means of proton 
pumps making the hydrolases active. The lysosome interacts with endosomes and phagosomes and digests 
and recycle their macromolecules, or secretes its content. 
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The lysosome has a double-layered membrane consisting of phospholipids, integral pro-
teins and a Na+/K+ ATPase that produces a pH in the lysosome of 4.5. (Figure 1.4.). The inner 
leaflet of the membrane around the lysosome contains a dense glycocalix that protects 
the cell form the degradative effects of lysosomal enzymes 13. The lysosomal enzymes are 
active at this acidic pH, and most are soluble and localized in the lysosomal lumen. The 
macromolecules that are degraded by the lysosomal enzymes come from phagocytosis of 
viruses and bacteria, autophagy of worn-out mitochondria, endoplasmatic reticula or cyto-
plasmatic material, or endocytosis of mycopolysaccharides, lipoproteins and cell remnants. 
There are estimates that there are at least 50–60 soluble hydrolases and at least 7 integral 
membrane proteins in lysosomes. Since many of the substrates are complex lipids, which 
are not water soluble, proteins that function as cofactors or activators are also involved in 
enzyme-substrate interactions. Other proteins are involved in protecting enzymes from be-
ing degraded themselves in this proteolytic environment. A third function of the proteins is 
the transportation of the degradation products 12 .
In principle, mutations in the genes that encode any of these proteins could cause a LSD. 
Over 40 LSDs that involve soluble hydrolases are known and recently, a number of diseases 
have been identified that involve the integral membrane proteins 11,13,14.
In lysosomal storage disorders, an enzyme deficiency causes storage of intermediary 
degradation products 
LSDs can be grouped according to various classifications, but perhaps the most useful 
one is based on characterization of the defective enzyme or protein, rather than on the 
nature of the accumulated substrate(s) (Table 1.1.) 15
Glucosaminoglycans or mucoplysaccharides are long, linear, charged polysaccharides that 
are composed of a repeating pair of sugars, of which one is an amino sugar. They are accu-
Figure 1.4. Glyco(sphingo)lipids are building blocks of eukaryotic membranes.
Glyco(sphingo)lipids are a part of the lipid bi-layer, with carbohydrate chains on the extracellular 
side of the cell.
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Table 1.1. Lysosomal storage disorders, adapted from Futerman et al.15.
Diseases Defective protein Main storage materials
Sphingolipidoses
Fabry ɲ-Galactosidase A Globotriasylceramide and blood-group-B substances
Farber lipogranulomatosis Ceramidase Ceramide
Gaucher ɴ-GiucosidaseSaposin-C activator Glucosylceramide
Globoid cell leukodystrophy 
(Krabbe) Galactocerebroside ɴ-galactosidase Galactosylceramide
Metachromatic leukodystrophy Arylsulphatase ASaposin-B activator Sulphated glycolipids and GM1 ganglioside
Niemann - Pick A and B Sphingomyelinase Sphingomyelin
Sphingoipid-activator deficiency Sphingolipid activator Glycolipids
GM1 gangliosidosis ɴ-Galactosidase GM1 ganglioside
GM2 gangliosidosis (Tay-Sachs) ɴ-Hexosaminidase A GM2 ganglioside and related glycolipids
GM2 gangliosidosis (Sandhoff) ɴ-Hexosaminidase A and B GM2 ganglioside and related glycolipids
GM2 gangliosidosis (GM2-activator 
deficiency) GM2-activator protein GM2 ganglioside and related glycolipids
Mucopolysaccharidoses (MPS)
MPS I (Hurler, Scheie, Hurler/Scheie) ɲ-lduronidase Dermatan sulphate and heparan sulphate
MPS II (Hunter) lduronate-2-sulphatase Dermatan sulphate and heparan sulphate
MPS IIIA (Sanfilippo) Heparan N-sulphatase (sulphamldase) Heparan sulphate
MPS IIIB (Sanfilippo) N-Acetyl-ɲ-glucosaminidase Heparan sulphate
MPS IIIC (Sanfilippo) Acetyl-CoA:ɲ-glucosamideN-acetyltransferase Heparan sulphate
MPS IIID (Sanfilippo) N-Acetylglucosamine-6-sulphatase Heparan sulphate
Morquio-A disease N-Acetylgalactosamine-4-sulphatase(arylsulphatase B) Keratan sulphate, chondroitin-6-sulphate
Morquio-B disease ɴ-Galactosidase Keratan sulphate
MPS VI (Maroteaux-Lamy) N-Acetylgalactosamine-4-sulphatase(arylsulphatase B) Dermatan sulphate
MPS VII (Sly) ɴ-Glucuronidase Heparan sulphate, dermatan sulphate, chondroitin-4- and -6-sulphates
MPS IX Hyaluronidase Hyaluronan
0ligosaccharidoses and glycoproteinosis
Aspartylglucosaminuria Aspartylglucosaminidase Aspartylglucosamine
Fucosidosis ɲ-Fucosidase Fucosides and glycolipids
ɲ-Mannosidosis ɲ-Mannosidase Mannose-containing oligosaccharides
ɴ-Mannosidosis ɴ-Mannosidase Man(ɴ1ї4)GlcNAc
Glycogen storage disease II
(Pompe disease) ɲ-Glucosidase Glycogen
Sialidosis Sialidase Sialyloligosaccharides and sialylglycopeptides
Schindler disease ɲ-N-Acetylgalactosaminidase Glycoconjugates contaning
ɲ-N-acetylgalactosaminyl
Lipidoses
Wolman disease and cholesterol-
ester storage disease  Acid lipase Cholesterol esters and triglycerides
Diseases caused by defects in integral membrane proteins
Cystinosis Cystinosin Cystine
Danon disease LAMP2 Cytoplasmic debris and glycogen
lnfantile sialic acid storage disease 
and Salla disease Sialin Sialic acid
Mucolipidosis (ML) IV Mucolipin-1 Lipids and acid mucopolysaccharides and lipids
Niemann-Pick C (NPC) NPC1 and 2 Cholesterol and sphingolipids
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mulated in the mucopolysaccharidoses, due to the impaired function of one of the 11 lyso-
somal enzymes that include exoglycosidases, sulphatases and non-hydrolytic transferases 
that are required for the sequential degradation of glycosaminoglycans. 
In the sphingolipidoses, unmetabolized sphingolipids accumulate due to the defective 
activity of one of a number of enzymes or activator proteins (see further sections). 
In the oligosaccharidoses, oligosaccharides accumulate. 
In some cases, a deficiency in a single enzyme can result in the accumulation of different 
substrates. For example, GM1 gangliosidosis and Morquio-B disease are both caused by 
defects in acid β-Galactosidase activity, but they result in GM1 ganglioside and keratansul-
phate accumulation, respectively, and each disease displays distinct clinical and biochemi-
cal features. Similarly, defects in oligosaccharide degradation can result in the accumulation 
of glycolipids, glycoproteins or proteoglycans 15.
As a group, the LSDs comprise at least 50 diseases that have a combined incidence of 1 
in 5000–7000 live births 16.
The clinical presentation of LSDs is extremely variable
At birth, except in case of hydrops fetalis, most newborns with LSDs appear normal, be-
cause many of the toxic metabolites cross the placenta during pregnancy and are cleared 
by the mother during gestation. Hydrops fetalis or congenital ascites may be an earlier 
manifestation of several different LSDs. The mechanism contributing to the development of 
hydrops in storage diseases is not fully understood. It may involve the obstruction of venous 
blood return resulting from organomegaly. It can also result from hypoproteinemia caused 
by liver dysfunction or from congestive heart failure and liver cirrhosis 16 .
Most LSDs give symptoms in the first months to years after birth, though some can be 
asymptomatic until late in adulthood. Most often these manifestations include hypotonia 
or weakness caused by toxic effects of accumulating metabolites in the muscles and central 
nervous system. Several different LSDs can present with respiratory distress. Other common 
symptoms are coarse facial features, organomegaly, skeletal dysplasia and skin changes. 
LSDs are monogenic (involve only a single gene), but, for most LSDs, extensive allelic 
heterogeneity has been described: numerous different mutations in the same gene can 
contribute to the disease. These mutations include missense, nonsense and splice-site 
mutations, deletions and insertions. Some mutations lead to the complete loss of enzyme 
activity, whereas others lead to reduced activity. There is no strong genotype–phenotype 
correlation for most LSDs and prediction of the clinical course of the disease usually cannot 
be made on the basis of a specific mutation. 
Next to the genotype, other factors influence the phenotype in a particular patient. 
Downstream secondary biochemical and cellular pathways are altered due to substrate ac-
cumulation in lysosomes. This is probably important, though is up to now largely unknown. 
In many LSDs, severe neuropathology is typical, which leads to death at an early age, 
whereas in other diseases, the symptoms are mainly restricted to peripheral tissues. 
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The majority of the LSDs are inherited in an autosomal recessive manner, with three ex-
ceptions: the X-linked disorders Fabry disease, Hunter syndrome (mucopolysaccharidosis 
type II) and Danon disease. 
In view of the recessive inheritance pattern, consanguinity is a key factor to consider in 
diagnosis of neonates from isolated communities. Certain ethnic groups have an increased 
carrier frequency for specific disorders. For example, Gaucher disease, which results from 
the deficiency of the enzyme glucocerebrosidase, is the most common genetic disorder in 
Ashkenazi Jews, with a frequency of ~1 in 855 live births 16. 
The recent development and availability of enzyme-replacement therapy for several of 
the LSDs makes diagnosis early in the clinical course particularly important. Early diagno-
sis and intervention is essential for maximizing the potential benefit from some of these 
therapies and may prevent irreversible organ damage. Early diagnosis can provide parents 
with realistic information about their child’s prognosis and can enable appropriate genetic 
counselling for future pregnancies. It can also help families avoid the “diagnostic odyssey” 
that many patients undergo before a diagnosis is made.
Sphingolipidoses are lysosomal storage disorders caused by accumulation of 
sphingolipid degradation products
Sphingolipids are building blocks of eukaryotic membranes
Sphingolipids, together with phospholipids, cholesterol and transmembranous proteins, 
are building blocks of eukaryotic membranes (Figure 1.3.). Sphingolipids contain a sphin-
goid base such as sphingosine acylated with a fatty acid (Figure 1.5.). This results in cera-
mide, which itself is hydrophobic, but it can carry hydrophilic head groups: phosphorylcho-
line in case of sphingomyelin or oligosaccharide chains, which are carbohydrate monomers 
or dimers in case of cerebrosides or globosides and complex carbohydrates in case of gangli-
osides. These ceramide-oligosaccharide molecules (the cerebrosides, globosides and gan-
gliosides) are called the glycosphingolipids (GSLs). The hydrophilic oligosaccharide chains 
are located at the extra-cytoplasmic side of the lipid bi-layer of the cell. There is a large 
variation of glycospingolipid expression, depending on species and cell type. Neuronal cells 
are especially rich in acid glycosphingolipids of the ganglio-series. This is the reason why 
defects in ganglioside degradation affect especially the nervous system 13.
The function of GSLs on the cell surface can be divided into two basic categories. First, 
they are involved in cell adhesion/recognition processes by interactions with GSLs and lec-
tins (proteins that recognize carbohydrates) on other cells. Second, they modulate signal 
transduction by influencing receptor proteins on the cell surface. GSLs do not distribute 
homogeneously in the outer plasma membrane. Together with cholesterol, they form semi-
ordered lipid micro-domains, also called “lipid rafts”. Certain proteins appear to associate 
with GSLs in these lipid rafts, such as the epidermal growth factor receptor and the insulin 
receptor. 
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Figure 1.5.  The structure of glycosphingolipids.
Sphingolipids play important roles in (patho)physiology: some examples:
• Heat shock, oxidative stress, and other damaging conditions induce cells to pro-
duce an elevated level of ceramide, which has been implicated in signal-transduc-
tion pathways that lead to apoptosis, and as such have anti-mitogenic effects. This 
has been used for therapeutic purposes; vascular stents have been coated with a 
ceramide analog and show reduced stenosis 17.
• Sphingosine-1-phosphate is an extracellular ligand for several G-protein-coupled 
receptors and is involved in many signalling pathways involving cell migration, cell 
growth, and angiogenesis. In general, sphingosine-1-phosphate has the opposite 
effect of ceramide, in that it promotes cell growth and survival. The balance be-
tween sphingosine-1-phosphate and ceramide is called the sphingolipid rheostat 
18 and is important in cancer pathogenesis. The acid ceramidase gene that causes 
Farber disease (a sphingolipidoses) is implicated in prostate cancer: its gene prod-
uct degrades ceramide and is overexpressed in prostate cancer cells 19. Drugs that 
inhibit acid ceramidase have shown to have anti-cancer effects 17.
• Sphingosylphosphorylcholine has been shown to stimulate cell division and has also 
been implicated in pro-inflammatory signalling pathways.
• During embryogenesis and the postnatal period a small subset of acidic gangliosides 
is highly expressed in the developing brain. The levels of gangliosides are much lower in 
the adult brain, but many more different types of gangliosides are expressed. In mouse 
models, selective deletion of glycosylceramidesynthase (GCS) in neural cells prevented 
Fabry disease among the sphingolipidosis and inborn errors of metabolism
19
the formation of the brain gangliosides and resulted in the birth of animals with severe 
neural defects that died within three weeks. Brain gangliosides have also been impli-
cated in several neurological diseases. A lowered GCS activity in the brain tissue of Alz-
heimer patients causes an increase in ceramide and a decrease in the levels of complex 
GSLs, which in turn may cause abnormal functioning of neural cells. In contrast to this, 
GM1-enriched membrane micro domains have also been shown to play a critical role in 
the pathology of Alzheimer disease by promoting the formation of amyloid deposits or 
plaques by aggregation of amyloid β protein.
• Ceramides and keratins are the essential components of the epidermal stratum cor-
neum, which makes the skin of all land-dwelling animals impermeable to water, thereby 
preventing lethal dehydration.
• GSLs are found at increased concentrations on the outer membranes of apical cells 
that line the inside of the stomach, intestines, and respiratory tract. Apical cells rep-
resent the initial barrier of the body to the external world and are the first to make 
contact with potential pathogens. Many pathogens have evolved mechanisms that 
exploit apical cell surface GSLs to infect and invade their host 20. For instance, 
sialic acids (= N-Acetylneuraminic acid or NANA) on gangliosides serve as parts 
of the bindings sites for influenza. The influenza virus uses neuraminidase, an en-
zyme that cleaves sialic acid groups from GSLs, to enable release from host cells 
after replication. The pharmacological inhibition of these enzymes with zanamivir 
(Relenza®) or oseltamivir (Tamiflu®) is the current basis of influenza treatment. 
• Globotriaosylceramide or Gb-3 is the cell surface receptor for Shiga toxins pro-
duced by E. coli strains, which are the cause of hemolytic uremic syndrome. Genet-
ically engineered mice with targeted disruption of Gb-3 synthase are asymptomatic 
and insensitive to Shiga toxins. Also the mouse model of Fabry disease is insensi-
tive to Shiga toxin 21.
• GSLs play an important role in HIV/AIDS. The viral envelope gp120 first recognizes 
its primary receptor on host cells, CD4. This interaction gives rise to a conforma-
tional change in gp120 which exposes its third variable loop (V3) which contains a 
consensus amino acid motif that allows for binding to a trans membrane-spanning 
chemokine co-receptor (CXCR4 or CCR5, Figure 1.6) 22. Both interactions are nec-
essary for viral fusion and entry. Apart from binding to this co-receptor, V3 also 
binds GLSs, especially Gb-3, which is normally not expressed on CD4+ T lympho-
cytes, and could have a protective role in HIV-1 infection. Studies in Fabry disease 
where Gb-3 accumulates revealed that Fabry disease had a protective effect on the 
infection of peripheral blood mononuclear cells (PBMCs) by R5 HIV-1. Additional 
studies assessed the ability of HIV to infect PBMCs from people having a low or 
high Gb-3 expression. Taken together, these results indicate that over-expressed 
Gb-3 acts as a natural resistance factor for HIV infection, likely due to its ability to 
interact with and compete for the chemokine co-receptor binding site within the 
V3 loop of gp120, thereby preventing interaction of gp120 with the chemokine co-
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Figure 1.6. Interaction of Gb-3 and HIV. (Adapted from Lingwood 21)
A. Hiv binds first via gp120 to CD4, causing a conformational change in gp120 and its binding to a chemokine co-
receptor (CXCR4 or CCR5), triggering gp41 and cell fusion. 
B. CD4-negative cells constitutively express or can be made to overexpress Gb-3, Gb-3 may bind directly to HIV gp120 
without HIV binding first CD4. This may result in diminished HIV fusion as the chemokine binding motif is blocked by 
Gb-3 binding to gp120.
C. If HIV binds to CD4 the binding affinity of Gb-3 to gp120 can be increased to result in an inability for HIV gp120 to 
bind to a chemokine co-receptor, preventing fusion.  Soluble Gb-3 analogue can bind to HIV gp120 independently of 
CD4 binding and prevent binding to CD4 and/or hemokine co-receptor, preventing HIV infection.
receptor and inhibiting subsequent fusion of HIV to the host cell membrane 22.
• Lysosphingolipids are present in high-density lipoprotein (HDL) and mediate 
atheroprotection via release of nitric oxide, and can also mediate anticoagulation. 
• Most tumour cells show altered GSL patterns on their surface as well as abnormal 
SL signalling and increased GSL biosynthesis, which together play a major role in 
tumour growth, angiogenesis, and metastasis. The human sialidase Neu3 cleaves 
terminal Neu5Ac residues from GSLs. It is overexpressed in many types of cancer 
and plays an important role in tumour growth and survival. Tumour cells also ac-
tively shed specific gangliosides from the cell surface to cloak themselves from the 
body’s immune system 20.
• Fingolimod (Gilenya®, code name FTY720 during the trials) is an oral agent ap-
proved for use for the treatment of relapsing forms of multiple sclerosis and was 
originally proposed as an antirejection medication indicated after kidney transplan-
tation. Fingolimod is rapidly converted in vivo to the active moiety S-fingolimod-
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phosphate, which binds with high affinity to Spingosine-1-phosphate (S1P) re-
ceptors, thereby sequestering lymphocytes in the lymph nodes and preventing 
their egress into the peripheral circulation 17. As a consequence, there is a reduction 
in the infiltration of auto-aggressive lymphocytes into the central nervous system or 
in a transplanted kidney.
Inborn errors of glycosphingolipid metabolism (Figure 1.7)
Degradation of (glyco)sphingolipids takes places in endosomes and secondary lys-
osomes. Together with other membrane components, most (glyco)sphingolipids enter the 
acidic compartment of the lysosome via endocytosis and are cleaved into their building 
blocks at the surface of intra-endosomal and intra-lysosomal membranes (Figure 1.3.). This 
requires the presence of hydrolytic enzymes (glycosidases) and co-factors: sphingoid ac-
tivator proteins (SAP or saposins A tot D) and GM2 activator proteins. (Glyco)sphingolipid 
degradation is a stepwise process and deficiency of one single step causes accumulation of 
the substrates in the endo-lysosomal compartment. Due to the lipid nature of the storage 
material, this cannot leave the compartment. 
Nutrient delivery through the endolysosomal system can be impaired by a “traffic jam” 
Figure 1.7. Inborn errors of glycosphingolipid metabolism..
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caused by storage material. For example, iron homeostasis is impaired in animals with two 
glycolipid storage diseases, the GM1- and Sandhoff-disease. Supplementation of the ani-
mals with iron ions improved their condition and increased their life expectancy by nearly 
40% 13. Another characteristic feature of sphingolipidoses is the accumulation of other li-
pids as secondary storage products, which arises from the lipid nature of the primary stor-
age compounds that co-precipitate. For example, secondary accumulation of ceramide and 
the ganglioside GM3 might account for insulin resistance observed in Gaucher disease pa-
tients 17.
With the exception of X-linked Fabry disease, sphingolipidoses are inherited in an auto-
somal recessive manner. In general, patients display large genotypic and phenotypic het-
erogeneity: different genotypes can cause similar clinical symptoms, and the outcome of a 
disease can be different even among patients with identical mutations. The manifestations 
of the diseases can vary drastically between different sphingolipidoses: while gangliosidos-
es affect predominantly the grey matter of the brain, Krabbe disease and metachromatic 
leukodysdrophy affect the white matter. Fabry disease is especially a disease of heart and 
kidney, and Farber disease affects the skin. Also within one and the same disease, broad 
heterogeneities can be observed. For example, in Gaucher disease, 95% of the patients suf-
fer from the non-neuropathic type 1 without involvement of the nervous system. The other 
patients have the more severe type 2 with infantile onset or type 3 with juvenile or early 
adult onset. 
Diagnosis
The diagnosis of sphingolipidoses is based on the evaluation of clinical symptoms, char-
acteristic pathological manifestations, analysis of storage compounds, and especially the 
measurement of enzyme activities. Enzyme sources are serum, leukocytes, cultured skin 
fibroblasts, amnion cells, chorion villi, or biopsy material. Disease markers like plasma chito-
triosidase in Gaucher disease are valuable means for diagnosis and for therapeutic monitor-
ing.
Sphingolipidoses are, at least theoretically, treatable
The theoretical basis for the therapeutic approach is the “threshold theory” 17. According 
to this theory, the ratio of substrate influx into the lysosomes and the degradation capacity 
determines storage and thus the severity of the disease. Both parameters can be addressed 
by therapeutic approaches, especially since the theory predicts that already slight changes 
in this ratio can improve the condition of the patient.
The objective of most of the causal therapies is the restoration of the defective degrada-
tion capacity within the lysosome by means of enzyme replacement therapy (ERT), cell-
mediated therapy including heterologous bone marrow transplantation, gene therapy 
and enzyme-enhancement therapy with chemical chaperones. An additional strategy for 
the treatment of sphingolipidoses consists in the reduction of substrate influx into the lys-
osomes. This can be achieved by substrate reduction (substrate deprivation) therapy.
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Enzyme replacement therapy 
Lysosomal enzymes have the unique characteristic that, although most of the expressed 
enzyme is targeted to the endosomal system via binding of the enzyme to the mannose 
6-phosphate receptor, a small percentage of expressed enzyme is also secreted from the cell, 
which can be taken up by distal cells and trafficked to the lysosome. Current ERT and bone 
marrow transplantation therapies take advantage of this process of uptake of secreted en-
zyme, which is also known as cross-correction 23. The result of this is a (partial) reduction 
in substrate storage by the exogenous supply of the defective lysosomal enzyme. The en-
zymes in ERT are targeted for uptake by the manose-6-phosphate receptor system, present 
in nearly all cells, or the mannose receptor, present in cells of the macrophage lineage. ERT is 
effective in depleting the storage in visceral organs in some LSDs such as non-neuropathic 
Gaucher disease and Fabry disease, but not for most LSDs that involve the central nervous 
system, since systemically administered enzyme cannot cross the blood-brain barrier. For 
delivery to the central nervous system, intrathecal routes of administration have been ex-
plored in Gaucher disease, mucopolysaccharidosis type 1 and other LSDs, in animal models 
as well as in human, with partial success 24.
Cell-mediated therapy 
After allogeneic bone marrow transplantation, donor cells could partially replace for the 
defective cell population, so that cells with normal enzyme activity would compensate for 
the defective cells as enzymes are secreted for uptake by deficient cells (cross correction). 
Over 500 patients with lysosomal and peroxisomal metabolic storage diseases due to 
deficiency of primary enzymes have been treated with hematopoietic stem cell transplan-
tation. One example is Hurler disease where the enzymatic leukocyte deficiency of α-L-
iduronidase has been totally corrected and has remained at normal levels, with great clinical 
benefit and spectacular amelioration of neurocognitive functioning 25. 
Gene therapy
Gene therapy aims at restoring gene function by insertion of a functional copy of the 
mutated gene into cells. 
The transfected gene should be stably expressed by a few cells, which might correct 
the phenotype of adjacent cells via cross-correction. To date, most gene therapy-mediated 
cross-correction strategies have targeted the liver as the production depot of therapeutic 
protein as hepatocytes normally synthesize and secrete many different proteins. Another 
way to deliver cells to the body who stably express the deficient enzyme is the transduc-
tion of autologous bone marrow or hematopoietic stem cells with a gene therapy vector 
to express the therapeutic protein and are then introduced into the affected individual 23. 
Despite the successes of cross-correction-based strategies, for both gene therapy and 
ERT, these strategies cannot overcome the blood-brain barrier, leaving the neuropathologi-
cal problems untreated. One problem is the relative inefficiency of the secretion – reuptake 
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mechanism in comparison with the primary pathway of intracellular production of lysoso-
mal proteins, which are processed via the usual pathway. Delivery of gene therapy vectors 
directly to affected tissue, allowing the deficient cell to produce the therapeutic protein in 
an autonomous manner is the most straightforward gene therapy strategy. The challenge 
in direct correction lies in the technical aspect of delivery of the gene e.g. to the central or 
peripheral nervous system. Animal model studies of LSDs including MPS, Sandhoff disease, 
metachromatic leukodystrophy and Neumann-Pick showed biochemical and histological 
correction in the brain and even improvement in behavioural symptoms after injection of a 
gene therapy vector 14,23.
Several viral vectors for gene therapy have been used; retroviruses, adenoviruses and 
adeno-associated viruses. Retroviruses are single-stranded, RNA-containing enveloped vi-
ruses. After entry into a cell, the viral genome is reversed-transcribed into DNA that can then 
integrate into chromosomal DNA. Adenoviruses are naked, double-stranded DNA viruses. 
Advantages of adenoviral vectors are the ability to infect a broad range of cell types, both 
dividing and nondividing, and the capacity for large foreign DNA constructs. Furthermore, 
recombinant adenoviral vectors generally do not integrate into chromosomal DNA and per-
sist as episomal DNA, thereby minimizing the risk of unwanted insertional mutagenesis. Ad-
eno-associated viruses are nonpathogenic, single-stranded DNA-containing parvoviruses, 
which as retroviruses and adenoviruses have been used successfully in both small and large 
animal models of several LSDs, including mucopolysaccharidosis, Fabry disease, and Pompe 
disease. For example, ventricular infusion of a lentivirus expressing β-glucuronidase in the 
MPS VII mouse resulted in widespread biochemical and histologic normalization of regions 
within the brain with significant improvement in behavioural performance 23. In a murine 
model of Krabbe disease, a recombinant adenovirus encoding for β-galactocerebrosidase 
was injected into the cerebral ventricle. Improvement in neurological symptoms and a pro-
longed lifespan were observed 26. These and other experiments suggest that gene therapy 
will be effective for the treatment of LSDs with CNS involvement. Human experiments 
are on their way, e.g. in Gaucher disease (NCT00004294). In this study, patients undergo 
autologous transplantation using peripheral blood stems cells stimulated with filgrastim 
(Granulocyte-colony stimulating factor) and transduced with a retroviral vector containing 
the human glucocerebrosidase gene. Patients may receive up to 4 transplants if a deficient 
glucocerebrosidase level is found in peripheral leukocytes 1 month following transplanta-
tion. Results from this study have not yet been published.
The innate and adaptive immune system has the capability of limiting the success of viral 
gene transfer. Immune reactions have been noted in individuals to all LSD receiving ERT result-
ing in hypersensitivity reactions and the production of antibodies against the enzyme, which is 
a protein that is foreign to the body. This can lead to neutralization of enzyme activity. Antihista-
mines and/or other immunosuppressive drugs can control these immune responses. A strategy 
to avoid immune response has been the timing of gene transfer to the neonatal or even the 
prenatal stage of development. Introduction of foreign proteins at this time could allow for tol-
erization to the therapeutic product. 
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To date, several Phase I/II clinical studies have been initiated for gene therapy- 
based treatments for LSDs (Table 1.2.) 23,27. 
Table 1.2. Phase I/II clinical studies for gene therapy in lysosomal storage disorders.
Lysosomal storage disorder Approved treatment Gene therapy clinical trial and viral vector
Fabry disease ERT (agalsidase ɲ and ɴ) NCT00001234RV-a-Galactosidase A
Gaucher's disease I ERT (imiglucerase, velaglucerase ɲ, taliglucerase ɲ); SRT (miglustat)
NCT00001234 and NCT00004294
RV-glucocerebrosidase
Gaucher's disease III ERT (imiglucerase)
Glycogen storage disease II 
(Pompe disease) ERT (aglucosidase ɲ)
AAV/NCT00976352
rAAV-CMV-GAA
Metachromatic leukodystrophy NCT01560182LV-ARSA
Mucopolysaccharidosis I ERT (laronidase)
Mucopolysaccharidosis II ERT (idursulfase) NCT00004454RV-iduronate-2-sulfatase
Mucopolysaccharidosis IIIA 
(Sanfilippo disease)
NCT01474343
rAAV·SGSH and rAAV·SUMF1
Mucopolysaccharidosis IVA ERT (galsulfase)
Mucopolysaccharidosis VI ERT (galsulfase)
Neuronal Ceroid lipofuscinosis 
(Batten disease)
NCT00151216, NCY01411985,
NCT01161576
rAAV-CUhCLN2
Niemann-Pick C Hydropropyl-ɴ-cyclodextrin; SRT (miglustat)
Enzyme-enhancement therapy
Inherited mutations can disrupt native protein folding, thereby producing proteins with 
misfolded conformations. These misfolded proteins are consequently degraded by endo-
plasmic reticulum-associated degradation and do not reach the lysosome, although some 
of them are catalytically partially active. Active-site-specific chaperones are small molecules 
that act as a folding template in the endoplasmic reticulum to facilitate folding of mutant 
proteins, thereby accelerating their escape from the endoplasmic reticulum-associated 
degradation to maintain a higher level of residual enzyme activity. In Fabry disease, many 
missense mutations result in misfolding of α-Gal A, and 1-deoxygalactonojirimycin (known 
as «DGJ») has also been shown to be the most effective active-site-specific chaperone for 
increasing residual enzyme activity in cultured fibroblasts and lymphoblasts established 
from Fabry patients with a variety of missense mutations 28.
In addition to Fabry disease, small molecules capable of specifically rescuing misfolded 
enzyme proteins have been identified for Gaucher disease, Tay-Sachs and Sandhoff disease 
and GM1-gangliosidosis 28. 
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Substrate reduction therapy (SRT)
The pathological accumulation of a substance in the lysosome occurs as long as bio-
synthesis continues. Using inhibitors of sphingolipid biosynthesis, the influx of substrate 
into the lysosomes may be reduced. The proof of principle of this approach has been dem-
onstrated in a genetic model: Sandhoff disease is caused by beta-hexosaminidases A and 
B deficiency. These catabolic enzymes are needed to degrade neuronal membrane com-
ponents e.g. the ganglioside GM2. Sandhoff mice were crossbred with mice defective in 
the biosynthetic enzyme GM2- synthase. Though the life span of these animals was much 
longer, they developed a late-onset neurological disease due to the accumulation of oli-
gosaccharides 20 Miglustat (Zavesca®) has been approved for treatment in type 1 Gaucher 
disease and Niemann-Pick disease type C. It is a small iminosugar molecule that acts as a 
competitive inhibitor of the enzyme, glucosylceramide synthase, which catalyses the first 
committed step in glycosphingolipid synthesis. Miglustat is able to cross the blood–brain 
barrier and was shown to reduce glycosphingolipid accumulation and cellular pathology in 
the brain, delay onset of neurological symptoms, and prolong survival during pre-clinical 
studies 29. Miglustat was approved for the treatment of progressive neurological manifesta-
tions in pediatric and adult patients with NP-C in the European Union in 2009 and has since 
been approved for this indication in a number of further countries.
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FABRY DISEASE: CASE STUDY 
In a second part of this chapter, a typical case of Fabry disease is presented that illus-trates the variable presenting symptoms, its X-linked inheritance and the fact that its diagnosis is postponed for many years. This is followed by a general review on Fabry 
disease.
A thirty-nine-year-old woman presented with oscillopsia, depth perception and word-
finding problems, talking gibberish, having a numb sensation with paresis of the right arm 
and coordination problems on the right side. These symptoms resolved gradually over a 
period of two hours. Afterwards she felt like having a hangover. In her family history, she 
mentions the death of her mother secondary to breast cancer. Her father was alive and 
suffered from migraine and hearing impairment. A second episode with oscillopsia and bal-
ance disturbances occurred during the same year, again for several hours. Magnetic reso-
nance imaging (MRI) of the brain showed no structural cerebral abnormalities. The diag-
nosis of transient ischemic attacks (TIA) in the cerebral posterior circulation was made and 
treatment with aspirin was prescribed. At the age of forty-three, a third episode occurred 
with transient paresis of the right arm for two hours. The patient had not started the treat-
ment with aspirin.
One year later, her 20-year-old nephew (her sisters son) was admitted with fever, head-
aches and neck pain with extension to the right arm. Clinical examination upon admis-
sion revealed some nuchal rigidity but otherwise unremarkable findings. A viral syndrome 
with meningism was diagnosed. Analysis of the cerebrospinal fluid showed no abnormali-
ties. During further observation he had an acute episode with visual disturbances (having 
blurred vision and difficulty recognizing faces and reading words). He felt dizzy and had 
equilibrium problems (ataxia). These symptoms slowly resolved within the next 3 hours. 
Neurological examination also revealed nystagmus, unilateral hearing loss and tinnitus. 
Medical history revealed episodic fever with myalgia besides intermittent important 
headache, hypohidrosis, fatigue and exercise intolerance. Ophthalmologic examination re-
vealed cornea verticillata, tortuous retinal vessels and lens opacities, supporting the clini-
cal diagnosis of Fabry disease. Cardiac ultrasound showed borderline septal left ventricular 
hypertrophy (11 mm) but was otherwise unremarkable. α-galactosidase A (α-Gal A) activity 
measured with dried blood spot was undetectable, and sequencing of the GLA gene yield-
ed the missense mutation GLA c.758C>T (p.Ile253Thr) which was also confirmed in his aunt, 
who had a normal  α-Gal A activity. At the time of diagnosis of Fabry disease in his aunt who 
had then reached the age of forty-nine, she already had developed important asymmetric 
white matter lesions visible on MRI scan of the brain besides concentric left ventricular hy-
pertrophy (septum thickness was 14 mm) associated with diastolic dysfunction. 
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A SHORT REVIEW ON FABRY DISEASE
Fabry disease (OMIM 301500) is an inborn error of metabolism with, caused by absent or deficient activity of lysosomal α-Gal A 3,4 (Figure 1.8.) This results in progressive accumulation of Gb-3 and to a lesser extent of other related glycosphingolipids in 
lysosomes and cytoplasm 30 in a variety of cells, including capillary endothelial cells, renal 
(podocytes, tubular cells, glomerular endothelial, mesangial and interstitial cells), cardiac 
(cardiomyocytes and fibroblasts) and nerve cells 30.This process starts in utero 31 although 
most patients remain clinically asymptomatic during the first years of their life. Gb-3 stor-
age eventually results in cell dysfunction and the development of irreversible tissue dam-
age 32-34. The first clinical symptoms appear between the ages of 3 and 10, generally a few 
years later in girls than in boys 35With increasing age, progressive damage to vital organ 
systems develops in both genders leading to organ failure, mainly involving kidneys, heart 
and brain, resulting in a reduced life expectancy.
Figure 1.8. Fabry disease is caused by α-Gal A deficiency.
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Epidemiology
The prevalence of Fabry disease has been estimated to range between one in 117,000 
births and one in 40,000 males (Desnick RJ et al. in 36,37) but this is probably an underesti-
mation, due to under-diagnosis as a result of the rarity and the complexity of the disease. 
Screening studies for Fabry disease in high-risk populations (left ventricular hypertrophy, 
stroke, dialysis) and in newborns yield much higher frequencies 38-41 but this is mainly due 
to the detection of attenuated (later-onset and milder) phenotypes. In a screening study 
in Italian newborns, the incidence of α-Gal A deficiency was 1 in 3,100 with an 11:1 ratio of 
patients with the later-onset versus classic phenotypes 40. The other newborn-screening 
studies showed comparable results (see also Chapter 4). 
Clinical description
1. Early symptoms: Fabry disease at the pediatric age 
Lysosomal accumulation of Gb-3 begins in utero 31,42 but symptoms can take years to 
appear. The earliest signs and symptoms can appear in early childhood, beginning a few 
years earlier in boys compared to girls 35,43. Neuropathic pain due to accumulation of Gb-3 
in small nerve fibers is one of the earliest and most prevalent symptoms in Fabry disease 
and is experienced in up to 80% of classically affected boys 44,45. The pain typically presents 
as acroparesthesia with a burning character. Both acute pain attacks (“Fabry crisis”) and 
chronic background pain have been reported and are a major cause of morbidity during 
the first two decades of life 44.
Gastrointestinal involvement is another common manifestation of pediatric Fabry dis-
ease 46. Patients may complain of abdominal pain (often after eating), diarrhoea, nausea, 
and vomiting, which are a significant cause of anorexia 47. Despite the high frequency of 
gastrointestinal symptoms, this does not appear to lead to malabsorpsion 47.
Absence or a decreased ability to sweat (an- or hypohidrosis) is a significant problem for 
patients and can contribute to heat and/or exercise intolerance 48.
Angiokeratomas are present in 53 % of males and 30 % of female pediatric Fabry patients 
45 (Figure 1.9.). These are non-blanching red to blue/black lesions 1 to 5 mm in diameter. 
They can be unique or appear in groups, first appearing in childhood and increasing during 
adolescence with lesions on genitals and groin in men, and in the lumbosacral area, gluteal 
cleft and trunk in both sexes (often in a typical “bathing trunk” distribution). Later in life, 
angiokeratomas can appear on lips, the umbilicus and palms, but isolated presence in these 
atypical areas is also possible 49.
Corneal changes (”cornea verticillata“) (Figure 1.10.) detectable by slit lamp examination 
is present in most children with Fabry disease 50
Renal intracellular Gb-3 deposits may be present in young children with normal GFR and 
minimal or absent micro-albuminuria 51. Podocyte foot process effacement has been re-
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Figure 1.9. Angiokeratoma (Adapted from Germain 61)
Figure 1.10. Cornea Verticillata (Adapted from Germain 61)
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ported and albuminuria is one of the cardinal first signs of Fabry nephropathy 52. Proteinuria 
progresses and deterioration of kidney function is possible from childhood 35. 
2.  Kidney involvement
One of the first signs of Fabry nephropathy is micro-albuminuria.  At an early stage, hy-
perfiltration may, as in diabetes, be a first sign of kidney damage. Proteinuria progresses 
and correlates with and also contributes to the decline in renal function 53,54. The yearly 
decline in renal function also correlates with the glomerular filtration rate (GFR) at presen-
tation  53. In a study of 105 male Fabry patients, mean annual loss of GFR reached  12.2 mL/
min/1,73m2/year 55. This is however probably an overestimation as other studies show less 
rapid deterioration of kidney function. Schiffmann et al. 53 found mean progression rates 
in males who developed or did not develop end-stage renal disease of -3.85 and -2.93 ml/
min/1.73m2/year, respectively. Wanner et al. 54 found estimated GFR slopes of -0.2 up to -5.6 
ml/min/1.73m2/year depending on the amount of proteinuria. 
Most patients with CKD stages 3 to 5 have proteinuria 56. Proteinuria in the nephrotic 
range (> 3.5 gr/24 h) is rarely seen (maximal 18% in 57), most often without a full nephrotic 
syndrome. 
CKD stage 5 is found in 50 % of adult male patients (vs. 20% of females) between the 
third and the fifth decade, with a mean age of 38, but it can be found as early as at the age 
of 16 58,59.
3. Cardiovascular involvement
In a large study in untreated Fabry patients, 49% of males and 35% of females had a car-
diac event at a mean age of 36.2 and 44.4 years, respectively 53. Cardiac involvement typical-
ly presents as a hypertrophic cardiomyopathy, which is typically non-obstructive 60. As the 
disease progresses, replacement myocardial fibrosis becomes important 60. This correlates 
with observations of relatively mild diastolic dysfunction in early stages of the disease pro-
gressing to systolic and diastolic ventricular impairment in the advanced (fibrotic) stage. Pa-
tients with Fabry disease may have angina despite angiographic normal coronary arteries. 
This may be caused by coronary microvascular dysfunction, as it was shown that coronary 
flow reserve, an index of coronary microvascular function, was diminished 61. Arrhythmia, 
including supraventricular, ventricular and brady-arrhythmia is the most common cardiac 
event, is reported in 42% males and 27% of females 53 and is responsible for a number of 
cardiac deaths in patients affected with Fabry disease.  Arrhythmia arises from Gb-3 accu-
mulation and subsequent ischemia and fibrosis of the sinus node or the conduction system 
and an imbalance between sympathetic and parasympathetic tone 62.
Right ventricle involvement is common in Fabry disease and ultimately progresses to 
severe systolic and diastolic RV dysfunction. These findings might explain why patients with 
preserved LV function can develop clinical features such as reduced exercise capacity and 
lymphedema 63.
Electrocardiographic (ECG) changes in patients with Fabry disease are frequent and show 
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evidence of LVH and ST-T wave changes 46. Less frequent abnormalities include a short PR 
interval (< 0.12 msec) 64 and AV block 65, for which a permanent pacemaker is implanted in 
a significant number of patients  60,66. 
4. Cerebrovascular involvement
Besides small fibre neuropathy causing pain, neurologic hallmarks of Fabry disease are 
cerebral micro- and macro-angiopathy with premature stroke 67. It has been estimated that 
during the course of Fabry disease 16% of patients will experience stroke 68. Cranial MRI 
shows progressive white matter lesions (WML) at an early age in both genders which are a 
candidate marker of central nervous system vascular involvement 69. Furthermore, females 
seem to be more likely than males to experience stroke as their only Fabry disease clinical 
event 70Boston, Mass. 02114, USA. All patients with Fabry disease, regardless of age or gen-
der, should be monitored for possible cerebrovascular complications, as stroke can occur in 
the absence of other key signs of the disease 70. Patients with Fabry disease are known to 
experience stroke at an early age compared to the general population. In the Fabry Registry, 
median age at first stroke was 39.0 years in males and 45.7 years in females 70. Stroke is even 
possible in the first two decades of life 70. 
The distribution of MRI-detectable lesions in the brain is typical of a secondary small-
vessel disease, presumably due to a combination of reduced vascular compliance and the 
activation of pro-thrombotic factors 71.
Different case studies reported cognitive deficits up to vascular dementia 72,73. One study 
examined neuropsychological performance in Fabry disease: mild language and attention 
deficits but no other cognitive impairment were demonstrated in 17 patients 74. Depressive 
syndromes are regarded as the most frequent psychiatric manifestation 73,75.
5. Other symptoms, quality of life 
Patients with Fabry disease have been found to have osteopenia and osteoporosis 76 
although this could be secondary to renal failure, malnutrition and low BMI.
Hearing loss and tinnitus are common symptoms in Fabry disease and increase in preva-
lence with age 77.
Airway obstruction and reduced diffusion capacity have been reported 78,79.
Fabry males experience decreased quality of life in physical functioning and bodily pain 
while general health perception is lowered in females 80.
Coarsening of facial features is frequent in a number of LSDs 12. In male Fabry patients, 
this is most apparent in the peri-orbital region. Peri-orbital fullness with bushy eyebrows, a 
broad nasal base, shorter and more bulbous nose, fullness of cheeks and a larger chin have 
been noted 81,82 (Figure 1.11.).
Fabry disease can present with many more symptoms mimicking other diseases (e.g. 
lymphedema, vertigo, fever, Raynaud, myopathy, etc.) 83,84, urging some authors to call it 
“the new great imposter” 6.  
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6. Atypical variants
As a result of screening studies during the past decade, clinical variants of Fabry disease 
have been described. A “cardiac variant” with isolated left ventricular hypertrophy and/or 
cardiomyopathy presenting in the sixth or seventh decade, lacking the classical disease 
symptoms and time course was first described 85,86. Patients suffering from this variant may 
have proteinuria, but their renal function is typically normal for their age. A “renal variant” 
phenotype has later been described in a screening study in a dialysis population, where 
patients again were lacking the classical manifestations, such as acroparesthesia, angiokera-
toma, hypohidrosis, or corneal and lenticular lesions. This phenotype was described as “in-
termediate” between the cardiac variant and the classic phenotype 87. These patients with 
cardiac and renal variants lacking the typical disease course starting at a young age are 
called atypical or attenuated Fabry disease patients, to distinguish them from classical pa-
tients with multi-organ disease and a first presentation at a young age.  It is believed 57 that 
the atypical cases are the result of missense mutations that encode mutant enzyme protein 
or intronic lesions that reduce transcript levels, both resulting in a reduced but significant 
residual enzyme function (1-10 % of normal). The residual enzyme function results in at-
tenuation of presenting symptoms 57. 
Heterozygous women, in spite of having a mutation compatible with typical disease, 
can also present this attenuated phenotype.  On the other hand, registry studies show that 
many females are symptomatic and at considerable risk for major organ involvement and 
decreased quality of life 88. In women, there is no good correlation between residual en-
zyme function and disease severity 89.
Figure 1.11. Facial features in two brothers with AFD and 
their unaffected sister, showing thickening of the lips and 
nasolabial folds in the affected males (Adapted from Mac-
dermot 82).
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Determination of enzyme activity is the gold standard for diagnosis of Fabry disease in 
males
The product of GLA, the gene responsible for Fabry disease located at Xq22.1 is α-Gal A, a 
lysosomal hydrolase that enzymatically cleaves α-galactosylresidues from glycosphingolip-
ids (Figure 1.8.). The product of NAGA, a gene located at Xq22.13 is α-N-acetylgalactosimidase 
(α-NAGA), also called α-Gal B. It cleaves α-N-acetylgalactosaminyl residues, but also has 
some activity cleaving α-galactosylresidues. In order to test for α-Gal A activity, α-Gal B 
has to be inhibited with α-N-galactosamine. The synthetic fluorogenic substrate, 4-methy-
lumbelliferyl-alfa-D-glucopyranosis can be used for measurement of Fabry disease in men, 
with a sensitivity and specificity reaching 100 % 90. Beta-galactosidase activity is used as an 
internal standard for evaluation of sample quality. α-Gal A acivity in leucocytes is regarded 
as the gold standard 90.
Recently, a dried blood spot test (DBS) using filter paper has been proposed as an alter-
native being as accurate as the leukocyte tests 91,92 .The samples are easy to transport and 
are stable at room temperature for many days, making it a most convenient screening tool 
in men, as it is a very sensitive tool with a negative predictive value reaching 100 %. 
In females, mutation analysis should confirm a clinical suspicion of Fabry disease
In women, enzyme activity measurement has a low sensitivity, as 1 in 3 women with 
Fabry disease have normal or nearly normal α-Gal A activity 93. 
One explanation for this lies in a skewed X- inactivation. X-inactivation or lyonisation 
was described in mice by Mary Lyon in 1961 94. In mammalian females, one in two X chro-
mosomes are inactivated, and present as heterochromatin, which consists of condensed 
and transcriptionally inactive DNA. This DNA material can be seen as the “Barr body” in the 
nucleus of the cell (Figure 1.12.). The purpose of X-inactivation or lyonisation is to prevent 
female to have a double amount of gene products compared to male. The X inactivation 
centre (XIC) on the X chromosome contains four RNA genes, one of which is X inactivation 
specific transcript (Xist). This RNA molecule is not translated into protein, but functions as a 
cover for the chromosome from which it is derived and silences the X chromosome in case 
there is not a “blocking” factor from autosomal origin which prevents the transcription of 
this molecule. As a result, early in the developing female, there is random X chromosome 
inactivation, but this can be skewed or non-random at the level of a patch, tissue or organ. 
In Fabry disease, depending on this epigenetic process, there can be significant or even 
normal α-Gal A activity in the blood if in a significant amount of cells the wild-type X chro-
mosome is active. At the level of the tissue or organ (brain, kidney or heart), this activity can 
be very low and the cause of Gb-3 deposition in lysosomes leading to organ damage. 
This theory has been debated. In a recent study 95, the X-chromosome inactivation ratio 
was determined in 77 samples from Fabry heterozygotes. Only 18.2% were highly skewed 
(80/20). There were no correlations between the X chromosome inactivation (XCI) ratios and 
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age, enzymatic activity of α-Gal A, Fabry severity scores, or with the clinical signs of cardiac 
involvement, neuropathic pain, or proteinuria. These findings are essentially the same as 
seen in normal non-elderly female population, raising the question of the mechanism un-
derlying symptomatic phenotypic expression in heterozygous females with Fabry disease.
Anyway, there is no good correlation between enzyme activity in circulating blood or 
leucocytes, and disease severity. For this reason, enzymatic tests are less suited and system-
atic genetic testing should be encouraged in females. In males, mutation analysis is a way 
of confirming diagnosis, subsequent to enzyme activity measurement. More than 600 mu-
tations have been identified so far (http://www.hgmd.cf.ac.uk/ac/index.php, last accessed 
august 2012). 
Most exonic and some intronic GLA sequence alterations are pathogenic
Exonic sequence alterations can cause premature stop-codons or frame shift mutations 
that result in nonsense-mediated decay of mRNA and loss of protein. Exonic sequence 
changes can also result in a catalytically inactive enzyme, e.g. in case of missense muta-
tions affecting one of the 15 residues in the enzyme active site or one of the 8 cysteine’s 
essential for proper three-dimensional folding of the protein. Intronic mutations can affect 
evolutionary conserved splice-site dinucleotides at the beginning or the end of the 6 GLA 
introns, interfering with proper splicing of GLA mRNA. Two deep-intronic mutations result 
in complex changes in the patterns of splicing (c.639+861C>T and c.639+919G>A) 90.
One example of an inert exonic polymorphism (or allelic variants) is the “D313Y” substitu-
tion (c.937 G>T). This polymorphism is present in up to 5 % of the population. At neutral pH 
(plasma), the enzyme activity is very low, while the in the in vitro expression COS 7 cells is 
60% of wild type activity, which is enough not lead to Fabry disease. This is now generally 
considered to be associated with a so-called pseudo-deficiency 96. 
Figure 1.12. X Lyonisation. 
Random X inactivation happens early in embryonic life, leading to afixed inactivation 
in all descending cells.
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Another (exonic) mutation that is prevalent across populations (p.Asn215Ser) affects in-
tracellular trafficking or packaging and secretion of α-Gal A, resulting in very low plasma 
enzyme activity and a slightly higher activity in leucocytes. It is found in several unrelated 
individuals with the cardiac variant phenotype 86.
Mutation detection and mutation scanning 
In order to explain a low α-Gal A activity or a phenotype compatible with Fabry disease, 
mutation scanning can be performed with complete GLA gene sequencing in addition to 
methods for deletion testing (see infra). 
Once a particular mutation has been found, other often less time consuming methods 
can be used for mutation detection, in order to detect patients and carriers, starting from an 
index patient. 
First, complete gene sequencing can detect different kinds of mutations, e.g. deletions, 
insertions and point mutations (nonsense, missense or splice site mutations) 97. These mu-
tations appear de novo in an individual in 3 to 10 % of cases 98. The majority of the mu-
tations are “private”, i.e. unique to a family, and therefore it is always possible to identify 
a previously undetected mutation. Intronic as well as exonic sequence alterations can be 
pathogenic (cfr supra) 90,99. 
A more economic method for mutation scanning is a targeted mutation analysis. This is 
the direct detection of one single mutation, e.g. in a family where the mutation has been de-
fined or a population where a mutation is highly prevalent such as GLA c.427G>C in Canada 
(also known as the Nova Scotia mutation). This mutation has a very high prevalence (50 in 
178 Fabry patients in the Canadian registry) 100 as the result of a founder effect. The founder 
effect is the loss of genetic variation that occurs when a new population is established by 
a very small number of individuals from a larger population, in an isolated region such as 
Nova Scotia in Canada. 
Rapid detection of carriers of a specific mutation is possible via allele-specific oligonu-
cleotide testing using a synthetic segment of DNA approximately 20 base pairs in length 
(an oligonucleotide) that binds to and hence identifies the complementary sequence in a 
DNA sample without sequencing the entire GLA gene. Direct sequencing will miss partial 
(exonic) deletions or whole-GLA-gene deletions, particularly in females. In male, this can 
be detected by PCR amplification before sequencing, which can suggest deletion of one 
or more exons, but this will also fail in female. Other methods (deletion testing) have been 
designed as a solution for this problem. With quantitative PCR, the DNA is amplified and at 
the same time quantified by means of e.g. fluorescent reporter probes; large deletions will 
then easily be detected, as they are not amplified. The method for deletion testing in our 
lab is Multiplex Ligation-dependent Probe Amplification (MLPA) 101. This is a variation of the 
multiplex polymerase chain reaction that permits multiple targets to be amplified with only 
a single primer pair. 
For each target DNA sequence, two adjacent probes are designed that contain the for-
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ward and reverse primer sequence, respectively. Each probe also contains a universal primer 
sequence. In addition, one of both probes contains a stuffer sequence of which the length 
can be varied. The probes are hybridized against the target DNA and subsequently ligated. 
Only if ligation happened, a functional PCR strand appears, so that amplification only hap-
pens if target DNA is present in the sample. Multiple probe pairs are pooled and amplified 
with the same primer pair.
Resulting amplification products are separated by electrophoresis. Since the forward 
primer is fluorescently labelled, each amplification product generates a fluorescent peak, 
which can be detected by a laser. Comparing the peak pattern obtained on a given sample 
with that obtained on various reference samples, the relative quantity of each amplicon can 
be determined. This ratio is a measure for the ratio in which the target sequence is present 
in the sample DNA.
Fabry disease has a wide phenotypical spectrum, a low genotype-phenotype correlation 
and is difficult to recognize
Fabry disease is under-ascertained because of its rarity and lack of knowledge by clini-
cians, but also because of its wide phenotypical spectrum. Hence, the presentation with 
stroke, left ventricular hypertrophy and renal failure is non-specific, and typical Fabry symp-
toms like angiokeratoma can be absent or easily overseen. The wide phenotypical spec-
trum, even within families, is in agreement with a poor genotype-phenotype correlation 
102, and even in males with virtually absent α-Gal A , the same mutation can result in a very 
different phenotype 103. This applies even more to women and makes the recognition of 
this heritable disease even more difficult. As a result, screening remains an important tool 
for case finding. Screening individuals has been performed in high-risk populations with 
dialysis, kidney transplantation, stroke and cardiac left ventricular hypertrophy. Variable 
frequencies (0 – 4.2 %) have been found largely due to selection bias and differences in 
screening tools 104. 
Screening has also been performed in newborns 40,41,105,106 (more details in Chapter 4), 
but this approach is controversial for several reasons. 
Conventional medical treatment of Fabry disease
Fabry disease is a progressive multi-organ disorder. As a consequence, effective manage-
ment requires a multidisciplinary approach.
Classic symptomatic treatment of neuropathic pain, gastro-intestinal symptoms and 
hearing impairment is recommended. Most experts recommend anti-platelet therapy with 
aspirin or clopidogrel for secondary prevention of stroke. 
Renal function Fabry disease is often associated with proteinuric chronic kidney dis-
ease and arterial hypertension, and can be treated with angiotensin converting enzyme 
inhibitors (ACEi) or angiotensin receptor blockers (ARB).  Many patients with Fabry disease 
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and renal involvement will require renal replacement therapy. Kidney transplantation has 
shown acceptable results 107. Ten years after transplantation, mortality increases quickly in 
comparison with non-diabetic transplant recipients, probably due to progression of Fabry 
Disease 108. 
Angina due to endothelial dysfunction with vasospasm and thrombotic events can be 
treated with ACEi, calcium channel blockers, and anti-platelet drugs. Drugs like amiodarone 
should be avoided as they may form complexes with cellular phospholipids that cannot 
be metabolized by lysosomal phospholipases 109. Beta-blockers should be used cautiously 
because bradycardia is a frequent problem. Cardiac pacing or implantation of cardioverter 
defibrillator devices (ICD) is increasingly used in patients with Fabry disease with atrioven-
tricular block or to prevent sudden cardiac death due to sustained ventricular tachycardia 
and malignant arrhythmia 60,66,110 . 
Enzyme replacement therapy in Fabry disease
Since 2001, two forms of recombinant alfa-galactosidase A have been approved in Eu-
rope: agalsidase alfa (Replagal®; Shire Human Genetic Therapies, Boston, MA, USA) and agal-
sidase beta (Fabrazyme®; Genzyme, Cambridge, MA, USA), both administered as an intrave-
nous infusion every 2 weeks.
From a recent Cochrane review 111, it appeared that the evidence base in favour of ERT is 
weak. Five (total N=187) poor quality randomized controlled trials (RCT’s) are available. Most 
RCT’s evaluate surrogate endpoints, such as decrease of plasma Gb-3 levels in plasma and 
tissues and less often evaluate for harder endpoints such as organ dysfunction or mortality. 
Besides RCT’s, open label studies and retrospective analyses have been performed showing 
that in male Fabry disease patients renal function remained stable under ERT during follow-
up periods of up to 24 months 112, however, in case of CKD stage 3 113 or proteinuria > 1 gr/
gr creatinine 114, renal function has a tendency to deteriorate. In conclusion, at most ERT 
stabilizes kidney function when it has not yet been damaged by Fabry disease. 
In patients with CKD stage 5, ERT can be performed during the hemodialysis session, 
which does not alter pharmacokinetics 115.
ERT is effective for neuropathic pain and quality of life 111 and reduces left ventricular size 
in patients who have an enlarged heart at baseline 116, but definitive proof of the long term 
beneficial effects of ERT on the heart are awaited. 
ERT does not cross blood-brain barrier, and while on treatment, variable progression of 
MRI abnormalities has been noted. Its preventive effect for stroke is also still unproven 117. 
Case study: Discussion 
A woman and her nephew presented both with symptoms and signs of TIA at a young 
age. She had three episodes, but only at the time of diagnosis in her nephew (ten years after 
her first presentation), she was diagnosed with Fabry disease. At that time, besides progres-
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sive white matter lesions visible on MRI of the brain and cardiac left ventricular hypertrophy, 
she had no serious organ damage, which is in agreement with an attenuated phenotype as 
it can present in female.
Her nephew presented at a young age with several TIAs, acroparesthesia and fever of un-
known origin. The latter is a rare but well-described symptom in Fabry disease 83. His family 
history with TIA in his aunt at a young age could have been helpful for reaching the correct 
diagnosis, but it was the astute ophthalmologist who finally suggested the diagnosis. 
Since five years, the male patient has been treated with ERT. The quality of life showed 
significant amelioration and there has been no event related to Fabry disease. 
Conclusion
Fabry disease is a rare inborn error of metabolism with variable clinical presentation 
whose diagnosis is frequently missed. Clinicians should consider Fabry disease in case of 
stroke at a young age and pay considerable attention to the family history, as this can sug-
gest the diagnosis. 
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AIMS AND OUTLINES OF THIS THESIS
The origin of my motivation for this research can be found in 2001, when I was treating a 40-year-old man after kidney transplantation. He was diagnosed with Fabry disease as a result of the diagnosis in his mother who died as a hemodialysis 
patient five years earlier. I was informed that in Flanders at that time, only about 5 patients 
were diagnosed with Fabry disease compared to over 30 in Wallonia. As I read that preva-
lence worldwide was at least 1 in 117.000 37, I wondered if the other 50 patients in Flanders 
with its population of over 6 million had been missed. 
The rarity of the disorder and the variability in its presentation have caused important 
diagnostic delays 68. In case of Fabry disease, with the advent of a promising ERT 118,119 ap-
proved in 2002 by the Food and Drug administration (FDA), this is all the more undesirable. 
Patients not only have to suffer the devastating consequences of their unexplained and 
threatening illness, but also remain devoid of the potential beneficial effects of therapy. 
We wanted to understand this disease and we wanted to find and treat these patients. 
The first aim of our research was to gain more insight in this rare disease.  In Chapter 1 
we studied the position of Fabry disease among the IEMs and LSDs. We discussed two cases 
of classical Fabry disease whose diagnosis was missed initially and we present a review on 
etiology, prevalence, disease manifestations and treatment. 
The second aim of this research was to look for undiagnosed cases of Fabry disease in 
Flanders in order to get insight in its prevalence, as we hypothesized that many cases were 
undiagnosed.  We aimed at developing and optimizing methods and strategies for a timely 
diagnosis of Fabry disease. Next, we wanted to make a detailed analysis of the phenotype 
of the mutations we found in Flanders. 
We decided to look for cases in high-risk groups: the first group we screened was the 
hemodialysis population, where patients without a clear-cut diagnosis were screened us-
ing a blood spot test for α-Gal A activity.  The kidney transplant population was screened 
consecutively, and a third high-risk group we examined was the patient group with left 
ventricular hypertrophy. The result of this research is described in Chapter 2. 
It became clear that Fabry disease is much more prevalent then was previously assumed, 
and that the phenotype of Fabry disease is very variable. In Flanders, the GLA p.Ala143Thr 
(c.427G>A) mutation, which was known to present with an attenuated phenotype, had a 
relatively high prevalence.  We did further research on this mutation, and we got serious 
doubts on its pathogenicity, which has important consequences for further counseling, di-
agnosis and treatment of these patients and their families.  In Chapter 3, we describe our 
findings on this subject. 
Next to screening in high-risk groups, we analyzed the results of screening studies in 
the healthy population. Indeed, screening for Fabry disease in newborns would be the best 
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method for early detection of Fabry patients, but in our opinion this clearly poses major 
problems. In Chapter 4, we discuss the ethical and medical issues concerning the screening 
of newborns in Italy, Taiwan and Austria, where the bulk of the GLA mutations discovered 
consisted of attenuated phenotypes. As we have only very few data genotype-phenotype 
correlation and are not able to predict progression and the effect of ERT, we felt that screen-
ing of healthy newborns was ethically unacceptable.  In order to overcome these problems, 
we developed a screening strategy for detecting classic Fabry disease in boys. 
The experience from this work was further applied to the population with Chronic Kidney 
Disease (CKD).  In Chapter 5, we present recommendations for screening for Fabry disease 
in patients with otherwise unexplained chronic kidney disease and discuss treating options. 
Finally in Chapter 6, a summary and a general discussion is given, and future projects 
are presented. 
Chapter 1
42
REFERENCES
1. Fabry, H. An historical overview of Fabry disease. J. Inherit. Metab. Dis. 24 Suppl 2, 3–7 (2001).
2. Germain, D. P. [Enzyme replacement therapies for lysosomal storage disorders.]. Med Sci (Paris) 21, 77–83 
(2005).
3. Brady, R., Gal, A., Bradley, R., Martensson, E. & Warshan, A. Enzymatic Defect in Fabry’s Disease — Cerami-
detrihexosidase Deficiency. N. Engl. J. Med. 276, 1163–1167 (1967).
4. Kint, J. A. Fabry’s disease: alpha-galactosidase deficiency. Science 167, 1268–1269 (1970).
5. Harris, H. Genetical theory and the “inborn errors of metabolism”. Br Med J 1, 321–327 (1970).
6. Lidove, O. et al. Fabry disease ‘The New Great Imposter’: results of the French Observatoire in Internal 
Medicine Departments (FIMeD). Clinical Genetics no–no (2011).
7. Recommendations for the diagnosis and management of Niemann-Pick disease type C: An update. 106, 
330–344 (2012).
8. Incidence of inborn errors of metabolism in British Columbia, 1969-1996. 105, e10 (2000).
9. De Duve, C. & Wattiaux, R. Functions of lysosomes. Annu. Rev. Physiol. 28, 435–492 (1966).
10. Imaging and imagination: understanding the endo-lysosomal system. 129, 253–266 (2008).
11. Boya, P. Lysosomal function and dysfunction: mechanism and disease. Antioxid. Redox Signal. 17, 766–774 
(2012).
12. Wraith, J. E. Lysosomal disorders. Semin Neonatol 7, 75–83 (2002).
13. Kolter, T. & Sandhoff, K. Lysosomal degradation of membrane lipids. FEBS Lett. 584, 1700–1712 (2010).
14. Kolter, T. & Sandhoff, K. Sphingolipid metabolism diseases. Biochim. Biophys. Acta 1758, 2057–2079 (2006).
15. Futerman, A. H. & van Meer, G. The cell biology of lysosomal storage disorders. Nat. Rev. Mol. Cell Biol. 5, 
554–565 (2004).
16. Staretz-Chacham, O., Lang, T. C., LaMarca, M. E., Krasnewich, D. & Sidransky, E. Lysosomal storage disorders 
in the newborn. Pediatrics 123, 1191–1207 (2009).
17. Kolter, T. A view on sphingolipids and disease. Chem. Phys. Lipids 164, 590–606 (2011).
18. Mandala, S. M. et al. Sphingoid base 1-phosphate phosphatase: a key regulator of sphingolipid metabo-
lism and stress response. Proc. Natl. Acad. Sci. U.S.A. 95, 150–155 (1998).
19. Seelan, R. S. et al. Human acid ceramidase is overexpressed but not mutated in prostate cancer. Genes 
Chromosomes Cancer 29, 137–146 (2000).
20. Wennekes, T. et al. Glycosphingolipids--nature, function, and pharmacological modulation. Angew. Chem. 
Int. Ed. Engl. 48, 8848–8869 (2009).
21. Psotka, M. A. et al. Shiga Toxin 2 Targets the Murine Renal Collecting Duct Epithelium. Infection and Immu-
nity 77, 959–969 (2009).
22. Lingwood, C. A. & Branch, D. R. The role of glycosphingolipids in HIV/AIDS. Discov Med 11, 303–313 (2011).
23. Byrne, B. J., Falk, D. J., Clément, N. & Mah, C. S. Gene therapy approaches for lysosomal storage disease: 
next-generation treatment. Hum. Gene Ther. 23, 808–815 (2012).
Fabry disease among the sphingolipidosis and inborn errors of metabolism
43
24. Lachmann, R. H. Enzyme replacement therapy for lysosomal storage diseases. Curr. Opin. Pediatr. 23, 
588–593 (2011).
25. Krivit, W. Allogeneic stem cell transplantation for the treatment of lysosomal and peroxisomal metabolic 
diseases. Springer Semin. Immunopathol. 26, 119–132 (2004).
26. Eto, Y., Shen, J.-S., Meng, X.-L. & Ohashi, T. Treatment of lysosomal storage disorders: cell therapy and gene 
therapy. J Inherit Metab Dis 27, 411–415 (2004).
27. Fan, J.-Q. & Ishii, S. Active-site-specific chaperone therapy for Fabry disease. FEBS Journal 274, 4962–4971 
(2007).
28. Fan, J.-Q. & Ishii, S. MINIREVIEW: Active-site-specific chaperone therapy for Fabry disease. FEBS Journal 274, 
4962–4971 (2007).
29. Venier, R. E. & Igdoura, S. A. Miglustat as a therapeutic agent: prospects and caveats. J. Med. Genet. 49, 
591–597 (2012).
30. Pastores, G. M. & Lien, Y.-H. H. Biochemical and molecular genetic basis of Fabry disease. J. Am. Soc. Nephrol. 
13 Suppl 2, S130–3 (2002).
31. Vedder, A. C. et al. Manifestations of Fabry disease in placental tissue. J Inherit Metab Dis 29, 106–111 
(2006).
32. De Francesco, P. N., Mucci, J. M., Ceci, R., Fossati, C. A. & Rozenfeld, P. A. Higher apoptotic state in Fabry 
disease peripheral blood mononuclear cells.: effect of globotriaosylceramide. Molecular Genetics and Me-
tabolism 104, 319–324 (2011).
33. Shen, J.-S. et al. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule 
expression in Fabry disease endothelial cells. Molecular Genetics and Metabolism 95, 163–168 (2008).
34. Biancini, G. B. et al. Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry 
patients treated with enzyme replacement therapy. Biochim. Biophys. Acta 1822, 226–232 (2012).
35. Hopkin, R. J. et al. Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr. 
Res. 64, 550–555 (2008).
36. Scriver, C. R. The metabolic and molecular bases of inherited disease. (McGraw-Hill Companies, 1995).
37. Meikle, P. J., Hopwood, J. J., Clague, A. E. & Carey, W. F. Prevalence of lysosomal storage disorders. JAMA 
281, 249–254 (1999).
38. Linthorst, G. E., Hollak, C. E. M., Donker-Koopman, W. E., Strijland, A. & Aerts, J. M. F. G. Enzyme therapy for 
Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 66, 1589–1595 (2004).
39. Lin, H.-Y. et al. Enzyme assay and clinical assessment in subjects with a Chinese hotspot late-onset Fabry 
mutation (IVS4 + 919G A). J Inherit Metab Dis 33, 619–624 (2010).
40. Spada, M. et al. High incidence of later-onset fabry disease revealed by newborn screening. Am. J. Hum. 
Genet. 79, 31–40 (2006).
41. Mechtler, T. P. et al. Neonatal screening for lysosomal storage disorders: feasibility and incidence from a 
nationwide study in Austria. Lancet 379, 335–341 (2012).
42. Tsutsumi, O. et al. Early prenatal diagnosis of inborn error of metabolism: a case report of a fetus affected 
with Fabry’s disease. Asia Oceania J Obstet Gynaecol 11, 39–45 (1985).
43. Ramaswami, U. et al. Fabry disease in children and response to enzyme replacement therapy: results from 
the Fabry Outcome Survey. Clinical Genetics (2011).doi:10.1111/j.1399-0004.2011.01671.x
Chapter 1
44
44. Hoffmann, B., Georg Koch, H., Schweitzer-Krantz, S., Wendel, U. & Mayatepek, E. Deficient α-galactosidase 
A activity in plasma but no Fabry disease – a pitfall in diagnosis. Clinical Chemistry and Laboratory Medicine 
43, 1276–1277 (2005).
45. Ries, M. & Schiffmann, R. Fabry disease: angiokeratoma, biomarker, and the effect of enzyme replacement 
therapy on kidney function. Arch Dermatol 141, 904–5; author reply 905–6 (2005).
46. Sheth, K. J. & Thomas, J. P. Electrocardiograms in Fabry’s disease. J Electrocardiol 15, 153–156 (1982).
47. Sheth, K. J., Werlin, S. L., Freeman, M. E. & Hodach, A. E. Gastrointestinal structure and function in Fabry’s 
disease. Am. J. Gastroenterol. 76, 246–251 (1981).
48. Orteu, C. H. et al. Fabry disease and the skin: data from FOS, the Fabry outcome survey. Br J Dermatol 157, 
331–337 (2007).
49. Zampetti, A. et al. Angiokeratoma: Decision Making Methodology for the Diagnosis of Fabry Disease. Br J 
Dermatol (2011).doi:10.1111/j.1365-2133.2011.10742.x
50. Ries, M. et al. The early clinical phenotype of Fabry disease: a study on 35 European children and adoles-
cents. Eur. J. Pediatr. 162, 767–772 (2003).
51. Najafian, B. et al. Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young 
patients with Fabry disease. Kidney Int 79, 663–670 (2010).
52. Tøndel, C., Bostad, L., Hirth, A. & Svarstad, E. Renal Biopsy Findings in Children and Adolescents With Fabry 
Disease and Minimal Albuminuria. American Journal of Kidney Diseases 51, 767–776 (2008).
53. Schiffmann, R. et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebro-
vascular events before enzyme replacement therapy. Nephrology Dialysis Transplantation 24, 2102–2111 
(2009).
54. Wanner, C. et al. Prognostic Indicators of Renal Disease Progression in Adults with Fabry Disease: Natural 
History Data from the Fabry Registry. Clinical Journal of the American Society of Nephrology 5, 2220–2228 
(2010).
55. Branton, M. H. et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and 
genetic mutations on clinical course. Medicine (Baltimore) 81, 122–138 (2002).
56. Ortiz, A. et al. Nephropathy in males and females with Fabry disease: cross-sectional description of patients 
before treatment with enzyme replacement therapy. Nephrology Dialysis Transplantation 23, 1600–1607 
(2008).
57. Branton, M., Schiffmann, R. & Kopp, J. B. Natural history and treatment of renal involvement in Fabry dis-
ease. J. Am. Soc. Nephrol. 13 Suppl 2, S139–43 (2002).
58. Meehan, S. M., Junsanto, T., Rydel, J. J. & Desnick, R. J. Fabry disease: renal involvement limited to podocyte 
pathology and proteinuria in a septuagenarian cardiac variant. Pathologic and therapeutic implications. 
American Journal of Kidney Diseases 43, 164–171 (2004).
59. Ortiz, A. et al. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry 
Registry. Nephrology Dialysis Transplantation 25, 769–775 (2010).
60. Linhart, A. et al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry 
outcome survey. European Heart Journal 28, 1228–1235 (2007).
61. Elliott, P. M. et al. Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and 
the effect of treatment with alpha galactosidase A. Heart 92, 357–360 (2006).
Fabry disease among the sphingolipidosis and inborn errors of metabolism
45
62. Germain, D. P. Fabry disease. Orphanet J Rare Dis 5, 30 (2010).
63. Kampmann, C. et al. The right ventricle in Fabry disease. Acta Paediatr Suppl 94, 15–8; discussion 9–10 
(2005).
64. Aryana, A., Fifer, M. A., Ruskin, J. N. & Mela, T. Short PR interval in the absence of preexcitation: a character-
istic finding in a patient with Fabry disease. Pacing Clin Electrophysiol 31, 782–783 (2008).
65. Namdar, M. et al. PQ Interval in Patients With Fabry Disease. Am. J. Cardiol. 105, 753–756 (2010).
66. Shah, J. S. et al. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am. J. 
Cardiol. 96, 842–846 (2005).
67. Fellgiebel, A., Müller, M. J. & Ginsberg, L. CNS manifestations of Fabry’s disease. Lancet Neurol 5, 791–795 
(2006).
68. Mehta, A. et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Out-
come Survey. Eur. J. Clin. Invest. 34, 236–242 (2004).
69. Fellgiebel, A. et al. Diagnostic utility of different MRI and MR angiography measures in Fabry disease. Neu-
rology 72, 63–68 (2009).
70. Sims, K., Politei, J., Banikazemi, M. & Lee, P. Stroke in Fabry disease frequently occurs before diagnosis and 
in the absence of other clinical events: natural history data from the Fabry Registry. Stroke 40, 788–794 
(2009).
71. Rombach, S. M. et al. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifesta-
tions of Fabry disease. Biochim. Biophys. Acta 1802, 741–748 (2010).
72. Mendez, M. F., Stanley, T. M., Medel, N. M., Li, Z. & Tedesco, D. T. The vascular dementia of Fabry’s disease. 
Dementia and geriatric cognitive disorders 8, 252–257 (1997).
73. Grewal, R. P. Psychiatric disorders in patients with Fabry’s disease. Int J Psychiatry Med 23, 307–312 (1993).
74. Low, M. et al. Neurology of Fabry disease. Intern Med J 37, 436–447 (2007).
75. Crosbie, T. W., Packman, W. & Packman, S. Psychological aspects of patients with Fabry disease. J Inherit 
Metab Dis 32, 745–753 (2009).
76. Germain, D. P., Benistan, K., Boutouyrie, P. & Mutschler, C. Osteopenia and osteoporosis: previously unrec-
ognized manifestations of Fabry disease. Clinical Genetics 68, 93–95 (2005).
77. Keilmann, A., Hajioff, D., Ramaswami, U.FOS Investigators Ear symptoms in children with Fabry disease: 
data from the Fabry Outcome Survey. Orphanet J Rare Dis 32, 739–744 (2010).
78. Wang, R. Y., Abe, J. T., Cohen, A. H. & Wilcox, W. R. Enzyme replacement therapy stabilizes obstructive 
pulmonary Fabry disease associated with respiratory globotriaosylceramide storage. J Inherit Metab Dis 31 
Suppl 2, S369–74 (2008).
79. Magage, S. et al. Natural history of the respiratory involvement in Anderson-Fabry disease. J Inherit Metab 
Dis 30, 790–799 (2007).
80. Bouwman, M. G. et al. Impact of growing up with Fabry disease on achievement of psychosocial mile-
stones and quality of life. Molecular Genetics and Metabolism 104, 308–313 (2011).
81. Cox-Brinkman, J. et al. Three-dimensional face shape in Fabry disease. Eur J Hum Genet 15, 535–542 (2007).
82. MacDermot, K. D., Holmes, A. & Miners, A. H. Anderson-Fabry disease: clinical manifestations and impact of 
disease in a cohort of 60 obligate carrier females. J. Med. Genet. 38, 769–775 (2001).
Chapter 1
46
83. Chao, C.-T., Yang, C.-C. & Kao, T.-W. Fabry disease: a rare cause of Fever of unknown origin. Am. J. Kidney Dis. 
59, 161–162 (2012).
84. Chimenti, C. et al. Cardiac and skeletal myopathy in Fabry disease: a clinicopathologic correlative study. 
Hum Pathol (2012).doi:10.1016/j.humpath.2011.09.020
85. Scheidt, von, W. et al. An atypical variant of Fabry’s disease with manifestations confined to the myocar-
dium. N. Engl. J. Med. 324, 395–399 (1991).
86. Nakao, S. et al. An atypical variant of Fabry’s disease in men with left ventricular hypertrophy. N. Engl. J. 
Med. 333, 288–293 (1995).
87. Nakao, S. et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a ‘renal 
variant’ phenotype. Kidney Int 64, 801–807 (2003).
88. Wilcox, W. R. et al. Females with Fabry disease frequently have major organ involvement: lessons from the 
Fabry Registry. Molecular Genetics and Metabolism 93, 112–128 (2008).
89. Mehta, A., Beck, M., Sunder-Plassmann, G., Ries, M. & Gal, A. Genotype–phenotype correlation in Fabry dis-
ease. (Oxford PharmaGenesis: Oxford, 2006).
90. Gal, A., Hughes, D. A. & Winchester, B. Toward a consensus in the laboratory diagnostics of Fabry disease - 
recommendations of a European expert group. J Inherit Metab Dis 34, 509–514 (2011).
91. Olivova, P. et al. Effect of sample collection on α-galactosidase A enzyme activity measurements in dried 
blood spots on filter paper. Clinica Chimica Acta 403, 159–162 (2009).
92. Reuser, A. J. et al. The use of dried blood spot samples in the diagnosis of lysosomal storage disorders-
-current status and perspectives. Molecular Genetics and Metabolism 104, 144–148 (2011).
93. Linthorst, G. E., Vedder, A. C., Aerts, J. M. F. G. & Hollak, C. E. M. Screening for Fabry disease using whole 
blood spots fails to identify one-third of female carriers. Clin. Chim. Acta 353, 201–203 (2005).
94. Gene action in the X-chromosome of the mouse (Mus musculus L.). 190, 372–373 (1961).
95. Elstein, D., Schachamorov, E., Beeri, R. & Altarescu, G. X-inactivation in Fabry disease. Gene 505, 266–268 
(2012).
96. Froissart, R., Guffon, N., Vanier, M. T., Desnick, R. J. & Maire, I. Fabry disease: D313Y is an alpha-galactosidase 
A sequence variant that causes pseudodeficient activity in plasma. Molecular Genetics and Metabolism 80, 
307–314 (2003).
97. Elstein, D., Altarescu, G. & Beck, M. Fabry Disease. (Springer Verlag, 2010).
98. Fabry Disease. (University of Washington, Seattle, 1993).at <http://eutils.ncbi.nlm.nih.gov/entrez/eutils/
elink.fcgi?dbfrom=pubmed&id=20301469&retmode=ref&cmd=prlinks>
99. Mignani, R. & Morrone, A. Is standard GLA gene mutation analysis definitive for the diagnosis of Fabry 
disease? Kidney Int 75, 1115–6; author reply 1115 (2009).
100. Sirrs, S. et al. Baseline characteristics of patients enrolled in the Canadian Fabry Disease Initiative. Molecular 
Genetics and Metabolism 99, 367–373 (2010).
101. Schirinzi, A. et al. Identification of GLA gene deletions in Fabry patients by Multiplex Ligation-dependent 
Probe Amplification (MLPA). Molecular Genetics and Metabolism 94, 382–385 (2008).
102. Eng, C. M., Resnick-Silverman, L. A., Niehaus, D. J., Astrin, K. H. & Desnick, R. J. Nature and frequency of 
mutations in the alpha-galactosidase A gene that cause Fabry disease. Am. J. Hum. Genet. 53, 1186–1197 
(1993).
Fabry disease among the sphingolipidosis and inborn errors of metabolism
47
103. Verovnik, F., Benko, D., Vujkovac, B. & Linthorst, G. E. Remarkable variability in renal disease in a large Slove-
nian family with Fabry disease. Eur J Hum Genet 12, 678–681 (2004).
104. Linthorst, G. E. et al. Screening for Fabry disease in high-risk populations: a systematic review. J. Med. Genet. 
47, 217–222 (2010).
105. Hwu, W.-L. et al. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset 
GLA mutation c.936+919G>A (IVS4+919G>A). Hum. Mutat. 30, 1397–1405 (2009).
106. Lin, H.-Y. et al. High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the 
Taiwan Chinese population. Circ Cardiovasc Genet 2, 450–456 (2009).
107. Ojo, A. et al. Excellent outcome of renal transplantation in patients with Fabry’s disease. Transplantation 69, 
2337–2339 (2000).
108. Inderbitzen N, D., Avital, I., Largiader, F., Vogt, B. & Cancidas, D. Kidney Transplantation Improves Survival 
and Is Indicated in Fabry’s Disease. Transplantation Proceedings 37, 4211–4214 (2005).
109. Ikeda, K. et al. Drug-induced phospholipidosis is caused by blockade of mannose 6-phosphate receptor-
mediated targeting of lysosomal enzymes. Biochem. Biophys. Res. Commun. 377, 268–274 (2008).
110. Pierre-Louis, B., Kumar, A. & Frishman, W. H. Fabry disease: cardiac manifestations and therapeutic options. 
Cardiol Rev 17, 31–35 (2009).
111. Dib RP, El, P. G. Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database of Systematic 
Reviews. 1–53 (2011).
112. Warnock, D. G. et al. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and 
timing of treatment initiation. Nephrology Dialysis Transplantation (2011).doi:10.1093/ndt/gfr420
113. Schiffmann, R. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal func-
tion in a home infusion setting. Nephrology Dialysis Transplantation 21, 345–354 (2005).
114. Germain, D. P. et al. Sustained, Long-Term Renal Stabilization After 54 Months of Agalsidase beta Therapy 
in Patients with Fabry Disease. Journal of the American Society of Nephrology 18, 1547–1557 (2007).
115. Pastores, G. M. et al. Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-
stage renal disease. Nephrology Dialysis Transplantation 22, 1920–1925 (2007).
116. Mehta, A. et al. Enzyme replacement therapy with agalsidase alfa in patients with Fabry’s disease: an analy-
sis of registry data. The Lancet 374, 1986–1996 (2009).
117. Sirrs, S. & Alfadhel Enzyme replacement therapy for Fabry disease: some answers but more questions. 
TCRM 69 (2011).
118. Eng, C. M. et al. Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in 
Fabry’s disease. N. Engl. J. Med. 345, 9–16 (2001).
119. Schiffmann, R. et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 
285, 2743–2749 (2001).
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in High-Risk Populations
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In order to detect index patients and to estimate the prevalence of Fabry disease in Flanders, we screened in total 2135 patients belonging to three high risk-
populations: hemodialysis patients, kidney transplant 
recipients and patients with left ventricular hypertrophy.
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Paper One
Two-tier approach for the detection of alpha galactosidase A 
deficiency in a predominantly female haemodialysis population
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Abstract
Introduction. Fabry’s disease (AFD) is an X-linked lysosomal storage disease, resulting from 
a deficiency in alpha-galactosidase A (Α-Gal A). Untreated, this leads to precocious failure 
of vital organ function and death. As enzyme replacement therapy is available, it is of vital 
importance that affected individuals can be traced.
Materials and methods. We set up a screening in the Flemish haemodialysis population us-
ing a two-tier approach. The first tier was a determination of alpha- galactosidase A activity 
using a dried blood spot on filter paper, in the second tier, patients with the lowest alpha-
galactosidase levels were further subjected to mutation analysis of the GLA gene.
Results. 1284 patients (1047 women, 237 men) were evaluated for inclusion, eliminating pa-
tients with definite renal diagnoses. Total 922 patients (71.8 %) were screened (742 women, 
180 men). Fifty seven patients were subjected to further genetic analysis. Three GLA mu-
tation carriers were identified: two apparently nonrelated female patients carry the mis- 
sense mutation p.Ala143Thr (c.427G > A), a missense mutation p.Trp236Arg (c.706T > C) 
was identified in a man. While the male patient had been clinically diagnosed with AFD, the 
female patients had remained unrecognized. Additional family based screening resulted in 
the identification of nine mutation carriers (four males and five females).
Discussion. We demonstrated that the prevalence of GLA mutation carriers in our haemodi-
alysis population is 0.3%. Our results show that the proposed approach accurately detects 
AFD patients. We conclude that screening for AFD in high risk populations is a cost-effective, 
technically feasible and clinically valuable objective.
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Introduction
Fabry disease (AFD) is an X-linked sphingolipidosis resulting from a quantitative or functional deficiency in alpha-galactosidase A (Α-Gal A) [1,2]. Its reported incidence ranges from 1/40 000 to 1/117 000 live births [3,4]. This enzyme defect leads to mul-
tiple organ dysfunction; in childhood, the invalidating neuropathic pain predominates. As 
from the second decade of life, renal, cardiac and neurological symptoms become apparent 
[4]. Due to its mode of inheritance, all affected males develop clinical symptoms; as a result 
of skewed lyonisation female carriers can develop the entire spectrum from asymptomatic 
carriers to classical AFD [5–7].
Several reports indicate that AFD is an underdiagnosed disease entity. This can be at-
tributed to various factors. First, clinical awareness might be low in atypical presentations. 
In addition, an overrepresentation of female relatives can obscure signs and symptoms in a 
condition with X-linked inheritance. Finally, the identification of genetic aberrations with a 
reduced penetration or variant phenotype is anticipated from increasingly sensitive screen-
ing analyses.
With the introduction of a safe and efficacious treatment for AFD, the implementation of 
screening programs in high risk populations seems a clinically relevant objective. Identifica-
tion of index cases in this setting often leads to detection of affected family members and 
opens possibilities for early enzyme replacement therapy.
We set up a community-wide screening program in Flemish haemodialysis centres, 
based on a two-tier approach: initial screening for α-Gal A deficiency using the dried blood 
spot technique (DBFP) [22], followed by standard genetic GLA gene mutation analysis of the 
high-risk persons identified in the first part of the study.
Materials and methods
Patient selection
The NBVN (Nederlandstalige Belgische Vereninging voor Nefrologie; a nephrology soci-
ety grouping all 27 Flemish dialysis centres) database was used for patient selection. This 
database contains regularly updated diagnostic data on all Flemish haemodialysis patients 
(n = 2828 at the moment of inclusion), and also specifies the strength of evidence for these 
diagnostic data. Haemodialysis patients without biopsy-proven renal diagnosis or without 
evident reason for dialysis requirement (e.g. polycystic kidney disease, bilateral nephrec-
tomy) were considered. Type 2 diabetes was not an exclusion criterion. Both genders were 
included, however with different age criteria: women older than 18 years (no upper age 
limit) and men between 18 and 60 years (at the moment of study) were included. In this 
patient group, one male patient was known to have AFD.
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Determination of α-Gal A using the technique of dried blood spot sampled in filter paper
The screening test was based on a technique of a dried blood spot sampled in filter paper 
(DBFP) as described by Chamoles et al. [22]. In brief, a standardized disc was punched out of 
the filter paper and consequently incubated at physiologic pH and at 37°C with 4-methyl-
umbelliferyl- a-galactopyranoside as substrate. Enzyme activity renders the enzyme prod-
uct 4-methyl umbelliferone (4-MU), a fluorescent molecule. The fluorescence (excitation, 
365 nm; emission, 450 nm) was measured on a Thermo Life Science fluorometer (Thermo 
Electron Corporation, Waltham, MA-USA). The fluorescence readings were corrected for 
blanks, and the results were compared with the fluorescence from a 4-methylumbelliferone 
calibrator. Enzymatic activities were expressed as micromoles of substrate hydrolysed per 
litre of blood per hour. To validate this technique in our laboratory setting, we performed 
an analysis of 50 patient samples (non-nephrology, non-ICU, non-haematology, non-paedi-
atric). Results were compared with literature data available. Each DBFP test for α-Gal A was 
validated by measurement of b-galactosidase; if no b-galactosidase activity was detectable 
in the DBFP test, the sample was rejected.
Determination of α-Gal A in white blood cells
Where appropriate, determination of α-Gal A levels in white blood cells were determined 
using the technique previously described by Desnick et al. [23].
Cut-off value for DNA mutation analysis
Because of the different distribution in the α-Gal A test results (see later) no cut-off value 
was used to select which patients could enter the second level of our two-tier screening 
analysis (mutation analysis). Instead, we performed mutation analysis of the GLA gene in 
patients within the lowest sixth percentile. This value was arbitrarily chosen, taking into 
consideration the feasibility and costs of the second tier of our protocol.
DNA mutation analysis
Genomic DNA was extracted from EDTA blood of the patients by standard protocols 
(PUREGENE DNA purification kit, Gentra) according to manufacturer’s instructions. Muta-
tion analysis was performed by PCR amplification followed by direct sequencing of the sev-
en exons and flanking intronic sequences of GLA (Genbank: X14448.1- genomic). Primers 
used were modified from Eng et al. [24].
Informed consent and ethics
The study protocol was approved by the Ethics committee of the Ghent University Hos-
pital and all patients gave written or oral witnessed consent to participation. The study pro-
tocol is in accordance with the Declaration of Helsinki.
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Results
Patient selection
All but one haemodialysis centre participated in the screening study (n = 26). From the 
2828 patients in the database, 1284 (1047 women, 237 men) were selected after applica-
tion of the inclusion criteria. Eventually, after informed consent, 922 patients (71.8%) were 
screened (742 women, 180 men).
α-Gal A levels in the control population
DBFP analysis of the 50 controls yielded a mean α-Gal A of 3.17 ± 1.6 mmol/l/h (2.5 and 
97.5 percentile were 1.62 and 8.39 mmol/l/h, respectively). This is in accordance with lit-
erature data showing mean α-Gal A in healthy males of 2.93 ± 1.7 mmol/l/h (2.5 and 97.5 
percentile were 1.37 and 7.66 mmol/l/h, respectively).
α-Gal A levels in the screening population
DBFP analysis of the 922 haemodialysis patients yielded a mean α-Gal A of 1.57 ± 1.5 
mmol/l/h (2.5 and 97.5 percentile were 0.0001 and 5.07 mmol/l/h, respectively). This was 
significantly lower than the activity in the control group. This difference in α-Gal A was con-
firmed by performing a determination of α-Gal A on white blood cells: in 31 haemo- dialysis 
patients the mean enzyme activity was 3.67 ± 1.2 mmol/l/109 WBC (2.5 and 97.5 percentile 
were 1.37 and 5.77 mmol/l/109 WBC, respectively); in 50 healthy individuals the mean en-
zyme activity was 5.43 ± 2.2 mmol/l/109 WBC (2.5 and 97.5 percentile were 2.07 and 9.91 
mmol/l/109 WBC, respectively) (Figure 2.1). Neither gender nor presence of b-galactosidase 
had any influence on this difference.
DNA mutation analysis
Fifty-seven patients were subjected to further genetic analysis. Two non-related female 
patients were found to carry the p.Ala143Thr (c.427G>A) missense mutation, Another mis-
sense mutation p.Trp236Arg (c.706T>C) was found in a male patient who was already diag-
nosed with AFD before the start of the study. Both missense mutations are pathogenic and 
have been reported previously in AFD patients [25,26].
Clinical correlation and family screening
Index patient 1 (elaborate pedigree is shown in Figure 2.2) was 74 years old on her first 
admission to the hospital participating in the screening program. She was known to have 
chronic hypertension and had a creatinine of 87 mmol/l 1 year before admission. On admis-
sion, she presented with cardiac angina. At that time, she had nephrotic range proteinuria 
(11 g/l) and renal insufficiency (creatinine 407 mmol/l). As she refused kidney biopsy, the 
renal insufficiency was attributed to nephrangiosclerosis and the frequent use of non-ste-
roidal anti-inflammatory drugs. The further work-up revealed she had left ventricular hyper-
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Figure 2.1.  α-Gal A activity in WBC in the control population and the dialysis patients.
Figure 2.2.  Pedigree of index patient  1; the index patient  is marked  by an oblique arrow.
trophy with a septum thickness of 15 mm on the first and 17 mm on the second echocardi-
ography. Also, during hospitalization she developed a homonymous quadrant anopsy with 
CT imaging suggestive of an ischaemic lesion in the left occipital region. The patient has 
since been in dialysis (for >5 years now) without major problems. When elaborating the pa-
tient’s history further, she revealed that after her first pregnancy (still birth), she developed 
invalidating pain in her lower limbs which, although not completely fitting the description 
of acroparesthesia, may be related to her underlying condition. The only additional clini-
cal information on this family that is available is the phenotype of the 41-year-old nephew 
(Figure 2.2). This patient was found to have the mutation, but did not have any clinical sign 
of AFD: no symptoms, no cardiac and brain MRI abnormalities, normal renal biopsy, no pro-
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teinuria, normal renal function, normal echocardiography).
Index patient 2 (elaborate pedigree is shown in Figure 2.3) presented with cardiac angina 
at the age of 64. A coronarography showed three-vessel disease. At that time, renal function 
was normal, there was no proteinuria. A coronary arterial bypass grafting (CABG) was per-
formed. Seventeen years later, she was referred again for cardiac angina. Coronarography 
showed recurrence of coronary ischaemia and aortic valve sclerosis. At that time, creatinine 
had risen to 168 mmol/l, there was no proteinuria. Imaging revealed she had an atrophic 
left kidney, and a right renal artery stenosis. The latter was dilated, and she underwent an-
Figure 2.3.  Pedigree of index patient 2; the index patient is marked by an oblique arrow.
other CABG. The renal insufficiency was attributed to nephrangiosclerosis and ischaemic 
nephropa- thy. The renal insufficiency deteriorated, and the patient was started on chronic 
haemodialysis. Echocardiography performed on multiple occasions never showed left ven-
tricular hypertrophy, nor were there signs of cerebral ischaemia. She died of cardiac arrest 
during dialysis. It is not clear whether the renal failure in this patient can be attributed to 
AFD; as the patient did not have proteinuria and taking into account the stenosis of the 
right renal artery and the atrophic left kidney, an alternative aetiology (renal ischaemia and 
vascular kidney disease) seems at least as likely. No additional clinical information is avail-
able on the other affected family members.
The third index patient had already been diagnosed with Fabry disease before the 
screening project, and had classical AFD.
Overall we screened 17 relatives of the two newly found index patients, which resulted 
in the identification of four male hemizygotes and five female heterozygotes (Figures 2.2 
and 2.3). Clinical evaluation and therapeutic counselling is ongoing and will be reported 
elsewhere.
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Discussion
A screening programme for a rare genetic disease is time-consuming and expensive. 
Therefore, some prerequisites are indispensable: confinement of the screening to a well-de-
fined population subgroup with a higher risk for the presence of the disease, the availability 
of a cheap and sensitive test method and the possibility to offer therapeutic and genetic 
counselling after a diagnosis is made [27].
Given the incidence data reported in literature [3,4], the number of patients carrying 
a mutation in the GLA gene in Flanders ranges from 50 to 150. In end-stage renal disease 
(haemodialysis subgroup), however, a much higher prevalence has been reported, ranging 
from 1.17% in Japan (exclusively men) [12], 0.22% in the Netherlands (exclusively men) [11] 
to 0.16% and 0.20% in Austria and the Czech Republic (both genders) [13,32]. Hence, based 
on literature data at least four GLA mutation carriers should theoretically be present in the 
Flemish dialysis population (n = 2828).
In the current report, we evaluated the clinical utility and the biochemical and molecular 
efficacy of a two-tier approach for AFD screening in haemodialysis patients without a defi-
nite renal diagnosis. It should be pointed out that excluding patients with a biopsy-proven 
renal diagnosis, leaves the possibility that some of the renal pathologists reading the biop-
sies might have overlooked the possibility of AFD.
We took advantage of the well-documented registry of our dialysis society to eliminate 
patients with a biopsy-proven renal diagnosis from the screening programme. The principle 
of the two-tier approach in this study was to further narrow down the number of patients 
using the relatively sensitive DBFP technique and then to submit these selected patients to 
the golden standard of mutation analysis.
Both genders were included in the screening protocol. Taking into consideration the 
knowledge on the natural history of Fabry disease [28,29] at the time of the study design, 
an upper age limit of 60 years in men was adopted. Meanwhile, however, Nakao et al. [12] 
reported ‘renal variants’ in older dialysis patients without classical symptoms. Hence, retro-
spectively, it would have been better to include the older male patient population. In wom-
en however, no upper age limit was applied, as skewed lyonisation can cause one organ to 
be severely affected, whereas other organs can be relatively spared [5]. As a consequence, 
in the relatively old Flemish haemodialysis population (mean age 68.8 years), more women 
than men were subjected to our screening protocol. In male haemodialysis patients our 
study may be underpowered to obtain representative results.
We decided to include and even focus on women in our screening programme, keeping 
in mind the major limitations of the DBFP test in this patient group.
Linthorst et al. [30] recently demonstrated that one-third of the female carriers are 
missed using this test method. Currently no cost-effective alternatives can be applied in 
daily practice. Whereas in men a low α-Gal A activity is diagnostic for Fabry disease, the only 
way to make the definite diagnosis in women is through mutation analysis. This is time-
consuming and expensive, hence beyond the scope of a screening programme. Given the 
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poorer sensitivity of our DBFP test in women, we were still able to detect two patients that 
would not have been detected by excluding them completely from the screening protocol.
The DBFP results in all haemodialysis patients tested were somewhat surprising, as the 
enzyme activity was significantly lower than the reference value in literature [13,22] and 
that obtained from our own reference population (these last two were not significantly 
different). This difference was again confirmed by sampling of α-Gal A enzyme activity in 
WBC, both in 50 control samples and 31 samples obtained from haemodialysis patients. 
This contrasts with literature data: in the Dutch screening study, previously frozen whole 
blood samples were examined using a similar fluorescence technique. Values obtained 
were more than 10-fold higher, however excitation and emission spectra were different and 
no reference values were given [11]. In the Japanese screening study [12], plasma activity 
was measured using the same fluorescence technique, with resulting values in the range 
comparable to that of healthy controls. However, no whole blood samples were examined 
from the screened population. Finally, in the Austrian nationwide screening [13], no data 
are available on the distribution of enzyme activity in comparison with that of a control 
popula tion. Our study demonstrated a remarkable and significantly lower enzyme activity 
in whole blood samples taken from dialysis patients, than in those taken from controls or 
found in literature data.
We excluded interference of uraemic toxins with our fluorescence method by determin-
ing the enzyme activity in WBC, which rendered similar results. Blood samples were taken 
before dialysis start, before patients had received anticoagulation. Further research in this 
field is needed to determine which factor is responsible for this decreased enzyme activity 
in patients on dialysis.
In adopting a two-tier approach in the protocol we tried to reduce the costs of the 
screening program. The costs of a single blood spot analysis in our centre is 5 euro, hence 
the first tier of the screening protocol costed 4610 euro. The second tier (genetic analysis) 
is more costly (300 euro per genetic analysis), but the total number of patients to be ex-
amined was reduced by the first tier. The second tier of the screening protocol costed 17 
100 euro. Hence, the total screening cost was 21710 euro. Had we ideally screened all male 
patients by a blood spot analysis and all female patients by a mutation analysis, the cost of 
our screening study would have amounted to (5 x 180) + (300 x 742) = 223 500 euro, result-
ing in more than a 10-fold increase in costs. Extrapolating this to all haemodialysis patients, 
this would have been even more accentuated. We considered our screening methods as 
the most cost-efficient, taking into account that according to Linthorst et al. we may have 
missed one third of the female patients and taking into account that we may have missed 
some older male patients and some patients with a biopsy-proven renal diagnosis.
Our results confirm the performance of the adopted methodology in detecting GLA mu-
tations, even in atypical clinical settings. While the male patient carrying the p.Trp236Arg 
was known with AFD, the p.Ala143Thr, previously reported in later-onset patients (e.g. [31]) 
and showing a considerable amount of transient expression in lysosomes [26], was detect-
ed in female patients, unsuspected of having AFD.
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Therefore screening efforts are expected to result in the detection of GLA mutations in 
patients presenting with variable phenotypes, even – as we demonstrated – in those with 
an attenuated phenotype.
The issue should be raised how not to miss the diagnosis in the future in these patients 
presenting with a non-classical pattern. In retrospect, in the first index patient some find-
ings might have triggered the diagnosis of AFD; renal failure, left ventricular hypertrophy, 
cerebral thrombosis, lower limb pain. However, in this setting, the working hypothesis of 
polyvascular disease was at least as acceptable, keeping in mind the respective incidences 
of these affections. The second index patient illustrates that AFD may easily be missed, and 
even be impossible to diagnose, without a screening program.
Clearly, in individual patients it is of pivotal importance to detect the disease as early as 
possible in its natural course. By then, some useful interventions can still be made to slow 
down, stabilize, or even reverse the end-organ damage. Given the low incidence of AFD, 
this will always remain problematical – even more so in patients with attenuated pheno-
types. Only well-established population and physician information campaigns can help to 
improve the awareness of AFD and its symptoms. One step further, it is more rewarding 
to screen high-risk groups (renal failure, hyperthrophic cardiomyopathy, cerebrovascular 
dis- ease). Steps should be undertaken to implement routine measurements of α-Gal A in 
these patients, supported by recommendations in national and international guidelines. As 
an illustration, in the Flemish ESRD patients, we are planning to perform a measurement 
of α-Gal A as a standard procedure when entering our registry. This could give us the op-
portunity to prospectively detect possible AFD carriers, which is even more useful than the 
trans- sectional study we performed in this report. Although finding an index patient in this 
late stage of disease is less advantageous for the patient him/herself, it is certainly useful to 
detect family members in earlier stages.
AFD leads to vital organ failure and early death if untreated in men [29]. In women, the 
phenotype is largely dependent on lyonisation and the entire clinical spectrum is possi-
ble [5]. Given the multi-system involvement of the disease in adulthood (central nervous 
system, heart, kidney), and the high costs of lifelong enzyme replacement therapy (ERT), 
we advocate the centralization of data on the natural history of the disease and on effect 
of treatment on different organ systems. The two-tier approach – suitable for the current 
setting – may in the future be substituted by a one-tier approach once high-through- put 
mutation analysis becomes readily available. In addition, a state-of-the art treatment should 
not only focus on ERT alone, but should be holistic in preventing disease progression by de-
livering basic support when needed. Further steps are taken to extend our present screen-
ing programme to transplanted patients and patients on peritoneal dialysis. It might also 
be considered to screen for AFD in patients with mild to moderate renal function impair-
ment. The diagnosis of AFD in these patients might be even more vital as adequate enzyme 
replacement therapy and standard supportive measures might stabilize or slow down the 
progression to end-stage renal disease in this group.
To date the first index patient is not treated by enzyme replacement therapy. This deci-
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sion was made by the treating physicians based on her age and moderate phenotype (apart 
from the renal and cardiac involvement). However, her prominent left ventricular hypertro-
phy might warrant enzyme treatment. The usefulness and effect of ERT on morbidity and 
mortality in a dialysis population over 80 have not been substantiated in a large series and 
opens the discussion on treatment options in this type of patient. As further observational 
studies will be needed to provide us with the answer to this question, we suggest in the 
meantime make the decision on ERT initiation based on the clinical patient status and the 
expected survival on dialysis, even without AFD.
As mentioned, the second index patient died. We have no further information on the 
treatment of affected family members
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Paper Two
Two-tier approach for the detection of alpha-galactosidase A 
deficiency in kidney transplant recipients
De Schoenmakere G, Poppe B, Wuyts B, Claes K, Cassiman D, Maes B, 
Verbeelen D, Vanholder R, Kuypers DR, Lameire N, De Paepe A, Terryn W. 
Nephrol Dial Transplant. 2008 Dec;23(12):4044-8
Abstract
Background. Anderson-Fabry disease (AFD) is an Xlinked condition originating from a defi-
ciency in alphagalactosidase, a lysosomal enzyme. Multi-organ involvement ensues in early 
adulthood and vital organs are affected: the kidneys, brain, heart. Several reports however 
suggest that AFD is underdiagnosed.
Methods. We screened a kidney transplant population using a two-tier approach. The first tier 
was the determination of alpha-galactosidase A (α-Gal A) activity using a dried blood spot 
on filter paper (DBFP); in the second tier, patients with the lowest alpha-galactosidase levels 
were further subjected to mutation analysis of the GLA gene.
Results. From the database of 2328 patients, 1233 subjects met the inclusion criteria. Finally, 
after informed consent, 673 patients were screened (54.5% – 395 women and 278 men). 
DBFP analysis resulted in a mean α-Gal A of 2.63 ± 2.48 μmol/L/h (2.5 and 97.5 percentile 
were 0.0001 and 5.07 μmol/L/h, respectively). Eleven patients were subjected to further ge-
netic analysis. In a male patient a pathogenic missense mutation p.Ala143Thr (c.427A>G) 
was identified.
Conclusions. Our results show that the proposed approach can detect AFD patients in a un-
til now seldomly screened high-risk group: kidney transplant patients. We conclude that 
screening for AFD in high-risk populations is a cost-effective, technically feasible and clini-
cally valuable objective.
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Introduction
Anderson-Fabry disease (AFD) originates from a deficiency in alpha-galactosidase A (α-Gal A), a lysosomal enzyme. This leads to the accumulation of glycosphin-golipids (compounds with a biological role in membrane structure, modulation of 
membrane protein function and cell-cell recognition) intracellularly in the lysosomes [1,2]. 
The disease is X-linked and various incidence rates of the classical phenotype have been 
reported ranging from 1/40 000 to 1/117 000 live births [3,4]. 
Following the glycosphyngolipid accumulation in various cell types, multi-organ involve-
ment ensues and vital organs are affected: the kidneys, brain, heart. Dysfunction of these 
systems leads to considerable morbidity and increased mortality [4]. This clinical evolution 
is a continuum with a predominance in childhood of neuropathic pain and heat intolerance 
[5] to organ dysfunction in adolescence or adult age. It should however be pointed out that 
even children can present with classical signs of AFD. Due to its mode of inheritance, affect-
ed males develop clinical symptoms [4]; as a result of skewed lyonization, female carriers 
can develop the entire spectrum ranging from asymptomatic carriers to classical AFD [6–8].
AFDis however an underdiagnosed entity, aswas demonstrated by screening studies 
performed in high-risk populations, such as patients on dialysis [9–13], patients with hyper-
trophic cardiomyopathy [14–17] and patients with cerebrovascular accidents at younger 
age [18,19]. Moreover, Spada et al. undertook a newborn screening by assaying the α-Gal A 
activity in blood spots from 37 104 consecutive Italian male neonates. Identification of 12 
neonates with a low α-Gal A and corresponding mutations in the gene encoding α-Gal A 
and subsequent family screening led to an incidence of 1 in 4600 in this population, with a 
predominance of later onset disease over the classical presentation [20]. Hence, care should 
be taken in interpreting previously reported incidence rates (often referring to the classical 
presentation of AFD).
In recent years a safe and efficacious treatment for AFD (enzyme replacement thera-
py; ERT) became available [21,22]. As a consequence, implementation of screening pro-
grammes in high-risk populations now seems a clinically relevant objective. Identifying in-
dex cases is not only of vital importance to these patients, but also to their family members, 
offering them the opportunity to be treated by ERT in an earlier disease stage. Following the 
successful screening by our group in haemodialysis patients [13], we extended our study to 
a risk group for Fabry disease for which data are scarce [30]: kidney transplant patients. We 
set up a community-wide screening programme in kidney transplant patients, based on a 
two-tier approach [23]: initial screening for α-Gal A deficiency using the dried blood spot 
on filter paper (DBFP) technique [13,24], followed by standard genetic GLA gene mutation 
analysis of the high-risk persons identified in the first part of the study [2].
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Materials and methods
Patient selection
In Flanders (the Dutch-speaking part of Belgium), the inventory of dialysis and transplant 
patients iswell structured. The NBVN (Nederlandstalige Belgische Vereniging voor Nefrolo-
gie; a nephrology society grouping all 27 Flemish nephrology centres) issues a regularly 
updated database containing renal diagnosis, as well as the strength of evidence for this 
diagnosis. By the time of the start of this AFD screening study, 2328 patients were in the fol-
lowup in one of the 27 Flemish nephrology centres after a successful transplantation (www.
nbvn.be). Those patients without biopsy-proven renal diagnosis or without clear reason for 
renal failure in their history prior to transplantation (e.g. autosomal dominant polycystic 
kidney disease, bilateral nephrectomy for kidney tumours) were enrolled. Given the prev-
alence of diabetes among patients with endstage renal disease, the latter were included 
in the screening provided they further complied with the inclusion criteria. Both genders 
older than 18 years were considered, without an upper-age limit. No known Fabry patients 
were enrolled. 
Determination of α-Gal A activity using the technique of dried blood spot sampled on filter 
paper 
The screening test was based on a technique as described by Chamoles et al. [24]. In 
brief, a 3.2-mm disc was punched and incubated at pH 4.4 and at 37°C with 4-methyl um-
belliferyl-alpha-galactopyranoside as substrate and N-acetyl-D-galactosamine as inhibitor 
for alpha-galactosidase B. Enzymatic activities measured on a Thermo life science fluorom-
eter (Thermo Electron Corporation,Waltham, MA, USA) were expressed as micromoles of 
substrate hydrolyzed per litre of blood per hour. This technique was previously validated 
in our laboratory as reported elsewhere [13]. Each DBFP viability was verified by measure-
ment of beta-galactosidase; if beta-galactosidase activity was decreased in the DBFP test, 
the sample was rejected.
Determination of α-Gal A in white blood cells
Where appropriate α-Gal A levels in white blood cells were determined using the tech-
nique previously described by Desnick et al. [2].
Cut-off value for DNA mutation analysis
The lower cut-off limit for α-Gal A in our laboratory was set at 0.64 μmol/L/h. All samples 
with activity levels below this threshold were re-examined and sample viability was verified 
using beta-galactosidase. If this rendered a too low value (normal lower cut-off limit for 
beta-galactosidase in our laboratory is 9.1 μmol/L/h), the sample was rejected. All samples 
with a low alpha-galactosidase and a normal beta-galactosidase were subjected to DNA-
mutation analysis.
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DNA mutation analysis
Genomic DNA was extracted from EDTA blood of the patients by standard protocols 
(Puregene DNA purification kit, Qiagen, Dusseldorf, Germany) according to the manufactur-
er’s instructions. Mutation analysis was performed by PCR amplification followed by direct 
sequencing of the seven exons and flanking intronic sequences of GLA (Genbank: X14448.1-
genomic). Primers used were modified from Eng et al. [25]. 
To exclude the presence of single- and multi-exon deletions in female patients, ML-
PAanalysis (multiplex ligationdependent probe amplification) (MRC Holland, P159) was 
performed. Our mutation detection strategy allows us to obtain a mutation detection fre-
quency in male and female patients of 100%.
Informed consent and Ethics
The study protocolwas approved by the Ethics committee of the Ghent University Hospi-
tal and all patients gave written or oral witnessed consent prior to participation. The study 
protocol is in accordance with the Declaration of Helsinki.
Results
Patient selection
Twenty nephrology units (74% of the total) participated in the screening study. From the 
database of 2328 patients, 1233 subjects met the inclusion criteria. Finally 673 patients gave 
informed consent and were screened (54.5% – 395 women and 278 men).
α-Gal A levels in the screening population (blood spot technique)
DBFP analysis of the 673 transplant patients resulted in a mean α-Gal A of 2.63 ± 2.48 
μmol/L/h (2.5 and 97.5 percentile were 0.0001 and 5.07 μmol/L/h, respectively). 
DNA mutation analysis
Based on the above-mentioned criteria, 11 patients with low α-Gal A (2 men and 9 
women) were subjected to further genetic analysis. In one male patient, the p.Ala143Thr 
(c.427A>G) missense mutation was identified.
Clinical correlation and family screening
This 67-year-old male index patient started chronic haemodialysis therapy at the age 
of 33 because of stage 5 chronic kidney disease (CKD) without known renal diagnosis (no 
histological diagnosis). Prolonged dialysis therapy was complicated by secondary (β2-
microglobulin) amyloidosis manifested by bilateral carpal tunnel syndrome. At the age of 
42 the patient suffered an ischaemic stroke; clinical recovery was incomplete with a residual 
mild left-sided hemiparesis. Fourteen years after dialysis initiation, he was transplanted with 
a renal allograft from a deceased donor. At present, 20 years later, the patient has remained 
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rejection free; renal allograft function is stable with a plasma creatinine concentration of 
1.34 mg/dL and a calculated glomerular filtration rate of 45 mL/min. Proteinuria is absent 
while the urinary sediment is normal. Maintenance immunosuppressive therapy still con-
sists of cyclosporin microemulsion (NeoralTM, Novartis, Basel, Switzerland), azathioprine 
(ImuranTM, GlaxoSmithKline, Genval, Belgium) and corticosteroids (MedrolTM, Upjohn, 
Diegem, Belgium). Thirteen years posttransplantation, at 60 years of age, a bilateral ne-
phrectomy of the native kidneys was performed because of multifocal mixed-type renal 
cell carcinoma (RCC) comprising partly a papillary (chromophilic) type and an eosinophilic 
variant of the clear cell type (staging T1aN0M0). This was recently reported by Cassiman et 
al. [26]. Further posttransplant complications included arterial hypertension, hypercholes-
terolaemia, osteoporosis, bilateral cataracts and inguinal hernia with surgical repair. In 2005, 
the patient was treated for a paroxysmal supraventricular tachycardia with a beta-blocker 
(sotalol) but the latter had to be promptly stopped because of severe bradycardia and bifas-
cicular conduction block. In 2006, a left-sided rolandic meningioma was diagnosed because 
of transient headaches; a conservative strategy was advised, postponing neurosurgical in-
tervention in case of signs of motoric dysfunction or radiological progression. In retrospect, 
symptoms and signs that could have suggested AFD were absent in this patient: there was 
no history of neuropathic limb pain, no typical skin lesions (telangiectasias, angiokerato-
mas) nor corneal alterations (cornea verticillata). The development of stage 5 CKD in the 
third life decade concurs with AFD-related kidney disease but histological examination of 
the non-malignant renal tissue obtained after bilateral nephrectomy showed chronic glo-
merulonephritis, hyalinization and severe arteriosclerosis, but no lesions typical for Fabry 
disease. Of course, these non-specific histological lesions found almost 30 years after the 
development of ESRD do not exclude the earlier presence of specific AFD-related changes. 
Cardiac involvement might have been suspected based on the echocardiographic findings 
revealing hypertrophy of the interventricular septum with normal systolic and diastolic left 
ventricular function. In this regard however, other possibly contributing factors to the sep-
tal hypertrophy not related to AFD should be taken into consideration, e.g. volume overload 
during dialysis, episodes of arterial hypertension. In addition, a typical thickened hyper-
echogenic layer [27], representing intracellular (sub)endocardial glycosphingolipid deposi-
tion, could not be clearly identified. The bifascicular block induced by a low dose of beta-
blocker was only in retrospect suggestive of AFD-related cardiac conductive abnormalities. 
While the occurrence of ischaemic stroke at a young age is a common sign of neurological 
involvement in AFD, no typical or suggestive MR signs, like T1-weighted hyperintensity in 
the pulvinar (thalamus) [28], could be identified on repetitive brain imaging.
An extensive analysis of the family history was not helpful in establishing the presence 
of clinical AFD. The patient’s mother died at the age of 91 years while the father died at age 
63 years. Neither parent was known to have neurological, cardiac or renal disease. The pa-
tient’s siblings (one brother of age 62 years and one sister of age 68 years) have no medical 
problems suggestive of AFD. However, the p.Ala143Thr (c.427A>G) missense mutation was 
detected in the sister (asymptomatic carrier) while the brother was confirmed to be non-
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carrier (Figure 2.4). The son of the former has a clearly reduced α-Gal A activity [<0.05 μmol/
L/h (0.64–3.82)]; genetic testing is pending. The patient has one son (age 42 years) with 3 
grandchildren (females: twins of 9 years, 12 years) and one daughter (age 43 years) with one 
grandson (age 23 years). The 43-year-old daughter was confirmed to carry the p.Ala143Thr 
(c.427A>G) missense mutation. Her son (23 years) has not been tested yet. None of these 
family members has AFD-related signs or symptoms. Despite the delayed diagnosis, treat-
ment with recombinant human α-Gal A is planned for the index patient. The results of his 
genetic confirmation test being pending, the nephew (37 years) of our index patient has a 
50% risk of inheriting the mutation of the respective mother.
Discussion
AFD is a rare genetic disorder [3,4], initially characterized by discrete and often non-spe-
cific signs and symptoms [5], with a natural evolution and progression often leading to vital 
organ failure. Although the clinical awareness for this disease has increased significantly 
in the last few years, systematic detection of carriers remains worthwhile. Screening entire 
populations (e.g. neonatal screening [20,23]) may be a valuable option to detect the disease 
in an early phase. A remarkable observation in this regard was made by Spada et al. [20] 
showing that the incidence of GLA mutations in male Italian neonates was considerably 
higher than that previously reported. The yield of population-wide screening programmes, 
however, is hampered by a considerable amount of false positives [23]. An additional draw-
back is that enzyme-based diagnosis of the disease is the gold standard in men, but using 
this technique only 2/3 of the female carriers are detected [29]. In women, these limitations 
should be appraised and taken into consideration.
Narrowing the screening programme to high-risk patient groups has already proven ef-
ficacious, aswas demonstrated previously for cryptogenic stroke and for patients with hy-
Figure 2.4. Pedigree of the index patient (arrow); black = mutation present; 
white = no mutation present; question mark = no genetic testing performed 
as yet; grey = low alpha-galactosidase A level, genetic testing pending – AFD 
very likely.
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pertrophic cardiomyopathy [14–19]. In haemodialysis patients a considerable number of 
successful screening studies have been reported in the literature, mainly in male patients 
and using different diagnostic techniques (blood spot, white blood cell enzyme detection, 
genetic analysis [9–13]). Our group recently reported a nation-wide screening study in a 
predominantly female dialysis patient group [13], and proved that, even taking into con-
sideration the lower detection limit for AFD of enzymatic tests in female patients, blood 
spot-based screening can be useful.
As for a considerable number of patients, haemodialysis or peritoneal dialysis is merely 
a transition to kidney transplantation, it can be hypothesized that in the renal transplant 
recipient group, some misdiagnosed or undiagnosed AFD patients may be found. It was the 
goal of this study to document and test this hypothesis.
We used a two-tier approach with a blood spot-based (and cheap) detection of ‘risk-
patients’ followed by a more expensive and time-consuming genetic analysis. We chose to 
screen women also by alpha-galactosidase activity, keeping in mind the limitations as re-
ported by Linthorst [29], showing that that only 2/3 of the female patients are detected by 
this approach. This enabled us however to screen more patients at lower cost.
In contrast to our previously reported dialysis screening programme, we did not impose 
an upper age limit in male patients, as recent reports point out that the spectrum of AFD 
presentations in male patients is much wider than that previously estimated. This decision 
is corroborated by the detection by this screening of a 67-year-old male transplanted Fabry 
patient.
Once the diagnosis established in the proband, screening for a genetic disease within a 
family can be very difficult as is illustrated by the family presented: the proband had a full 
clinical and genetic work-up, but his ‘hemizygous’ sister only had an enzymatic and genetic 
work-up (she refused further clinical and biochemical testing, because she was ‘well’ and, 
to her standards, ‘aged enough not to bother about that kind of things’); the hemizygous 
sister’s son had enzyme testing which was clearly abnormal, but he has refused further test-
ing so far (‘I’m well’). The proband’s daughter is an obligatory ‘carrier’, which was confirmed 
genetically and enzymatically; she has no apparent cardiovascular, neurological or renal 
involvement. Her only son was only informed of the disease running in his family last week, 
due to relational problems in the family. Further family screening and detailed mapping of 
disease burden in possibly affected members will of course be pursued ceaselessly.
It is of interest to note that in 10 out of the 11 genetically tested patients with low 
α-Gal A, no mutation in the GLA gene was found. Mutation analysis was performed by two 
complementary techniques: direct sequencing of the seven GLA exons and exon-flanking 
boundaries in male and female individuals and MLPA, exclusively in female patients. In af-
fected males, the sensitivity of direct sequencing is estimated to approximate 100%. In het-
erozygous females, the sensitivity of direct sequencing is most certainly lower as whole 
gene and full exonic deletions will be missed. These genetic aberrations will, however, be 
reliably detected by the MLPA analyses we included for female patients.
Therefore, we are confident that the adopted strategy is sufficiently sensitive. Of note, di-
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rect sequencing (with or without MLPA) was the method of choice in most recent screening 
studies for Fabry’s disease. Evidently, it should be appreciated that certain, albeit extremely 
rare, pathogenic genetic alterations (such as mutations in or methylation of the GLA promo-
tor) will not be detected by the adopted strategy. As a consequence, the concern of missing 
pathogenic mutations remains an important issue in selected cases. In a suggestive clinical 
setting, clinicians are therefore encouraged to demonstrate globotriaosylceramide deposi-
tion by alternative and complementary analyses such as electronmicrosopic studies of skin 
or renal biopsy specimens. This however is beyond the scope of this screening project and 
merits further investigation.
The total cost of this screening is small, as compared to the gains. As our blood spot 
technique costs 6.25 euro per analysis, the first tier of our test costed 4206.25 euro. The 
second tier (genetic analysis) costed 11×337.5 euro= 3712 euro. Hence the total cost of the 
screening programme amounted to ~8000 euro. Had we omitted the first tier in female 
patients to apply the second tier directly, those costs would have been considerably higher 
[(278 × 6.25 euro) + (2 × 337.5 euro) + (395 × 337.5 euro) = 135 725 euro], with only a limited 
increase in the power of our screening. Andrade et al. recently discussed the possible limita-
tions of the blood spot assay [30]. These should of course be kept in mind, but need further 
confirmation as these statements were based on the screening of a very heterogenous pa-
tient population (chronic renal failure, patients on renal replacement therapy, transplant pa-
tients) and no GLA mutation carriers were detected. The validation of our blood spot test for 
alpha-galactosidase activitywas reported previously [13] and showed reproducible results.
Our results show that this two-tier method can detect Fabry disease in renal transplant 
recipients, even in atypical clinical settings and in patients not previously considered high-
risk (renal transplant recipients). As we mentioned previously [13], the detection of a GLA 
mutation is not only of vital importance to the patient under study, but also to putatively 
affected family members, who can be treated in an earlier phase of the disease, before vital 
organ damage is installed. Indeed, in the reported family, a hitherto asymptomatic grand-
son was identified. ERT in this patient may lead to prevention of organ damage, stabilization 
of incurred damage or even improvement. In contrast, the obligatory heterozygous carrier 
state of the patient’s mother who died at 91 years also suggests that the possible ERT of 
these carriers should be carefully balanced with the life expectancy and influence of the 
expensive treatment on changing this life expectancy.
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Paper Three
Prevalence of Fabry disease in a predominantly hypertensive 
population with left ventricular hypertrophy
Terryn W, Deschoenmakere G, De Keyser J, Meersseman W, Van Biesen W, Wuyts B, 
Hemelsoet D, Pascale H, De Backer J, De Paepe A, Poppe B, Vanholder R. 
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Abstract
Background: Patients with Fabry disease (FD) develop progressive left ventricular hypertro-
phy (LVH). In screening studies in patients with LVH, the prevalence of FD ranges from 0 to 
12%. This variability is attributable to different factors like diverging inclusion and exclu-
sion criteria, the evaluation of selected populations and suboptimal screening methods.
In this study, we aimed to determine the prevalence of FD in an unselected population 
of everyday clinical practice presenting LVH, defined as a maximal end-diastolic septal or 
posterior wall thickness ≥13 mm, without exclusion of patients with arterial hypertension 
or valvular pathology, and using optimal screening methods.
Methods: In adult males, a two-tier approach was used; α-Galactosidase A (α-Gal A) activity 
was measured using a dried bloodspot test (DBS) and diagnosis was confirmed by muta-
tion analysis of the GLA gene. In females, mutation analysis was the primary screening tool.
Results: 362 men and 178 women were screened. Six patients were diagnosed with a ge-
netic sequence alteration of the GLA gene. One man had a novel mutation, GLA p.Ala5Glu 
(c.44C>A), presenting as classical FD. Another man and three women had the previously 
described GLA p.Ala143Thr (c.427G>A) mutation, which generally presents as an attenuated 
phenotype. One woman had a novel sequence alteration c.639+6A>C, which appeared to 
be a polymorphism. All true Fabry patients had arterial hypertension (AHT), and one had 
hypertrophic obstructive cardiomyopathy (HOCM).
Conclusions: In a group of unselected patients with LVH, we found a prevalence of Fabry dis-
ease of 0.9%. AHT or type of hypertrophy should not be an exclusion criterion for screening 
for FD.
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Introduction
Fabry disease (FD) is an X-linked lysosomal storage disease caused by abnormalities in the GLA gene leading to a partial or absolute deficiency of the lysosomal enzyme α-Galactosidase A (α-Gal A). This results in the accumulation of glycosphingolipids, 
especially globotriaosylceramide (Gb-3) in the lysosomes of various cells, which leads to 
various end-organ manifestations including left ventricular concentric remodeling and sub-
sequent hypertrophy. Though rare, asymmetric hypertrophy has also been described [1,2]. 
Cardiovascular involvement contributes substantially to disease-related morbidity and 
mortality in FD [3]. Enzyme replacement therapy has been shown to reduce left ventricular 
mass and wall thickness [4–6]. As a consequence, early diagnosis and treatment of these 
patients has the potential to modify the natural course of the disease and reduce morbidity 
and mortality and offers the possibility to diagnose family members in an earlier stage of 
the disease. 
Over the past decade, a number of studies have suggested that FD can present in pa-
tients with an echocardiographic phenotype of hypertrophic cardiomyopathy (HCM), de-
Table 2.1. Summary of previous studies of FD in LVH.
Authors 7-14 Population LVH selection criteria
Screening 
method Prevalence Limitations
Nakao
1995 230 males
LVH ш 13 mm
Otherwise 
unselected
ɲ-Gal A 3%
Only males
Single centre; tertiary referral centre
In 5/7 cases, no mutation was found in the coding 
regions of the GLA gene
Sachdev
2002
79 males ш 40 y
74 males <40 y
HCM ш 13 mm ɲ-Gal A
6.3 %
1.4 %
Only males
Exclusion of hypertension and valvular disease
Single centre; tertiary referral centre
Ommen
2003 100 (44 males) 
Symptomatic
HOCM
Myomectomy; 
electron 
microscopy
0
Asymmetric hypertrophy is rare in FD
Exclusion of hypertension and valvular disease
Retrospective study
Single centre; tertiary referral centre
Chimenti 
2004 96 (62 males) HCM ш 13 mm
Myocardial 
biopsy
6.2%
in female 12%
Exclusion of hypertension and valvular disease
Biopsy study; selection bias ? (suspicion of 
infiltrative disease)
Single centre; tertiary referral centre
Arad
2005 75 (45 males) HCM ш 13 mm genetic 0
Exclusion of hypertension and valvular disease
Single centre; tertiary referral centre
Inclusion of very young (> 12y)
Monserrat
2007 508 (328 males) HCM ɲ-Gal A 1%
Exclusion of hypertension and valvular disease
Use of ɲ-Gal A in females
Havndrup
2010 90 (56 males) HCM genetic 3%
Single centre; tertiary referral centre
Low number of patients
Hagège
2011 392 (278 males) HCM ш 15 mm ɲ-Gal A
1% (1.5% in 
men >18y 
and 1.8% in 
men >40y
Exclusion of hypertension and valvular disease
Use of ɲ-Gal A in females
High cut-off for LVH (15 mm instead of 13 mm)
Elliot
2011 1386 (885 males) HCM ш 15 mm genetic 0.5%
Exclusion of hypertension and valvular disease
Age limitation (35+ for men and 40+ for female)
High cut-off for LVH (15 mm instead of 13 mm)
LVH = Left Ventricular Hypertrophy; HCM = Hypertrophic Cardiomyopathy; HOCM = Hypertrophic Obstructive Cardiomyopathy; 
ɲ-Gal A = ɲ-Galactosidase A activity measurement
Screening for Fabry disease in high-risk populations
75
fined by the presence of LVH in the absence of abnormal loading conditions such as arterial 
hypertension (AHT) or aortic valve abnormalities (Table 2.1 [1,7–14]). It was supposed that 
these abnormal loading conditions generally explained LVH and therefore these patients 
were excluded in screening studies for FD. The only exception is an older study [7]. Fifty-
three percent of the patients had AHT and 5% had aortic valve dysfunction. Nevertheless, 
an unexpectedly high number of patients (3%) were diagnosed with a low α-Gal A activity 
and/or Gb-3 deposits in themyocardial cells. A possible explanation for this high prevalence 
is selection bias as this study was undertaken in a highly selected population of only males 
attending a single tertiary reference center.
As a considerable part of the Fabry population has AHT [15,16] and most of the patients 
with LVH followed by cardiologists in everyday practice have hypertension or valvular dis-
ease, we think that screening for FD in patients with LVH should include patients with hyper-
tension and aortic valve disease. This would allow the determination of the true prevalence 
of FD in patients with LVH and would allow answering the question whether this prevalence 
is high enough towarrant overall screening in such populations.
Most of the published prevalence studies focusing on FD in LVH have methodological 
shortcomings including selection bias (predominantly in male patients or in single, highly 
specialized referral centers) and the use of inappropriate screening methods, such as α-Gal 
A activity measurement in women [17].
The purpose of this study is to determine the prevalence of FD in patients with LVH at-
tending everyday hospital practices for cardiological examination, using optimal screening 
tools.
Materials and methods
Primary hypothesis
FD is likely to account for an unknown but considerable number of LVH even in unse-
lected patients.
Study centers
Ten cardiologists in eight secondary care hospitals and two tertiary care hospitals (Ap-
pendix 1), in Flanders, Belgium, participated in the study, guaranteeing the recruitment of 
an unselected patient population.
Study population
All patients (male and female) of 18 years or older who underwent an echocardiography 
were eligible to be included in the screening program. Patients were eligible for inclusion if 
on 2D echocardiography the maximal end-diastolic septal or posterior wall thickness was 
≥13 mm. Wall thickness was measured by 2D-guided M-mode at papillary muscle level in 
parasternal long axis or parasternal short axis view. All measurements were made at end-
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diastole (at onset of the R wave).
AHT, valvular disease or other possible causes for LVH were not an exclusion criterion. 
AHT was defined as ≥140 mm Hg systolic blood pressure or being on antihypertensive
medication.
Ethical issues
The design of the study was approved by the ethics committee of the Ghent University 
Hospital (EC nr 2009/35) and by the local ethics committees in all participating centers and 
conforms to the ethical guidelines of the 1975 Declaration of Helsinki. Since it was designed 
as a purely observational study, patients received therapy and diagnostic procedures ac-
cording to local practice. Written informed consent was obtained from all patients.
The authors of this manuscript have certified that they comply with the Principles of Ethi-
cal Publishing in the International Journal of Cardiology [18].
Echocardiographic measurements
Echocardiographic measurements were performed according to the European Guide-
lines of Chamber Quantification [19].
Determination of α-Gal A using the technique of dried blood spot sampled in filter paper
The screening test in males was based on dried blood spots (DBS) sampled on filter paper 
as described by Chamoles et al [20]. In brief, a standardized disk was punched out of a filter 
paper and consequently incubated at physiologic pH (7.365) and at 37 °C with 4-methylum-
belliferyl-alpha-galactopyranoside as substrate. Enzyme activity renders the enzyme prod-
uct 4-methylumbelliferone (4-MU), a fluorescent molecule. The fluorescence (excitation, 
365 nm; emission, 450 nm) was measured on a Thermo Life Science fluorometer (Thermo 
Electron Corporation, Waltham, MA, USA). The fluorescence readings were corrected for 
blanks, and the results were compared with the fluorescence from a 4-methylumbelliferone 
calibrator. Enzymatic activities were expressed as micromoles of substrate hydrolyzed per 
liter of blood per hour. To validate this technique in our laboratory setting, we performed 
an analysis of 50 patient samples (non-nephrology, non-ICU, non-hematology, non-pediat-
ric). Results were compared with literature data. Each DBS test for α-Gal A was validated by 
measurement of β-Galactosidase (as a technical comparator for enzymatic analysis). If no 
β-Galactosidase activity was detectable in the DBS test, the sample was rejected.
2.7. Genetic screening
Mutation analysis was performed in all female patients and in men with an absent or 
low (b0.64 μmol/L/h) α-Gal A activity measured with DBS test. Genomic DNA was extracted 
from EDTA blood by standard protocols. Mutation analysis was performed by PCR amplifica-
tion followed by direct sequencing of the 7 exons and flanking intronic sequences of GLA 
gene according to Ploos van Amstel et al. [21]. The presence of large gene rearrangements 
was evaluated by QF PCR (custom made kit by Prestagen). Sequence variations found in the 
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Table 2.2. Characteristics of the study population.
Overall population Male Female
Number (%)* 540 (100) 362 (67) 178 (33)
Mean age (y) (SD, range) 68.8 (14.25, 19-93) 66.8 (14.48, 19-93) 73.0 (12.79, 34-93)
N (%) with GLA mutation 5 (0.94) 2 (0.55) 3 (1.68)
Mean septum thickness (mm)(SD, range) † 15.87 (3.22, 13-39.1) 15.94 (3.26, 13-38) 15.72 (3.11, 13-39.1)
N (%) with RR syst 140 mmHg or more 287 (53.1) 185 (51.1) 102 (57.3)
N (%) taking antihypertensive medication 440 (81.5) 284 (78.5) 156 (87.6)
N (%) syst RR 140 mmHg or more or taking antihy-
pertensive medication 488 (90.4) 322 (89.0) 166 (93.3)
N (%) with a family member in the first or second 
degree with kidney disease, precocious CVA or sud-
den death
93 (17.2) 64 (17.7) 29 (16.3)
* one CFR was missing, † calculated in 533 patients as 7 data were missing 
GLA gene were compared with published data on known pathogenic mutations and non-
disease-causing polymorphisms.
Results
Screening results
540 patients (362 males and 178 females) were screened (Table 2.2). 488 patients (90.4%) 
had a systolic blood pressure of ≥140 mm Hg or were on antihypertensive medication. The 
mean (SD) diameter of the left ventricular septum or posterior wall thickness was 15.87 
(3.22) mm, with a range of 13.0–39.1 mm. The population had a mean age of 68.8 y (range 
19–93 years).
Two male patients had a confirmed low α-Gal A activity measured with DBS, and both had 
a missense mutation, yielding a mutation prevalence in men of 0.55%. The GLA p.Ala5Glu 
(c.44C>A) was a novel mutation, while the GLA p.Ala143Thr (c.427G>A) mutation has previ-
ously been described as associated with an attenuated phenotype [22]. Four females were 
found to carry a GLA missense sequence alteration. The c.639+6A>C sequence alteration in 
1 patient was novel, whereas the other females had the GLA p.Ala143Thr (c.427G>A) muta-
tion. All five Fabry patients detected in this screening study were unrelated and lived at 
geographic distant locations through Flanders.
Patient description (Table 2.3)
GLA p.Ala143Thr (c.427G>A). Patient 1 is a 48-year-old man with AHT, concentric LVH 
with a septum of 14 mm and a normal systolic left ventricular function, but a slow relaxa-
tion. His α-Gal A activity is undetectable. In his medical history, we note type 2 diabetes 
since 13 years, peripheral polyneuropathy, erectile dysfunction and a diabetic foot at the 
age of 46 years. He has renal insufficiency with a creatinine clearance of 35 mL/min (meas-
ured with 24 h urine collection) and a proteinuria of 3 g/24 h. For a year, he has had dif-
fuse headaches with anorexia and weight loss. On clinical neurological examination, there 
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Table 2.3. Patients with FD mutations.
Patient 1 2 3 4 5
Age/sex M/48 F/78 F/70 F/83 M/38
Angiokeratoma - - - - -
Acroparesthesia - - - - +
Hypohidrosis - - - - +
Hearing impairment - - - - +
Arterial hypertension + + + + +
Septal wall thickness (mm) 14 23 16 20 13
Asymmetric hypertrophy - - - + -
ɲGAL A activity* 0 NA 0.25 0.48 0
GLA mutation c.427G>A c.427G>A c.427G>A c.427G>A c.44C>A
NA: not available; * normal values 0.64-3.82 ʅmol/l/h
was no apparent deficit. Magnetic resonance imaging of the brain however showedmul-
tiple brain lesions: acute ischemic lesions and white matter lesions, which could be older 
ischemic lesions. Ophthalmologic examination shows a diabetic proliferative retinopathy, 
but no tortuous vessels or cornea verticillata. A kidney biopsy shows a Kimmelstiel–Wilson 
nephropathywith no signs of Gb-3 deposits. He has only one sister carrying the mutation, 
without signs of organ involvement at thorough clinical workup, including a kidney biopsy 
because of micro-albuminuria. The sister’s children, in their twenties, were reluctant to par-
ticipate in further investigation. The patient has four daughters between 10 and 20 years of 
age who are obligate carriers butwho have no complaints. The oldest daughter has a lowα-
Gal A activity (0.27 μmol/L/h). His parents died at old age of unknown cause.
Patient 2 is a 78-year-old woman with AHT, symmetric cardiac hypertrophy and a maxi-
mal ventricular wall thickness of 23 mm with normal left ventricular ejection fraction. She 
has a serum creatinine of 1.36 mg/dL and an estimated glomerular filtration rate (MDRD) 
of 38 mL/min. Because of amonoclonal gammopathy, amyocardial biopsy is taken, which 
shows amyloid light chain amyloidosis and Gb-3 deposits. She died during her hospitaliza-
tion because of decompensated diastolic heart failure. As the treating cardiologist did not 
consider the mutation significant, he did not inform the general practitioner and the family 
of this mutation.
Patient 3 is a 70-year-old woman who was successfully treated for AHT with a beta-block-
er and an ACE inhibitor. She has symmetric LVH with a left ventricular wall thickness of 16 
mm, which increased progressively despite control of hypertension. She has no cornea ver-
ticillata, no neurological signs or symptoms, a normal serum creatinine and no proteinuria. 
She has a family history of sudden death, with her father dying at the age of 52. One of her 
brothers suffers from atrial fibrillation, and another brother had a myocardial infarction and 
suffers from heart failure.
Patient 4 is an 83-year-old woman admitted to the hospital because of ischemic stroke. 
She has a history of AHT, ischemic stroke, HOCM and arrhythmia. She has a serum creatinine 
of 1.02 mg/dL and no proteinuria. She has asymmetric LVH with a maximal left ventricular 
wall thickness of 20 mm. Her α-Gal A activity is 0.48 μmol/L/h (normal range 0.64–3.82). Her 
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Table 2.4. Clinical manifestations of affected family members of the patient with GLA p.Ala5Glu (c.44C>A).
II3 II4 II5 III2 III3 III4 III6
Age, Sex 64,F 45,F 39,M 46,M 60,F 49,M
Angiokeratoma + - - -
Acroparesthesia + + - +
Hypohidrosis + - +
Hearing impairment + + - -
Stroke + + - - +
White matter lesions + +
Renal failure + + - +
Arterial Hypertension + - +
LVH + - +
ɲGAL A activity (ʅmol/l/h) 0 ‘low’ 0
Blank spaces means the information is not available; “–“ means the symptom is absent; ‘low’ means under the lower normal level (no further 
detail available)
brother, two sisters and parents died at an advanced age of unknown cause.
3.3. GLA p.Ala5Glu (c.44C>A) ( Fig. 2.5, Table 2.4)
Patient 5 is a 46-year-old man with a history of AHT. LVH is suggested by electrocardio-
gram (ECG) and confirmed with echocardiography showing a left ventricular septum of 13 
mm. He suffers from hearing loss and coronary artery disease for which he had several coro-
nary stents. In his childhood, he suffered fromanhydrosis and paresthesia. On clinical exami-
nation, he has no angiokeratoma. He has a serum creatinine of 1.40 mg/dL, an eGFR (MDRD) 
of 54 mL/min/1.73 m2 [2] and no proteinuria (under treatment with an ACE inhibitor). A 
kidney biopsy was suggested, but as the patient had recently received several coronary 
stents, for which he took clopidogrel, it was considered not safe. In addition, this patient 
and his pedigree has a classical Fabry phenotype, this leaves no doubts about the diagnosis 
and no real need for a biopsy to complete the diagnosis. Α-Gal A activity is undetectable. 
His pedigree shows several family members with classical Fabry symptoms. His mother died 
at the age of 64 as the consequence of stroke, and his aunt died at 45 with vascular disease 
Figure 2.5. Family pedigree of the patient with p.Ala5Glu (c.44C>A). Legend: circles are fema-
les and squares are males. Filled symbols are affected patients. Dashed symbols are deceased 
patients. The arrow indicates the index patient. Dotted means carriers without symptoms.
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and renal failure. His brother and cousin also have typical Fabry symptoms. His niece (60 
years of age) carries the same mutation but is asymptomatic. He has two young daughters 
who are carriers but who have no signs or symptoms of FD.
The GLA p.Ala5Glu (c.44C>A) mutation has not been described in the literature, and ap-
pears to result in classical FD.
3.4. C.639+6A>C
A 75 year old female with AHT, coronary artery disease and LVH(basal septum 15 mm) 
has a sequence variation in an intronic location c.639+6A>C, which has not yet been de-
scribed in literature and which was not encountered in our control population (healthy 
population) nor in the other patients sequenced in this study. She has two sons of 44 and 
47 years of age, carriers of the same sequence variation, who have a normal α-Gal A and no 
clinical signs or symptoms compatible with FD. It is concluded that this sequence variation 
is a low-prevalence polymorphism.
Discussion
In an unselected albeit predominantly hypertensive, older population with LVH, we 
found 2 male and 3 female patients with mutations in the GLA gene yielding an overall 
prevalence of 0.93%. Four out of five patients, who are apparently unrelated and live at 
distant locations from each other, have the same GLA p.Ala143Thr (c.427G>A) mutation. In 
a recent newborn screening in Austria this mutation was found in 6 out of 9 Fabry patients 
[23], which is in accordance with the high prevalence we found in the present study. FD 
is a rare disease with a reported prevalence of 0.02 to 0.09 per 10,000 persons in the gen-
eral population [24] but is probably under-ascertained because of its rarity and because 
presenting symptoms are frequently nonspecific and variable. Screening studies for FD in 
high risk populations (left ventricular hypertrophy, stroke, dialysis) [25] and in newborns 
[23,26,27] yield much higher frequencies but this is for a large part due to the detection of 
attenuated (later-onset) phenotypes. Many patients (males and females) with FD develop 
LVH. In a cross-sectional study of untreated FD patients, half of the men and one third of the 
women were classified as having LVH (defined as LVMi of ≥51 g/m2.7 for males and ≥48 g/
m2.7 for females) [28]. In general, hypertension on its own is considered to be responsible 
for LVH. Hence, hypertensive patients are almost systematically excluded from screening 
studies for metabolic heart disease. Currently (April 2012), nine papers documented the 
prevalence of FD in patients with LVH, yielding frequencies from 0 to 12% (Table 2.1). Of the 
nine screening studies, eight screened only in hypertrophic cardiomyopathy (HCM), and 
hypertensive patients were explicitly excluded in seven. The only study that included hyper-
tensive patients for screening for FD was performed in a uniquely male population in whom 
hypertension was present in 53% [7]. An unexpectedly high prevalence of 3% was found, 
although selection bias cannot be excluded as the study was restricted to one single tertiary 
referral center. Most likely, this explains why FD was almost 6 times more prevalent than in 
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males in our study group from an everyday in- and outpatient hospital population (0.55%).
The prevalence of FD has been underestimated mainly because of the high prevalence 
of later-onset phenotypes. At this age, Fabry patients with LVH may also have hyperten-
sion, considering the high prevalence of hypertension in the general population and the 
possibility of hypertension secondary to renal disease in these patients. For this reason, 
we decided to include hypertensive patients in our screening protocol. Indeed, all of our 
patients with a molecular diagnosis of Fabry disease were previously treated for hyperten-
sion. This proves that screening for FD in general cardiology practice, which has a very high 
prevalence of hypertension (90% in our patients) is not futile. Furthermore, it is important to 
screen for FD in hypertensive LVH patients because AHT and LVH are not rare in FD and are 
particularly associated with a higher cardiovascular morbidity [29]. 
Most previous studies have been performed in highly selected populations in tertiary 
treatment centers, and only two studies were multicentric similar to our evaluation while 
they also evaluated both genders [11,12].However, in those studies, female cases could 
have been missed, as α-Gal A activity measurement was used as a screening tool which can 
be falsely normal in up to 40% of women with FD [17]. For this reason, it is now accepted 
that in women, the primary screening tool should be mutation analysis [30], which was also 
the approach followed in our study. 
Asymmetric septal hypertrophy indistinguishable from that seen in sarcomeric cardio-
myopathies, accounts for 5% of FD patients with LVH [31]. Dynamic left ventricular outflow 
obstruction is rare, but does occur, as in our patient 4. As a consequence, it is conceivable 
that also asymmetric LVH should not be an exclusion criterion for screening for FD.
The patientwith the novel GLA p.Ala5Glu (c.44C>A) mutation presented with a classical 
clinical picture of FD (including acroparesthesia, hearing impairment, anhydrosis, LVH and 
renal insufficiency). There was also a suggestive familial history for FD. In this case, a careful 
personal and family survey could have provided useful information for a correct diagnosis. 
More precisely, the patient was not specifically asked for the presence of anhydrosis and 
the predominant symptom was hearing loss, a feature whereby clinicians did not consider 
the possibility of FD. Thus, this classic case of FD was missed in everyday medical practice, 
which demonstrates that FD remains underdiagnosed, and is easily overlooked, and that di-
agnostic screening combined with pedigree analysis remains important for case detection.
Clinical implications and conclusion
The present study demonstrates that, since FD is present in approximately 1% of unse-
lected patients with LVH, this disease should be considered in the differential diagnosis of 
all patients with LVH, without exclusion of AHT, asymmetric hypertrophy, women or older 
patients. Screening remains an important tool for case finding as even classical FD may oth-
erwise go undetected, while a correct diagnosis is important in view of recent advances in 
the treatment of FD which may offer stabilization and even reversal of cardiovascular mani-
festations and other symptoms [4,5].
Tree of the five patients were 70 years or older. We cannot exclude in these cases that 
Chapter 2
82
other causes, besides hypertension and FD, contributed to LVH (e.g. amyloidosis in case 2). 
Moreover, it needs to be determined whether in these older patients an expensive treat-
ment such as enzyme replacement therapy is still worthwhile to consider. Probably, pedi-
gree analysis is the only beneficial consequence of finding a mutation in these older pa-
tients.
Four out of five Fabry cases in this study had a mutation that is generally associated with 
later-onset Fabry disease (GLA p.Ala143Thr (c.427G>A) ).
The contribution of the mutation to the clinical picture (stroke, renal failure and even 
LVH) should be the subject of a thorough clinical workup in a center with expertise in FD.
Limitations
Although biochemical screening is generally accepted to be very sensitive in screening 
in males and DBS is probably as accurate as the gold standard (determination of α-Gal A 
activity in leukocytes) Andrade [32] showed that using plasma may fail to detect some male 
patients with FD. Our method using DBS test could be prone to the same bias. However, if 
this were the case, this would mean that the real prevalence of FD in males with LVH might 
even be higher than described here.
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Chapter 3 3
We report the phenotype associated with the GLA p.Ala143Thr (c.427G>A) mutation in 12 patients aged 42–83 years. We com-
pare our data with literature and data from the Fabry 
Outcome Survey.  We conclude that care should be taken 
with attribution of vital organ dysfunction (renal failure, 
stroke and left ventricular hypertrophy) to GLA sequence 
alterations. In case of the p.Ala143Thr mutation, and pos-
sibly also other mutations associated with an attenuated 
phenotype, diagnostic tools such as biopsy and imaging 
should critically evaluate the relation of end-organ failure 
with Fabry disease, as this has important consequences 
for  counseling and enzyme replacement therapy.
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Paper Four
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Implications for Screening Studies and ERT
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Abstract
 Fabry disease is an X-linked inborn error of glycosphingolipid metabolism caused by quan-
titative or qualitative defects in the lysosomal enzyme alfa-Galactosidase A (α-Gal A), ulti-
mately resulting in vital organ dysfunction. Mainly the kidneys, the heart, and the central 
nervous system are involved.While the classical phenotype of Fabry disease is readily recog-
nizable, screening studies have identified clinical variants. Here, we report the phenotype 
associated with the GLA p.Ala143Thr (c.427G>A) mutation in 12 patients aged 42–83 years. 
None of the patients had classical Fabry signs or symptoms as angiokeratoma, hypohidro-
sis, acroparesthesia, or cornea verticillata. Possible Fabry manifestations were renal failure 
(5/12), stroke (7/12), and left ventricular hypertrophy (5/12), but these were not necessarily 
attributable to the p.Ala143Thr mutation, as a cardiac biopsy in one female and left ven-
tricular hypertrophy and kidney biopsies in two males with renal failure and microalbumi-
nuria lacked Gb-3 deposits. The literature data on this mutation as well as data collected in 
the Fabry Outcome Survey (FOS) database confirm these findings. The association of renal 
failure, stroke, and left ventricular hypertrophy with this mutation could be the result of 
selection bias, as most patients were detected in screening studies. 
 We conclude that care should be taken with attribution of vital organ dysfunction to GLA 
sequence alterations. In case of the p.Ala143Thr mutation, and possibly also other muta-
tions associated with an attenuated phenotype, diagnostic tools such as biopsy and imag-
ing should critically evaluate the relation of end-organ failure with Fabry disease, as this has 
important consequences for enzyme replacement therapy. 
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Introduction
Fabry disease (FD, MIM ID #301500) is an X-linked inborn error of glycosphingolipid metabolism caused by quantitative or qualitative defects in the lysosomal enzyme alfa-Galactosidase A (α-Gal A). As a result, glycosphingolipids, mainly globotriaosyl-
ceramide (Gb-3), accumulate in different cells throughout the body, ultimately resulting in 
organ failure (Kint 1970; Brady et al. 1967). Classical FD has been described as a multisystem 
disease predominantly presenting in males with angiokeratoma, hypohidrosis, and acro-
paresthesia in childhood, followed by renal failure, left ventricular hypertrophy, stroke, and 
premature death in the fourth and fifth decade of life. Besides these cases, attenuated forms 
have been described with a less severe phenotype and a later onset. In males, a specific 
mutation, associated with a significant residual enzyme activity, can result in a less severe 
phenotype that presents later in life (e.g., the “cardiac variants”) (NAKAO et al. 1995; Scheidt 
von Wet al. 1991). In females, residual enzyme activity can be the consequence of skewed 
X-chromosome inactivation. In the present paper, we present clinical and pathological data 
on a series of 12 patients with the p.Ala143Thr mutation and compare these data with litera-
ture data (9 patients) and data from the Fabry Outcome Survey (FOS) (20 patients).
Patients and Methods
We retrospectively reviewed the charts of patients with the p.Ala143Thr mutation diag-
nosed in our different screening studies and in the subsequent pedigree analyses (Terryn et 
al. 2008; De Schoenmakere et al. 2008). These studies were conducted according the World 
Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving 
Human and were approved by the Ethics Institution Review Boards of participating centers. 
All patients gave written informed consent. 
Measurement of α-Gal A activity was based on a technique involving a dried blood spot 
sampled on filter paper (DBS) as described by Chamoles et al. (2001). To validate this tech-
nique in our laboratory setting, we performed an analysis of 50 control samples (nonneph-
rology, non-ICU, non-hematology, non-pediatric). In case of low α-Gal A activity, DBS was 
repeated in a new blood sample.
In a second part, previously published cases of the p. Ala143Thr mutation were identified 
through a PubMed search from 1966 to September 6, 2011, entering “p.Ala143Thr”, “A143T,” 
AND “Fabry Disease” as MESH terms.
A third part of this study consists of the analysis of FOS data. FOS – the Fabry Outcome 
Survey – is a European outcomes database for patients with Fabry disease who are receiv-
ing, or are candidates for, Enzyme Replacement Therapy (ERT) with agalsidase alfa. Data 
from all consenting patients are entered into the database following a structured clinical as-
sessment by a physician or a specialized nurse. FOS has been approved by the Ethics Institu-
tion Review Boards of participating centers and all patients gave written informed consent. 
All measurements performed routinely in clinical practice are entered into the database. 
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Anonymous data are submitted electronically by participating physicians to the central 
FOS database. We summarized baseline available data on all adult (18+) patients with the 
p.Ala143Thr mutation in this database.
Kidney Biopsies
If kidney biopsies were available, they were reviewed by a local pathologist and by a 
renal pathologist with expertise in FD (AF). Sections were stained with H & E, PAS, Jones, 
Congo Red, toluidine blue, and trichrome. 
Results
In total, 41 patients with the GLA p.Ala143Thr mutation were identified. 
Twelve patients (three males and nine females) were detected through our screening 
studies and subsequent pedigree analysis (Table 3.1). “Classical” symptoms of FD (angioker-
atoma, acroparesthesia, cornea verticillata, and hypohydrosis) were absent. A significant 
number of patients had left ventricular hypertrophy (N = 5) or a history of stroke (N = 7), 
but this could be due to a selection bias, as most of these patients were detected as a result 
of screening studies in populations with left ventricular hypertrophy or stroke (Terryn et al. 
2008, accepted in the International Journal of Cardiology). Of note, residual enzyme func-
tion could be demonstrated in all patients. Patient 1, 2, and 5 had a kidney biopsy showing 
no signs of Fabry nephropathy. Proteinuria and renal failure in patient 1 could be attributed 
to diabetic nephropathy. Patient 2 was detected as a result of pedigree analysis and despite 
his low α-Gal A he had no signs of FD and was asymptomatic besides intermittent paresthe-
sias in both arms, that were aspecific according to an expert neurologist. 
One female patient with pronounced left ventricular hypertrophy (LVH) and heart failure 
(patient 7) had a myocardial biopsy showing AL amyloid and no typical Gb-3 deposition. In 
our screening studies in high-risk populations (Table 3.2), GLA mutations were detected in 
nine apparently unrelated patients, with seven having the GLA p.Ala143Thr mutation.
The cases with p.Ala143Thr from literature are summarized in Table 3.3. Only two patients 
were diagnosed as the result of symptoms and signs (patient 4 and 7). One patient (patient 
7) had a single angiokeratome. A second patient (patient 4) had a cramp-fasciculation syn-
drome. The other seven patients were diagnosed as the consequence of screening studies 
and had no typical Fabry symptoms. One male (patient 4) had a kidney biopsy. Typical Fabry 
inclusions were only noted in a few collecting ducts and distal tubules but not in podocytes 
or in the endothelium. Another male (patient 9) had a nephrectomy after transplantation 
because of bilateral renal cell carcinoma. Histological examination of the nonmalignant re-
nal tissue showed chronic glomerulonephritis, hyalinization, and severe arteriosclerosis, but 
no lesions typical for Fabry disease.
The FOS data are summarized in Table 3.4. Among 1933 registered Fabry patients, 20 
adults (12 females and 8 males) from the United Kingdom, Germany, France and Belgium 
had the p.Ala143Thr mutation. The median baseline eGFR (MDRD) in female patients was 83 
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Table 3.2. Screening in high risk groups in Flanders.
Females 
(N)
Muta-
tions in 
females 
(N) (%)
Males 
(N)
Muta-
tions in 
males 
(N) (%)
Total 
patients 
(N)
Muta-
tions
(N) (%)
GLA 
p.Ala143Thr 
(c. 427G>A)
GLA 
p.Trp236Arg 
(c.706T>C)
GLA 
p.Ala5Glu 
(c.44C>A)
Hemodialysis1 742 2(0.27%) 180
1
(0.56%) 922
3
(0.33%) 2 1 0
Kidney 
transplantation2 395 0 278
1
(0.36%) 673
1
(0.15%) 1 0 0
Left Ventricular 
Hypertrophy3 178
3
(1.7%) 362
2  
(0.55%) 540
5
(0.93%) 4 0 1
Total high risk 
population 178
5
(0.38%) 820
4
(0.49%) 2135
9
(0.42%)
7
(0.33%)
1
(0.046%)
1
(0.046%)
1Wim Terryn et al., Two-Tier Approach for the Detection of Alpha-Galactosidase a Deficiency in a Predominantly Female Haemodialysis Popula-
tion. Nephrol Dial Transplant 23: 294–300, 2008.
2Gert De Schoenmakere et al., Two-Tier Approach for the Detection of Alpha-Galactosidase a Deficiency in Kidney Transplant Recipient”. Nephrol 
Dial Transplant 23: 4044–4048, 2008.
3Wim Terryn et al., Prevalence of Fabry disease in a predominantly hypertensive population with left ventricular hypertrophy.  Int J Cardiol (ac-
cepted June 2012).
mL/min/1.73 m2 at a mean age of 39. In males, this was 74 mL/min for a median age of 45.
Only limited data were available on the subsequent evolution of kidney function in these 
patients before ERT was started. In females, median delta eGFR (mL/min/1.73 m2/year) was 
–3.3, which is comparable with literature data on Fabry nephropathy. In males, however, 
median delta eGFR (mL/min/year) was +1.35 mL/min/1.73 m2/year, which is in contradic-
tion with expected kidney function deterioration in Fabry males which is up to –12.2 mL/
min/ 1.73 m2/year (Branton et al. 2002).
Many patients (male and female) had micro-albuminuria. Only three had macro-albu-
minuria (> 300 mg/24 h). The cause of albuminuria was not clear, as only two patients had 
been biopsied. The male (patient 16) did not show Fabry nephropathy but lupus nephritis, 
and was successfully treated with immunosuppressive therapy. Stroke was mentioned in 
only one 80-year-old female (patient 8); at this age, stroke cannot simply be attributed to 
FD alone.
Discussion
The p.Ala143Thr mutation is a previously reported missense mutation: resulting from a 
G to A transition at nucleotide position 247 in exon 3, leading to an Alanine to Threonine 
substitution and has been reported as being pathogenic (Eng et al. 1997).
The p.Ala143Thr mutation was first reported in 1997 (Eng et al. 1997). The propositus was 
a 1-month-old male infant serendipitously found to have deficient α-Gal A activity with no 
family history of FD. It was concluded in the same paper that the phenotype associated with 
this mutation was unknown. In 2002, this mutation was detected in patients as a result of 
screening in dialysis patients (Spada 2002 JIMD abstract). In a second abstract (Spada 2003), 
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the same author considered this mutation to be related to late-onset end-stage renal dis-
ease. From that time, we read in literature this is a “known pathogenic mutation,” but it was 
not supported with biopsy data as proof of its pathogenicity. The association of this muta-
tion with renal failure, as in our screening studies (Table 3.2) in renal failure or left ventricular 
hypertrophy, might thus be the result of selection bias. 
In vitro expression of this mutant allele in COS 7 cells has been studied (Spada et al. 2006). 
There is 36 % of expressed α-Gal A wild-type activity which is in agreement with residual 
enzyme function in our patients. The finding of a low α-Gal A activity however is not directly 
related to FD. We found that the p.Ala143Thr mutation indeed is associated with a low α-Gal 
A activity, but its contribution to the phenotype of our patients (stroke, renal failure, left 
ventricular hypertrophy) is unclear. We performed three kidney biopsies, all lacking typical 
Gb-3 deposits which are universally present in Fabry patients (Noël et al. 2012). Moreover, 
among the remaining patients described in this study, we could not find one patient with 
this mutation and renal failure in whom significant renal Fabry disease was proven by kid-
ney biopsy. In the sphingolipidosis, the ratio of substrate influx into the lysosome and the 
capacity of the degrading system determines the storage and as such the course and se-
verity of the disease. This is treated in quantitative terms by the so-called threshold theory 
(Kolter 2011). Only the decrease of enzyme activity below the critical threshold value causes 
storage of the corresponding lipid substrate. Decrease of enzyme activity to the calculated 
threshold value does not influence the turnover rate of the substrate (as above this thresh-
old, there is no (linear) relation between enzyme activity and turnover) and pathological 
storage occurs only below this level. With the exception of acid ceramidase, a decrease of 
enzyme activity to values of 20 % of normal cells, a typical range for heterozygote carriers of 
inherited diseases, has no impact on the turnover rate (Kolter 2011).
Our findings corroborate these findings, as we found no deposition of Gb-3 in the lys-
osomes of the cells of our patients with the p. Ala143Thr mutation. On the basis of the 
“threshold theory” and the in vitro studies of Spada et al. (2006), this could be predicted, 
as the in vitro expression of α-Gal A in this genotype was 36 % of the wild type expression, 
which is well over the 20 % mentioned by Kolter 2011.
In FOS, kidney function in patients with p.Ala143Thr remains well preserved in males 
until their 40s, which is in contradiction with studies on natural history (Branton et al. 2002). 
Unfortunately, we have no biopsy data in all of these patients, so we cannot ascertain or 
exclude renal FD in many patients.
Attenuated Fabry phenotypes lacking the classical FD symptoms have been described as 
a consequence of residual α-Gal A activity. Some mutations result in residual α-Gal A activ-
ity. This has been described to result in “cardiac variants” that present later in life, with pre-
dominantly cardiac manifestations (Scheidt von W et al. 1991). Most of the female patients 
in this study could be regarded as “variants”; they have significant residual enzyme function, 
no classical FD symptoms, and mostly cardiac and neurological symptoms.
On the other hand, as FD remains the subject of screening studies in high-risk popula-
tions including patients with renal failure and/or stroke, there is a danger of misdiagnosis 
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as a result of selection bias, especially as the p.Ala143Thr mutation was not only detected 
in screening studies in Belgium (Terryn et al. 2008; De Schoenmakere et al. 2008; Brouns et 
al. 2010) but also in newborn screenings in Italy (Spada et al. 2006), Taiwan (Lin et al. 2009) 
Austria (Mechtler et al. 2012), and in other screening studies (Monserrat et al. 2007; Elliott 
et al. 2011). 
The prevalence of the p.Ala143Thr mutation in our highrisk populations (0.33 %, Table 
3.3) is almost 20 times higher than in a European newborn population (0.017 %, Mechtler 
et al. 2012). Low a-α-Gal A activity could be one cofactor contributing to endothelial stress, 
provoking stroke, renal failure, or other signs, and symptoms classically associated with 
FD. The lack of Gb-3 deposits on electron microscopy does not preclude high intracellullar 
Table 3.4. FOS data on adult patients with the p.Ala143Thr mutation.
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5 F 33 0.17 2 71 107 11 -7.6 No No Yes
6 F 38 0.79 2 82 110 22 -1.6 No No No
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8 F 80 NA 27 NA 30 -5.6 Yes Yes No
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10 F 64 0.69 2 67 140 8 -11.5 No No Yes
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NA = not available , MDRD = Modification of Diet in Renal Disease, ERT =  Enzyme Replacement Therapy
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(lyso)-Gb3 levels that could be pathogenic and cause endothelial cell dysfunction (Namdar 
et al. 2012), though this should be confirmed with further studies.
Despite the coexistence of renal failure, proteinuria, and low α-Gal A activity in patient 1 
from our database (Table 3.1), the diagnosis of Fabry nephropathy was offset by the biopsy 
that showed a typical case of diabetic nephropathy. Proteinuria and renal failure in patient 
16 in the FOS database (Table 3.4) was secondary to lupus nephritis. The cardiac biopsy in 
patient 7 from our own database (Table 3.1) with LVH and heart failure showed AL amyloid. 
These examples prove that before accepting the diagnosis of FD, confirmation of a mu-
tation and diminished enzyme activity are needed, as well as comprehensive clinical and 
pathological workup of the patients, where biopsies of the involved organ, next to other 
diagnostics tools as MRI in left ventricular hypertrophy, should confirm the diagnosis.
Only two patients with the p.Ala143Thr in FOS were reported to have had a kidney bi-
opsy, in spite of a larger number of patients with renal failure. Nevertheless, most of the 
included patients were treated with ERT. This expensive treatment is possibly not warranted 
in these patients. 
In stroke, establishing a diagnosis of FD is even more difficult as is the case also in sev-
eral of our own cases, as biopsy of the affected organ is impossible. Diagnosis is especially 
difficult when other typical features of FD are lacking, as is the case for the p.Ala143Thr 
mutation. 
It has been proposed by expert panels to start treatment in all adult (>16 years) male 
Fabry patients, and in all patients, pediatric, male, or female, “as soon as clinical signs and 
symptoms are observed” (Eng et al. 2006). In our cases, however, we have no knowledge on 
the contribution of the enzymatic defect to the patients’ morbidity and no reliable prognos-
tic data are available on the evolution in case of an “atypical” variant like the p.Ala143Thr. 
It is even questionable if these patients have Fabry disease at all; it has been suggested to 
call such mutations, biochemically true positive but clinically false positive, as “fringe muta-
tions” (Houge et al. 2011). Moreover, ERT has been studied in the classical phenotype, but 
there are no studies on the effects in the atypical variants.
The inclusion of patients with the p.Ala143Thr or other mutations associated with an 
attenuated phenotype (e.g., N215S or p.Asn215Ser, Branton et al. 2002) in studies on the 
effectiveness of ERT could confound results and should be studied separately. The place of 
ERT in patients with the p.Ala143Thr mutation is still unclear and should be the subject of 
close study. The currently available databases such as the industry-sponsored FOS cannot 
answer this question. An independent international database with mandatory data collec-
tion could provide quality data for further study. 
Based on our data, we conclude that the expressivity of the p.Ala143Thr mutation is ex-
tremely variable. The presence of this mutation is not to be directly associated with pathol-
ogy, and we have no compelling data that label this mutation as “pathogenic.” At most, it 
is “possibly” pathogenic. As a consequence, biopsy and clinical data should be collected in 
order to be able to understand the natural evolution and to decide on the need for ERT.
Chapter 3
96
References
Brady R, Gal A, Bradley R, Martensson E, Warshan A (1967) Enzymatic defect in Fabry’s disease — cerami-
detrihexosidase deficiency. N Engl J Med 276:1163–1167
Branton M, Schiffmann R, Kopp JB (2002) Natural history and treatment of renal involvement in Fabry disease. J 
Am Soc Nephrol 13(Suppl 2):S139–143
Brouns R, Thijs V, Eyskens F et al (2010) Belgian Fabry Study: prevalence of Fabry disease in a cohort of 1000 
young patients with cerebrovascular disease. Stroke; J Cerebral Circulation 41(5):863–868
Chamoles NA, Blanco M, Gaggioli D (2001) Fabry disease: enzymatic diagnosis in dried blood spots on filter 
paper. Clin Chim Acta 308(1–2):195–196
De Schoenmakere G, Poppe B, Wuyts B et al (2008) Two-tier approach for the detection of alpha-galactosidase 
A deficiency in kidney transplant recipients. Nephrol Dial Transplant 23(12): 4044–4048
Elliott P, Baker R, Pasquale F et al (2011) Prevalence of Anderson- Fabry disease in patients with hypertrophic 
cardiomyopathy: the European Anderson-Fabry Disease Survey. Heart 97(23): 1957–1960
Eng CM, Ashley GA, Burgert TS, Enriquez AL, D’Souza M, Desnick RJ (1997) Fabry disease: thirty-five mutations 
in the alphagalactosidase A gene in patients with classic and variant phenotypes. Mol Med 3(3):174–182
Eng CM, Germain DP, Banikazemi M et al (2006) Fabry disease: guidelines for the evaluation and management 
of multi-organ system involvement. Genetics Med 8(9):539–548
Houge G, Tøndel C, Kaarbøe Ø, Hirth A, Bostad L, Svarstad E (2011) Fabry or not Fabry – a question of ascertain-
ment. Eur J Human Genetics 19(11):1111–1112
Kint JA (1970) Fabry’s disease: alpha-galactosidase deficiency. Science (NewYork, NY) 167(3922):1268–1269
Kolter T (2011) A view on sphingolipids and disease. Chem Phys Lipids 164(6):590–606
Lin HY, Chong KW, Hsu JH, Yu HC, Shih CC, Huang CH, Lin SJ, Chen CH, Chiang CC, Ho HJ, Lee PC, Kao CH, Cheng 
KH, Hsueh C, Niu DM (2009) High incidence of the cardiac variant of Fabry disease revealed by newborn 
screening in the Taiwan Chinese population. Circ Cardiovasc Genet 2(5):450–456
Mechtler TP, Stary S, Metz TF et al (2012) Neonatal screening for lysosomal storage disorders: feasibility and 
incidence from a nationwide study in Austria. Lancet 379(9813):335–341
Monserrat L, Gimeno-Blanes JR, Marín F et al (2007) Prevalence of Fabry disease in a cohort of 508 unrelated 
patients with hypertrophic cardiomyopathy. J Amer College Cardiol 50 (25):2399–2403
Nakao S, Takenaka T, Maeda M et al (1995) An atypical variant of Fabry’s disease in men with left ventricular 
hypertrophy. N Engl J Med 333(5):288–293
Namdar M, Gebhard C, Studiger R et al (2012) Globotriaosylsphingosine accumulation and not alpha-galactosi-
dase-a deficiency causes endothelial dysfunction in Fabry disease. PLoS ONE 7(4):e36373
Noël L-H, Laurent B, Gr€unfeld J-P (2012) Renal biopsies in Fabry disease: A multicenter French study. Neph-
rologie Therapeutique
von Scheidt W, Eng CM, Fitzmaurice TF et al (1991) An atypical variant of Fabry’s disease with manifestations 
confined to the myocardium. N Engl J Med 324(6):395–399
Spada M, Pagliardini S (2002) Screening for Fabry Disease in endstage nephropathies. J Inherit Metab Dis 25 
(Suppl. 1), p 113, Abstract number 226–P
Attenuated Fabry Disease
97
Spada M, Pagliardini S (2003) Prevalence and characteristics of Fabry disease in nephrolgoy: a lesson from 
the screening of 6378 male patients on dialysis. J Inherit Metab Dis 26 (Suppl 2), p. 145, Abstract number 
289–O
Spada M, Pagliardini S, Yasuda M et al (2006) High incidence of later-onset Fabry disease revealed by newborn 
screening. Am J Hum Genet 79(1):31–40
Terryn W, Poppe B, Wuyts B et al (2008) Two-tier approach for the detection of alpha-galactosidase A deficiency 
in a predominantly female haemodialysis population. Nephrol Dial Transplant 23(1): 294–300

Screening and Treatment
in Chronic Kidney Disease
Chapter 4 4
From our screening studies in high-risk populations, we conclude that Fabry disease is under-diagnosed in patients with chronic kidney disease. One of the 
reasons for this is the fact that nephrologists are not fa-
miliar with this disease.  The European Renal Best Practice 
(ERBP) is the official guideline body of the European Renal 
Association/European Dialysis and Transplant Association 
(ERA/EDTA). The ERBP advisory board considered it use-
ful to develop guidance in the field of rare diseases with 
nephrological relevance, and invited a group of experts 
to collaborate in order to develop guidance for nephrolo-
gists to diagnose and treat Fabry disease. The following 
paper is the result of this work: systematic literature re-
view, a consensus meeting with an international panel of 
experts and peer review.
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Paper Five
Fabry nephropathy: indications for screening and
guidance for diagnosis and treatment by ERBP
Wim Terryn, Pierre Cochat, Roseline Froissart, Alberto Ortiz, Yves Pirson, Bruce Poppe, 
Andreas Serra, Wim Van Biesen, Raymond Vanholder, Christoph Wanner. 
Nephrol Dial Transplant. 2012 Dec 12. [Epub ahead of print]. 
Abstract
 Fabry disease (FD) is an X-linked disorder of glycosphingolipid catabolism resulting in the 
accumulation of glycolipids including globotriaosylceramide in cells of various tissues re-
sulting in end-organ manifestations. Initially, FD is typically characterized by angiokeratoma 
and recurrent episodes of neuropathic pain in the extremities occurring during childhood 
or adolescence. Most affected patients also exhibit a decreased ability to sweat. Later in life, 
FD results in left ventricular hypertrophy, proteinuria, renal failure and stroke. These later 
disease manifestations are non-specific and also common in diabetes, hypertension and 
atheromatosis and thus for most practitioners do not point into the direction of FD. As a 
consequence, FD is under-diagnosed and screening of high-risk groups is important for case 
finding, as is a thorough pedigree analysis of affected patients. In the nephrology clinic, we 
suggest to screen patients for FD when there is unexplained chronic kidney disease in males 
younger than 50 years and females of any age. In men, this can be performed by measur-
ing !-galactosidase A activity in plasma, white blood cells or dried blood spots. In women, 
mutation analysis is necessary, as enzyme measurement alone could miss over one-third 
of female Fabry patients. A multidisciplinary team should closely monitor all known Fabry 
patients, with the nephrologist screening kidney impairment (glomerular filtration rate and 
proteinuria) on a regular basis. Transplanted Fabry patients have a higher mortality than 
the regular transplant population, but have acceptable outcomes, compared with Fabry 
patients remaining on dialysis. It is unclear whether enzyme replacement therapy (ERT) pre-
vents deterioration of kidney function. In view of the lack of compelling evidence for ERT, 
and the low likelihood that a sufficiently powered randomized controlled trial on this topic 
will be performed, data of all patients with FD should be collected in a central registry. 
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Introduction
European Renal Best Practice (ERBP) is the official guideline body of the European Renal Association/European Dialysis and Transplant Association (ERA/EDTA). The mission of ERBP is to improve the outcome of patients with kidney disease in a sus-
tainable way, through enhancing the accessibility of knowledge on patient care, in a format 
that stimulates its use in clinical practice. In line with this mission, and in view of its phi-
losophy [1], the ERBP advisory board considered it useful to develop guidance in the field 
of orphan diseases with nephrological relevance. Typical for these diseases are the rather 
low patient number, and consequently, the lack of large trials. As a consequence, formal ev-
idence-based medicine is nearly impossible in this field. Nevertheless, nephrologists need 
guidance on how to approach patients with these diseases. Therefore, ERBP decided to use 
the combination of formal systematic literature reviews, a consensus meeting with an inter-
national panel of experts and peer review as a suitable model to develop guidance in the 
field of orphan diseases. A first paper on oxalosis has already been published in this series 
[2]. This paper presents the results of a guidance process on the topic of Fabry disease (FD).
FD (OMIM ID #301500) is an X-linked inborn error of glycosphingolipid catabolism 
caused by quantitative or qualitative defects in the lysosomal enzyme !-galactosidase A (!-
Gal A). As a result, glycosphingolipids, mainly globotriaosylceramide (Gb-3), accumulate in 
the lysosomes of different cells throughout the body, ultimately resulting in organ failure [3, 
4]. Patients with FD have a markedly limited life expectancy due to cardiovascular, neuro-
logical and renal involvement. Enzyme replacement therapy (ERT) has been made available 
since 2001. Intravenous infusion every other week results in the removal of a part of the 
Gb-3 deposits, diminishes Fabry-related symptoms and possibly protects organs to a cer-
tain extent [5, 6]. The effects of ERT on progression of renal disease ( proteinuria and renal 
function) are unclear. 
Aims of this publication
The first aim of this paper is to review the current literature on renal disease in Fabry patients, in 
order to provide guidance to the nephrologist on when to screen for this disease and why, 
and to understand the preferred methods that should be used for screening.
The second aim is to provide guidance on the follow-up, prevention and treatment of renal 
disease, and its complications (proteinuria, renal failure). The role of ERT, angiotensin-con-
verting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB) and renal replace-
ment therapy (RRT) is reviewed.
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Methods
A literature search was conducted using the PubMed database (most recent search July 
2012). The search term used was ‘Fabry Disease’ with limits: ‘Humans’, ‘Clinical Trial’, ‘Meta-
Analysis’, ‘Practice Guideline’, ‘Randomized Controlled Trial’, ‘Review’, ‘English’, ‘French’. A total 
of 357 articles were retrieved; the articles were classified to the following topics (one paper 
can be attributed to more than one classification):
(i)  epidemiology, screening studies;
(ii)  diagnostic methods;
(iii) Fabry nephropathy: natural history, complications (hypertension), mechanisms, renal 
pathology;
(iv) treatment of Fabry nephropathy; with ERT, ACEi and ARB, RRT; efficacy and safety issues.
Articles out of scope and review articles that presented no new data were excluded. Ar-
ticles on experimental, non-registered treatments were also excluded.
The reference lists of the identified relevant studies were manually searched for addi-
tional citations.
After all relevant publications were retrieved, a consensus meeting was held with all co-
authors. The resulting paper was sent for internal review before submission, as explained in 
the ‘instructions to authors’ section of the ERBP website [7].
Epidemiology and the need for screening
1.1  We do not recommend screening in the general population. (Ungraded statement)
1.2  We recommend obtaining informed consent from the patient before screening, using 
an information form drafted in collaboration with a clinical geneticist. (Ungraded state-
ment)
1.3  We recommend screening for FD in male chronic kidney disease (CKD) patients below 50 
years of age in whom a reliable renal diagnosis is absent. (Ungraded statement)
1.4  We suggest screening for FD in females with unexplained CKD, irrespective of age, with 
other unexplained symptoms potentially associated with FD. (Ungraded statement)
1.5  We recommend discussing with the patient the implications of diagnosing a genetic dis-
ease and the possible implications for the at-risk relatives. (Level 1C)
Rationale
Classical FD is a progressive multisystem disease predominantly presenting in males, 
characterized by angiokeratoma, hypohidrosis and acroparesthesia (neuropathic pain) in 
childhood, followed by renal failure, left ventricular hypertrophy (LVH), stroke and prema-
ture death in the fourth or fifth decade of life [8]. In male patients, levels of α-Gal A activity 
are classically very low or undetectable. However, as a result of screening studies during the 
past decade, clinical variants of FD in male patients with varying degrees of residual activity 
of α-Gal A have been described. The first described was the ‘cardiac variant’ with isolated 
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LVH and/or cardiomyopathy presenting in the sixth or seventh decade, lacking the classical 
disease symptoms and time course [9, 10]. Patients suffering from this variant may have pro-
teinuria, but their renal function is typically normal for their age. Later a ‘renal variant’ phe-
notype was described in a screening study in a dialysis population, where patients again 
were lacking the classical manifestations. This phenotype was described as ‘intermediate’ 
between the cardiac variant and the classic phenotype [11]. These patients with cardiac and 
renal variants are called ‘atypical’ or ‘attenuated’ FD patients. The genetic basis of this vari-
able penetrance and expression is unclear. It is believed that the atypical cases are the result 
of missense mutations that encode mutant enzyme protein or intronic lesions that reduce 
transcript levels, both resulting in a reduced but significant residual enzyme function (1-
12% of normal) [12], although this has been debated, and others found no genotype–phe-
notype correlation [13]. Heterozygous women, in spite of having a mutation compatible 
with typical disease, can also present this attenuated phenotype as it was hypothesized 
that skewed X-inactivation can result in significant residual enzyme function. However, it 
must be stressed that most females have the classical phenotype, but with a delayed and/
or milder presentation of symptoms [14].
As a consequence, reported prevalence varies with the population studied and the test 
used for screening, and genetic screening might find female index cases that are not found 
by enzyme-based methods [15]. The prevalence of classical FD has been estimated at 1 in 
117 000 births [14] and 1 in 40 000 males [8]. In several screening studies in high-risk popu-
lations, the frequency was up to 1% or even higher, especially in populations with unex-
plained LVH [16]. In newborns [17-19], the incidence of α-Gal A deficiency was 1 in 3100 
with an 11 to 1 ratio of 2 W. Terryn et al. patients with the later-onset versus the classic phe-
notype. In the haemodialysis population, a prevalence of 0.33% in male and 0.10% in female 
patients has been found in a cross-sectional screening study [16]. Only two studies screened 
kidney transplant patients. In cryptogenic stroke, a prevalence of 0.8% [20] up to 2.4% [21] 
and 3.9% [22] was found; however, in the second study [21], half of the patients had the 
p.D313Y mutation, which is now generally regarded as a pseudo-deficiency, and in the last 
study [22], the specific mutations were not mentioned and could also have been polymor-
phisms. Many screening studies are not conclusive for the female population, as they most 
frequently used α-Gal A activity screening, which is in women, as described above, not a 
sensitive screening tool.
Although there are no studies in the CKD population not on dialysis, we recommend 
screening for FD in patients with CKD without a clear diagnosis. In classical FD, most males 
reach CKD Stage 5 or die before the age of 50 [12, 23]. As a consequence, we recommend 
screening in males only below the age of 50 years. We recommend screening even in the 
case of a negative family history as de novo mutations can occur, and the family history is 
not always suggestive for FD, given the broad phenotypic spectrum of the disease. Arte-
rial hypertension should not be an exclusion criterion as more than 50% of FD patients 
have mild to moderate hypertension, especially when estimated glomerular filtration rate 
(eGFR) is <60 mL/min/1.73 m2 [23–25]. In women, disease onset can be later, so when there 
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is unexplained kidney disease associated with manifestations suggestive of FD, we suggest 
screening for FD regardless of age.
The real prevalence should be derived from screening in the healthy population at a 
young age; this has been done in four studies in newborns [17–19, 26]. However, this ap-
proach remains problematic for several reasons. The American College of Medical Genetics 
(ACMG) has proposed newborn screening for 29 disorders, but screening for FD was not in-
cluded in this list (available online at: http://mchb.hrsa.gov/screening/). Although measure-
ment of !-Gal A has a good sensitivity and specificity in males, it has a low positive predictive 
value in the healthy population. This will result in unnecessary expensive tests. In addition, 
the majority of the detected cases in the newborn studies are ‘atypical’ mutations, giving an 
attenuated phenotype or a cardiac variant. The finding of a genetic predisposition for a pos-
sible late-onset disease where the treatment effectiveness is unclear has ethical and legal 
implications that constrain a systematic screening of newborns. In these cases, it would be 
difficult to decide on ERT, as the natural history of patients carrying atypical mutations is 
poorly characterized, effects of ERT in mild cases have not been studied, and a lifelong treat-
ment is a psychological burden for the patient and a financial one for both the individual 
and society with, on top of that, uncertain results. As a consequence, we do not recommend 
screening for FD in the general population.
As FD is an X-linked disease with variable but significant morbidity both in males and 
females, its diagnosis might have profound consequences for the proband and his relatives. 
As a consequence, we recommend obtaining informed consent from the proband before 
screening, when possible in cooperation with an expert in genetic counselling. (Example in 
Appendix page 120.)
Once the diagnosis is made, it is important to make up a pedigree in order to identify all 
relatives at risk. FD is an X-linked disease where all carriers can be symptomatic. It should 
be kept in mind that ‘skipping’ of a generation is possible because of variable expression.
The patient should receive further guidance in communication with his family. He must 
be able to provide sufficient information (e.g. by using flyers written by the treating team), 
and one must anticipate a number of possible problems in the communication with his 
family. Some people do not want a work-up to the diagnosis of FD, and it should be ex-
plained to the patient that they do have the right not to know their genetic status.
Screening methods
2.1 We recommend using enzyme activity measurement for α-Gal A as a primary tool in 
males, followed by confirmation with mutation analysis when positive. (Ungraded state-
ment)
2.2 We suggest using mutation analysis as a primary tool for screening in females. (Ungrad-
ed statement) 
Measurement of α-Gal A activity in leucocytes using the fluorogenic substrate 
4-methylumbelliferyl-α-D-galactopyranoside is the gold standard for FD in men, with a sen-
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sitivity and specificity of nearly 100%. Recently, a dried blood spot test (DBS) using filter 
paper has been proposed as an alternative to the leucocyte tests [27]. These samples are 
easy to transport and are stable at room temperature for many days, making it a most con-
venient screening tool in men, as it is a very sensitive tool with a negative predictive value 
reaching 100%.
In women, due to skewed X inactivation, enzyme activity measurement has a low sen-
sitivity, as one in three women with FD have normal or nearly normal α-Gal A activity [15]. 
For this reason, enzymatic tests are less suitable and systematic genetic testing should be 
encouraged in females with unexplained CKD and manifestations suggestive for FD. As ge-
netic testing is expensive (150–1000 Euro and more per test), a thorough anamnesis, family 
history and clinical investigation could help to select female CKD patients in whom testing 
is cost-effective (Figure 4.1).
In FD, gene mutation analysis is a way of confirming diagnosis in male patients, subse-
quent to enzyme activity measurement. A fresh blood sample can be collected for this pur-
pose, or polymerase chain reaction amplification can be performed on DNA eluted directly 
from the filter paper used for the DBS α-Gal A measurement [28]. GLA gene mutations caus-
ing FD include single base changes leading to missense or nonsense mutations, or affecting 
Figure 4.1. Flowchart for screening for FD in CKD patients.
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consensus splice sites, small deletions or insertions, but also large gene rearrangements in 
<5% of the patients. Correlations between a specific mutation, i.e. the genotype, and the se-
verity of the disease, the phenotype, are poor in FD. In a few cases, however, knowledge on 
the underlying mutation can provide information concerning prognosis and therapy and 
help the clinician in counselling. Some mutations are frequently associated with an attenu-
ated phenotype, such as the mutation p. N215S, which gives a cardiac phenotype with only 
LVH [29]. These mutations are associated with a residual enzyme function [30]. A significant 
proportion of the mutations in men are, however, associated with a very low or absent en-
zyme function and the classic phenotype.
The GLA gene should be sequenced. As most of the mutations are ‘private’, i.e. unique to 
a family, it is always possible to completely identify a previously undetected mutation, and 
regular updates of such new mutations are available (http://www.hgmd.cf.ac.uk/ac/index.
php). The pathogenicity of novel gene alterations such as missense or intronic mutations 
must always be evaluated. However, in females with normal biochemical tests, it may be 
difficult to confirm or exclude the diagnosis of FD when a variant of unknown significance 
is present.
In a suggestive clinical situation, most sequence alterations in exonic regions are patho-
genic with very few exceptions. One example of such inert exonic polymorphism is the p. 
‘D313Y’ substitution (G to T at cDNA nucleotide 937); while the plasma enzyme activity to-
wards the artificial substrate is significantly reduced, additional studies demonstrated high 
residual lysosomal enzyme activity and no pathologic excretion of urinary Gb-3. As a result, 
the p.D313Y substitution is now generally considered to be a so-called pseudo-deficiency.
If one finds a novel sequence variation in an intronic region or a novel missense muta-
tion that is not known to be a polymorphism present in the general population, several 
methods allow non-invasive diagnostic analysis to establish whether it is disease causing. 
First, it should be checked whether these sequence variations exist in the normal popula-
tion (using electronic databases or an own control population). The second step is to check 
male relatives of the index case who are carriers of the sequence variation for α-A activity. 
If the sequence variation is present in some of them, despite a normal α-Gal A activity and 
absence of clinical manifestations of FD, the sequence variation can be considered to be a 
polymorphism. If it coincides with a deficient α-Gal A in one or more of the male relatives, 
the possibility of a disease causing mutation is realistic, and in this case, a work-up of all 
carriers for the presence of (subclinical) FD disease manifestations should be considered.
Besides enzyme activity measurement and mutation analysis, detection of the accumu-
lating substances (glycosphingolipids) has been studied as a tool for diagnosis. Globotria-
osylceramide (Gb-3) is the most important glycosphingolipid, and it should be measured in 
urine rather than in plasma. Urinary Gb-3 can be a useful diagnostic tool in female heterozy-
gotes with classical FD as it is increased in 95% of them. However, the proportion is much 
lower in heterozygotes with variant forms. It can also be used in males as a surrogate marker 
to evaluate the response to ERT [31]. Mass spectrometric profiling of Gb-3 isoforms may also 
help to identify heterozygotes [32].
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In plasma, deacylated Gb-3 (globotriaosylsphingosine, ‘lysoGb-3’) has been shown to 
have a better correlation with FD. It is elevated 200-400 times in males with classical disease, 
from an early phase in the disease, but its levels can remain low in asymptomatic females 
or in the ‘cardiac variant’ p.N215S in males [33-37]. The examination of the urinary sediment 
with phase-contrast microscopy under polarized light shows tubular cells containing par-
ticles with birefringent Maltese Crosses, having a lamellated appearance with protrusions, 
and consisting of accumulated Gb-3. In the hands of Selvarajah et al. [38], this was a highly 
sensitive and specific tool for screening of FD, but its accuracy is strongly operatordepend-
ent and therefore, it is probably an unrealistic option for large-scale screening studies.
Work-up of a patient with FD
3.1 We recommend that the detailed baseline and followup data of all patients with estab-
lished FD should be transferred to a central registry. (Ungraded statement)
3.2 We recommend baseline and subsequent yearly evaluation by a multidisciplinary team, 
including kidney function and albuminuria, in all patients with established FD (cardiol-
ogy, neurology and nephrology). (Ungraded statement)
3.3 We recommend not considering female carriers for living donation, unless in exceptional 
cases. In these cases, we recommend a kidney biopsy to evaluate the risk for the donor 
and acceptor. (Ungraded statement)
Once an index patient is diagnosed, a baseline evaluation is indicated. As FD is a progres-
sive multisystem disease, baseline evaluation is optimally performed by a multidisciplinary 
team (Table 4.1, adapted from Eng et al. [39]). The baseline evaluation should be performed 
in male and all female carriers, as the phenotype can be equally severe. 
As this document is written from the nephrology perspective, we will focus on renal in-
volvement in what follows. For evaluation and pathophysiology of other organs, we refer to 
the guidelines of the respective subspecialities. 
Renal involvement is a cardinal feature of FD. Gb-3 deposition in renal cells is progressive 
and begins early in life. Besides these deposits, pathogenic mechanisms result in glomeru-
lar ischaemia with subsequent glomerulosclerosis and tubular atrophy, even very early in 
the disease course. Vacuolization of podocytes and epithelial cells is a characteristic optical 
microscopy histological finding. These vacuoles are filled with deposits on electron micros-
copy, or following toluidine blue staining of samples prepared for electron microscopy. At 
an early stage, hyperfiltration may, as in diabetes, be the first sign of kidney damage.
As FD can progress subclinically, adolescent and adult patients should have urinary al-
bumin measurement, as this is one of the first signs of Fabry nephropathy. We suggest as-
sessing the amount of albumin normalized for creatinine on a fresh morning sample as di-
agnostic test. We suggest measuring urinary albumin rather than total protein, as it is more 
sensitive. Renal function can be assessed using serum creatinine and eventually formulas to 
translate serum creatinine to estimated clearances. Even in the absence of albuminuria or 
renal failure, all these parameters should be re-evaluated at least yearly in order to detect 
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Table 4.1. Proposed assessments in FD patients [39].
Organ system Assessment Recommendation
General General status, school or work performance, sports, depression, 
anxiety, drug use, pedigree update, somatic growth
Complete physical examination SF-36®Health Survey, or PedsQL™
Measurement Mode
Genetic counselling
Genotype
Baseline (at first visit), every 6 months
Baseline, every 6 months
Baseline, every 6 months for new issues
If not previously determined
Kidney Serum electrolytes, creatinine, BUN; 24-h urine or spot urine for 
total protein/creatinine, albumin/creatine, sodium, creatinine
Baseline, every 3 months if CKD Stage 1 or 
2 and >1
g/day of proteinuria or CKD Stage 4
Every 6 months if CKD Stage 3
Every 12 months if CKD Stage 1 or 2 and <1 
g/day of proteinuria
Cardiac Palpitations, angina
Blood pressure, rhythm
ECG, echocardiography 2D with Doppler
Holter monitoring, 30-day event monitoring
MRI, strain rate imaging
Coronary angiography 
Baseline, every 6 months
Every evaluation visit
Baseline, every other year for patients ч35 
years of age, every year thereafter
If an arrhythmia is suspected or palpita-
tions are present
Optional
If clinical signs of angina
Neurologic Acroparesthesias, fatigue, fever, sweating, heat and cold intoler-
ance, joint pains, stroke-related symptoms, TIA
Neurologic exam, Brief Pain or McGill Pain Inventory
Brain MRI without contrast
Magnetic resonance angiography
Cold and heat intolerance, pain, vibratory thresholds, sweat out-
put, postganglionic sudomotor function, superficial skin blood 
flow
Co-morbid stroke risk factors: cholesterol (Total, LDL, HDL), triglyc-
erides
Lipoprotein A, total plasma homocysteine, factor V Leiden 
(G1691A), Protein C, Protein S, prothrombin G20210A, an-
tithrombin III, abticardiolipin antibody, lupus anticoagulant
Baseline, every 6 months
Baseline, every 6 months
Baseline, at the time of a TIA or stroke 
event or in females to document CNS 
involvement
If cerebral vasculopathy should be ex-
cluded
When available
Annually
At baseline, single assessment
ENT Tinnitus, hearing loss, vertigo, dizziness
Audiometry, tympanometry, otoacoustic emissions
Baseline, every 6 months
Baseline, and yearly thereafter
Ophthalmo-
logic
Visual disturbances, light sensitivity
General ophtalmologic exam (slit-lamp, direct ophtalmoscopy, 
best corrected visual acuity, visual fields)
Retinal disfunction testing (ERG, colour vision testing, visual-
evoked potentials, retinal angiography), tear secretion testing
Baseline, every 6 months
Baseline, every 12 months
If clinically indicated
Pulmonology Cough, exertional dyspnoea, wheezing, exercise intolerance
Spirometry, including response to bronchodilators, treadmill exer-
cise testing, oximetry, chest X-ray
Baseline, every 6 months
Baseline, every 2 years or more frequently 
for clinical indications
Gastrointes-
tinal
Postprandial abdominal pain, bloating, diarrhoea, nausea, vomit-
ing, early satiety, difficulty gaining weight
Endoscopic or radiographic evaluations
Baseline, every 6 months
If symptoms persist or worsen despite 
treatment
Skeletal Bone mineral density Baseline
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progressive disease.
Renal intracellular Gb-3 deposits may be present even in young children with normal 
GFR and minimal or absent micro-albuminuria. In a recent study of 14 young Fabry patients 
aged 4-19 years with normal GFR, there was an association between the volume of Gb-3 
deposition in the podocytes, and age. The volume of Gb-3 deposition was also correlated 
with urinary protein excretion rates [40]. Tøndel et al. [41] found segmental foot process ef-
facement in all young Fabry patients, despite the fact they were normo-albuminuric (below 
30 mg/day). Thus, in the case of patients at risk of FD, any albuminuria, even if in the ‘normal’ 
range, should be considered as suspect.
Proteinuria progresses and correlates with and probably also contributes to the decline 
in renal function, e.g. male Fabry patients with a proteinuria >1 g/24 h had a greater yearly 
decline in renal function (-6.9 mL/min/1.73 m2) than patients with proteinuria between 0.1 
and 1 g/24 h (-2.2 mL/min/1.73 m2) and patients with proteinuria <0.1 mg/24 h (-0.6 mL/
min/1.73 m2) [42]. Other studies confirm that the urinary protein to urinary creatinine ratio 
(UP/Cr) is the most important indicator of renal disease progression [43]. The yearly decline 
in renal function also correlates with GFR at presentation (in males, -3 mL/min/ 1.73 m2 
with GFR >60 mL/min/1.73 m2 versus -6.8 mL/ min/1.73 m2 with GFR ! 60 mL/min/1.73 m2; 
in females -0.9 mL/min/1.73 m2 versus -2.1 mL/min/1.73 m2) [42]. Most patients with CKD 
Stages 3-5 have some degree of proteinuria [23]. Proteinuria in the nephrotic range (>3.5 
g/24 h) is, however, rarely seen (maximal 18% in [12]).
CKD Stage 5 usually develops between the third and the fifth decade, with a mean age at 
diagnosis of 38, but can appear as early as at the age of 16 [44, 45]. Interestingly, the mean 
age at initiation of RRT is similar for males and females, although the proportion of male 
versus female FD patients on RRT was 9 to 1 [42]. 
Living related donation in FD can pose a problem if apparently asymptomatic female 
carriers consider donating a kidney. Even in the case of a normal renal function and in the 
absence of albuminuria, significant Gb-3 deposits can be abundant in a renal biopsy [46] 
and thus female carriers are, in our opinion, not eligible for living kidney donation.
The Fabry population is small and heterogeneous which makes it difficult to study its 
natural course and to conduct larger-scale, placebo-controlled or open-label clinical trials. 
For these reasons, a high quality registry with all treated and untreated patients on a Euro-
pean scale, developed independently of industry, is highly desirable.
Treatment of Fabry nephropathy
4.1 We do not recommend starting ERT in patients with proteinuria [ protein-to-creatinine 
ratio >1 g/g (>0.1 = gram/mol) creatinine] or eGFR <60 mL/min/ 1.73 m2, except for non-
renal indications. (1D)
4.2  We recommend that when ERT is deemed indicated, it should be started as part of a well-
designed clinical trial, either observational or interventional. (Ungraded statement)
4.3  In a patient on haemodialysis, and when ERT is deemed indicated, we recommend ad-
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ministering the ERT during a haemodialysis session. (1A)
4.4 We recommend kidney transplantation as a valuable option in patients who are eligible 
for this intervention. (Ungraded statement)
4.5  After renal transplantation, we do not suggest ERT for renal indications, but it can be 
continued for non-renal indications. (Ungraded statement)
As discussed above, proteinuria is an important risk factor for the progression of renal 
FD. The use of ACE-i and ARB has been shown to be nephro-protective in other proteinuric 
renal diseases, and could thus be important in FD as well. As such, the use of ACE-i or sar-
tane would be acceptable in FD. In a recent paper [47], it has been demonstrated that ERT 
interacts with ACE and inhibits its activity, possibly by removing the galactose residues from 
the enzyme. The clinical relevance of this observation is unclear, and should not be seen as 
a reason to prohibit the use of ACE-i.
Kidney Disease Improving Global Outcomes (KDIGO) guidelines suggest that in patients 
with CKD Stages 3–5, vitamin D deficiency be corrected [48]. Emerging evidence in patients 
with CKD show that vitamin D can reduce proteinuria or albuminuria even in the presence 
of angiotensin-converting enzyme inhibition [49]. Selective activation of the vitamin D 
receptor with paricalcitol lowered urinary albumin excretion, as was demonstrated in pa-
tients with Type 2 diabetes in a recent randomized controlled trial [50]. In cultured human 
podocytes, vitamin D receptor activation prevented lyso-Gb-3- induced, TGF”1-mediated, 
up-regulation of extracellular matrix proteins [51]. Even lacking more definitive evidence of 
a beneficial effect of vitamin D on Fabry nephropathy, it seems advisable to place particular 
emphasis in following guidelines on vitamin D management in CKD patients in patients 
with FD. 
Two forms of recombinant α-Gal A have been approved in Europe: agalsidase alpha 
(Replagal®; Shire Human Genetic Therapies, Boston, MA) and agalsidase beta (Fabrazyme®; 
Genzyme, Cambridge, MA). Agalsidase alpha is produced in a continuous human cell line 
and is administered as an intravenous infusion over 40 min at a dose of 0.2 mg/kg body 
weight every 2 weeks. Agalsidase beta is produced in Chinese hamster ovary (CHO) cells 
and is given as an intravenous infusion over a 4-h period at a dose of 1.0 mg/kg body weight 
every 2 weeks.
According to a recent Cochrane review, the evidence base in favour of ERT is weak. Only 
five (total n = 187) poor quality randomized controlled trials are available. They all concern 
surrogate end points, such as decrease in plasma Gb-3 levels in plasma and tissues and evo-
lution of renal function. According to the Cochrane review, these studies show no evidence 
for a clinical benefit of the use of agalsidase alpha or beta to treat Fabry nephropathy [52]. 
As there are at present no hard data that ERT alters the natural course of Fabry nephropathy 
(Table 4.2), we recommend starting ERT only in the context of a clinical trial, interventional 
or observational. All data from observational trials should be entered in a central registry.
Besides randomized controlled trials open-label studies and retrospective analyses have 
been performed. It is of interest to compare the evolution of renal disease in the histori-
cal untreated and treated cohorts of an international industry sponsored registry on FD 
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[43, 53]. It is difficult to compare the data presented in both publications, as the design of 
the analyses and the presentation of data were different, and there was a substantial risk 
for selection bias, as only a minor proportion of all those enrolled could be evaluated be-
cause of missing data. Nevertheless, in both studies, patients were stratified into quartiles 
according to severity indices of renal involvement. The slope of change in GFR was similar 
in comparable quartiles of the treated and untreated cohorts, especially in men. Hence, one 
cannot deny the reflection that ERT might have no marked impact on the decline of kidney 
function. From this comparison, it is also clear that, irrespective of ERT, proteinuria was the 
strongest predictor of outcome. In patients without proteinuria, renal function remained 
stable, equally in males as in females. In those with proteinuria, the slope of deterioration 
of eGFR appeared to be similar with or without ERT. It is unclear what the implications of 
these observations are with regard to ERT: either it implies that ERT should be given before 
proteinuria develops (but these subjects have no deterioration of kidney function anyway) 
or that it should not be given for renal protection in those with already existing heavy pro-
teinuria. It would be interesting to include complete data sets in a registry of patients devel-
oping proteinuria at early stages to see how the evolution of renal function is in this cohort. 
Remarkably, in the Fabry Registry, data on proteinuria were available in only 462 of 2850 
(historical cohort) and 213 of 2887 (ERT cohort) patients [43].
Other observational studies in male FD patients showed that renal function remained 
Table 4.2. Randomized controlled trials in ERT; data concerning the kidney [52].
Comparison I: Agalsidase alpha versus 
placebo
Agalsidase 
alpha (n) Mean (SD) 
Placebo 
(n)  Mean (SD) Mean difference, 95% CI
Urinary sediment Gb3
Schiffmann 2001 up to 6 months 14 1683 (1657) 11 2495 (1104) о812,00 (о1897.83, 273.83)
Kidney Gb3
Schiffmann 2001 up to 6 months 14 15.6 (5.98) 11 18.1 (10.54)  о2.5 (о9.47, 4.47)
Creatinine clearance
Schiffmann 2001 up to 6 months 13 94.8 (27.76) 1  84.5 (35.15) 10.30 (о15.37, 35.97)
Insulin clearance
Schiffmann 2001 up to 6 months 13 71 (16.11) 11 71.5 (32.03) о0.50 (о21.36, 20.36)
Mesangial widening
Schiffmann 2001 up to 6 months 12 25.7 (20.78) 9 40.4 (28.5) о14.70 (о36.72, 7.32)
Glomeruli with segmental sclerosis
Schiffmann 2001 up to 6 months 12 6.8 (8.66) 9 3 (5.7) 3.80 (о2.35, 9.95)
Obsolescent glomeruli
Schiffmann 2001 up to 6 months 12 19.5 (20.78) 9 13 (15.3) 6.50 (о8.93, 21.93)
Comparison II: Agalsidase beta versus 
placebo
Agalsidase 
beta (n) Mean (SD) 
Placebo 
(n)  Mean (SD) Mean difference, 95% CI
Renal microvascular endothelial deposits
Eng 2001 up to 6 months 29 0.4 (0.7) 29 2.1 (0.8)  о1.7 (2.09, о1.31)
Renal events
Banikazemi 2007 intention-to-treat 10/51 7/31 13 (15.3 0.87 (0.37, 2.04)
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stable under ERT during a follow-up period up to 54 months in the case of normal or near 
normal baseline function (CKD 1-2) and low proteinuria (<1 g/g creatinine) in the majority 
of patients [54]. However, as only treated patients were observed, it cannot be excluded 
that these patients would have had no progression even without therapy, as it is clear from 
registry data that proteinuria <0.3 g/g creatinine is a favourable prognostic marker. Other 
publications demonstrate that in FD patients with CKD Stage 4, or with glomerulosclerosis 
>50% or proteinuria >1 g/g creatinine, renal function continues to deteriorate despite ERT 
(decline in renal function varying from 6.4 to 8.9 mL/min/1.73 m2/year [54, 55]. In the case of 
CKD Stage 3, the decline in eGFR seems to be attenuated by ERT in comparison with histori-
cal data [-3.0 (male) and -1.0 versus -6.8 mL/ min/1.73 m2/year) [56]. Again, these data are 
small-scaled and use historic data as controls.
Few studies report on the effect of ERT on renal function in females. In a recent retrospec-
tive study of the Fabry Outcome Survey (FOS), the rate of decline in eGFR in females under 
ERT was similar to the normal expected age-related rate over a 4-year follow-up period, 
whereas the rate in men was approximately double the expected age-related rate of decline 
[57]. Another study reported on a stable renal function in female patients treated with ERT 
[58].
In summary, these studies suggest that, for the renal aspect of FD, treatment is at best 
only effective in CKD Stage 1 or 2, before the deterioration of renal function or onset of overt 
proteinuria, as it does not reduce proteinuria per se. Once proteinuria (>1 g/day) or CKD 
Stage 3 (eGFR <60 mL/min/1.73 m2) develops, there are no data supporting a potential pro-
tective effect of ERT. Taking this and the very high cost (>200 000 Euro/year) into account, 
we do not recommend treatment in these cases. ERT has few side effects, except for mild 
infusionrelated reactions consisting primarily of chills that can be treated with paracetamol, 
antihistamines or steroids. It has been shown that the infusions can be safely performed in 
a home setting [59, 60].
The administration of ERT leads to the formation of antibodies in the majority of patients, 
and this is for both brands. These antibodies, especially the IgG, have inhibitory effects on 
the enzyme activity in vitro [5, 6, 61, 62]. Although both agalsidase alpha and agalsidase 
beta have been associated with IgG formation, the reported incidence of antibodies has 
generally been higher for agalsidase beta [62]. In a study in 134 males and females, there 
was no correlation between anti α-Gal A IgG titres and the onset of clinical events or the rate 
in change in estimated GFR during treatment. However, a statistically significant associa-
tion was found between anti-α-Gal A IgG titers and Gb-3 deposition in the dermal capillary 
endothelial cells during treatment, suggesting that Gb-3 clearance could be impaired [63]. 
In another study, there was less normalization of urinary Gb-3 in the seropositive patients 
compared with the seronegative ones [64, 65]. Analysing the consequences of antibodies 
is challenging because the assays are not uniform and there are no international antibody 
standards. Currently, numerous laboratories are performing !-Gal A-antibody testing. Poten-
tial differences between antibody assays and their respective sensitivities make comparison 
of titre values across the Fabry community difficult. The objective of the Fabry Antibody 
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Standardization Initiative is to identify differences in analytical methods and to standard-
ize !-Gal A antibody assays across the industry to allow the medical community involved in 
treatment to interpret antibody data equally [66]. We have very few data on the efficiency of 
higher doses than the ones registered for agalsidase alpha (0.2 mg/kg EOW) and agalsidase 
beta (1 mg/kg EOW). One open-label trial studied 11 adult male patients with FD who dem-
onstrated a continuing decline in renal function despite 2-4 years of conventionally dosed 
agalsidase alpha therapy (0.2 mg/kg EOW) [67]. After switching to weekly dosing, three pa-
tients demonstrated an improvement in eGFR and six patients demonstrated a slow down 
in the rate of eGFR decline. Two patients failed to improve their eGFR slope. A multiple re-
gression model confirmed that the weekly infusion regimen was the strongest explanatory 
variable for the change in eGFR, with a weaker contribution from the concomitant use of 
angiotensin-converting enzyme inhibitors/ARB, but the patient number was too low to al-
low meaningful conclusions.
We also have very few data comparing the two formulas. In a study by Vedder et al. [65], 
the low number of patients and the dose of agalsidase beta that was used (0.2 mg/kg in-
stead of the licensed 1.0 mg/kg) precluded firm conclusions. In a larger group of patients 
(n = 146), there was no difference in a composite outcome of renal, cardiac and neurologi-
cal events after 30 months of treatment (West, Molecular Genetics and Metabolism, 2011, 
abstract). 
Tahir et al. found stabilization of renal function in a small open-label observational study 
in patients with CKD Stage 1-2 (n = 4) and CKD Stage 3-4 (n = 6) treated with a combina-
tion of agalsidase beta 1 mg/kg EOWand ACEi or ARB. The surprisingly favourable response 
in patients with GFR <60 mL/1.73 m2/min and proteinuria >1 g/day was unexpected and 
should be confirmed in a larger study [68]. It is unclear in how far the positive effect, when 
confirmed, should be attributed to the ACE-i or the ERT.
There is an on-going open-label, prospective, multi-centre study [The Fabrazyme® 
and ARB’s and ACE Inhibitor Treatment (FAACET) Study, registered at ClinicalTrials. gov 
NCT00446862], with as primary hypothesis that titration of ACEi and ARBs to reduce urine 
protein excretion to <500 mg/day in Fabry patients receiving agalsidase beta therapy at 1 
mg/kg every 2 weeks will slow the progression rate of decline of GFR compared with case- 
controls drawn from a Genzyme-sponsored Phase III extension study (GFR 60–125 mL/
min/1.73 m2, urine protein >1 g/day) or the Phase IV study (GFR 20 to 60 mL/min/1.73 m2, 
urine protein >0.5 g/day). 
Survival of Fabry patients on RRT is poor, with a reported 3-year survival of 60–63%, 
which is lower than that of non-diabetic-matched controls [69]. There is no proof of an im-
proved survival in RRT patients on ERT.
In patients with CKD Stage 5, where ERT is deemed to be an appropriate option, ERT can 
be performed during the haemodialysis sessions, which do not alter pharmacokinetics [70].
ERT diminished extra renal symptoms, and improved quality of life and in CKD Stage 
5 patients on dialysis in a small (n = 9), non-placebo controlled cross-sectional study [71]. 
In another observational cross-sectional study (n = 16) on dialysis patients, with a mean 
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follow-up of 45 months of ERT, mortality was very high (7/11), when patients were not trans-
planted [72]. These limited data suggest that, although typical Fabry symptoms such as pain 
crises can be controlled with ERT, we have no proof of improvement of cerebrovascular 
or cardiac morbidity or mortality in CKD Stage 5. Instead, mortality remains high if these 
patients are not transplanted. Transplantation without ERT has shown acceptable results. 
In a retrospective study, patient and graft survival was good for the first 10 years, although 
this study was probably undertaken in a selected patient group with little co-morbidity. 
After 10 years, mortality increases very quickly, probably due to progression of FD [73]. Data 
from the organ procurement Transplant Network/United Network for Organ Sharing (n = 
197) were compared with a matched cohort of non- Fabry and non-diabetic CKD Stage 5 
patients; although 5- year graft survival was similar, Fabry patients had a higher risk of death 
[RR 2.15 (1.52–3.02)] [74]. All these data seem to indicate that transplantation can be suc-
cessful in patients with Fabry nephropathy, and that transplanted patients have a stable 
kidney function without ERT.
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APPENDIX TO CHAPTER 4:
PATIENT INFORMATION AND INFORMED CONSENT FORM:
FABRY DISEASE SCREENING
Your treating nephrologist would like to do a test for Fabry disease. This is a rare inherited condition that causes signs and symptoms that can range from mild to severe to even life threatening. In people with Fabry disease, the enzyme alpha-
galactosidase A (or α-Gal A) that helps the body to break down a fatty substance called 
globotriaosylceramide or Gb-3 is insufficiently present. Without enough of this enzyme, the 
Gb-3 substance builds up in kidney cells and in the cells of other organs and may cause 
severe kidney problems, including kidney failure.
Signs and Symptoms
Because Fabry disease is rare and not always well recognized, its symptoms are some-
times overlooked or attributed to other more common conditions. There are, however, a 
number of signs and symptoms that people with Fabry disease typically experience from a 
young age:
• Burning, tingling pain in the hands and feet
• Impaired sweating
• Heat/cold intolerance
• Skin rashes (angiokeratoma)
• Hearing problems
• Gastrointestinal problems, such as diarrhea or vomiting
• Heart problems (including enlarged heart and arrhythmia)
• Kidney problems
• Nervous system problems, such as stroke
• Psychological issues, such as depression
Signs and symptoms may present in childhood, but because physicians often do not at-
tribute these symptoms to Fabry disease, patients may not be diagnosed until adulthood.
Fabry disease is a progressive disorder; therefore it can be important that patients be 
identified as early as possible. 
Fabry disease is a genetic disease passed down (or inherited) from parents to children. 
The Fabry gene is located on the X chromosome. As a consequence, a father with Fabry 
disease will pass the gene onto all of his daughters and none of his sons. As women have 
two X chromosomes, they sometimes experience a less severe disease than men. If a moth-
er carries the Fabry gene, there is a 50% risk that she will pass the gene onto her sons or 
daughters. Fabry disease can affect anyone who inherits the mutated gene - both males and 
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females. Virtually all males with the Fabry gene develop the disease and are likely to express 
some or many of the classic Fabry symptoms. In women with the Fabry gene, however, 
symptoms can range from none (in asymptomatic carriers) to very serious manifestations 
similar to those seen in males. 
Testing for Fabry disease
Nephrologists (kidney specialists) are advised to screen for Fabry disease in patients with 
renal failure or proteinuria (= having a significant amount of protein in the urine). The test is 
done by means of a simple blood sample. 
Genetic Counseling
If you have been diagnosed with Fabry disease, you know that some of your family mem-
bers could also have the disease. In order to deal with this information, you may benefit 
from the support of a genetic counselor. Genetic counselors are professionals who can help 
you learn more about the disease and assist you with issues such as disease inheritance, 
family planning, genetic testing, and communicating with family members about your di-
agnosis. As Fabry disease can present itself with a wide range of symptoms, from very mild 
to very severe and even life threatening, and as there is no efficient treatment available that 
can stop the disease, some people might not want to know they have the disease or not. It 
is important to know that people have the right not to know whether or not they have the 
disease. This decision can also impact on their family, as also other family members can be 
affected. The genetic counselor can help you understand the disease and its impact on your 
life and of your family. 
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Informed consent
I hereby declare that I consent with a genetic analysis for Fabry disease. No other genetic 
analysis will performed on my blood or DNA sample without my permission.
I had the possibility to ask questions to dr. ………………. and I have received answers 
that I can comprehend. When the results of the genetic analysis are available, I will be in-
vited to discuss the results. The results of the genetic analysis will be communicated to me 
at the occasion of a medical consultation. When the results are available, I still have the op-
portunity to refuse to be confronted with the results of the genetic analysis. The results of 
the genetic analysis will not be communicated to other parties, without my prior consent.
If the genetic analysis does not reveal a pathogenic mutation, I consent to future genetic 
analysis for novel genetic aberrations that might explain a genetic predisposition for Fabry 
disease. When these results have relevant medical implications for me or for my relatives, I 
will be invited to the consultation to discuss these results.
Date……………………………………
Physician………………………………
Patient…………………………………. 
Completed in duplicate, of which I have received one copy.
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General Discussion
The first aim of this thesis was to study the prevalence of Fabry disease. We hypothe-sized that Fabry disease was under-ascertained. The low prevalence of the disease, variability in clinical expression and lack of highly specific symptoms preclude an 
easy diagnosis by clinicians. In addition, as Fabry disease is a progressive disease, an early di-
agnosis is important, as treatment has to be initiated before the onset of irreversible organ 
damage. For these reasons, the study of the prevalence and the detection of index cases 
and their subsequent pedigree analysis seemed an important goal. This prompted us to 
screen in high-risk populations. 
In total, we screened 2135 patients belonging to three high-risk populations: hemodi-
alysis patients, kidney transplant recipients and patients with left ventricular hypertrophy 
(Table 5.1). We found 9 index cases. The overall prevalence of GLA mutations was 0.42 % (1 
in 237) in high-risk patients. Only one of these patients had been previously diagnosed with 
Fabry disease. Seven (78%) (Table 5.2) of these patients had the GLA p.Ala143Thr (c.427G>A) 
mutation, which is associated with an attenuated phenotype (Chapter 3). The other two 
mutations were associated with a classic Fabry phenotype. GLA p.Ala5Glu (c.44C>A) had not 
been described up to now in literature and the diagnosis of Fabry disease had not yet been 
made before the screening took place. 
Table 5.1. Screening in high risk groups in Flanders.
Hemodialysis Kidney transplantation
Left Ventricular 
Hypertrophy
Total high risk 
population
Females screened 742 395 178 1315
Mutation in females, N (%) 2 (0.27%) 0 3 (1.7%) 5 (0.38%)
Males screened 180 278 362 820
Mutation in males, N (%) 1 (0.56%) 1 (0.36%) 2  (0.55%) 4 (0.49%)
Total patients 922 673 540 2135
Mutations, N (%) 3 (0.33%) 1 (0.15%) 5 (0.93%) 9 (0.42%)
Table 5.2. GLA mutations detected in screening studies in high-risk populations in Flanders.
Hemodialysis Kidney transplantation
Left Ventricular 
Hypertrophy
Total high risk 
population 
N (%)
GLA p.Ala143Thr
(c. 427G>A)
2 1 4 7 (0.33%)
GLA p.Trp236Arg
(c.706T>C)
1 0 0 1 (0.046 %)
GLA p.Ala5Glu
(c.44C>A)
0 0 1 1 (0.046 %)
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With other screening studies, our studies demonstrate that Fabry disease is under-ascer-
tained and much more prevalent than previously assumed, but this high prevalence is for a 
large part due to attenuated cases and less to classical Fabry disease. Classical Fabry disease 
was also under-ascertained, as exemplified by one of the two cases in our study, despite the 
fact that the patient had a typical phenotype and a positive family history. 
We conclude that screening of high-risk groups is efficient, as it permits to detect and 
counsel Fabry patients at reasonable cost. Our strategy to screen in hemodialysis patients 
who have no evident renal diagnosis has already been copied by the NBVN (Nederlandsta-
lige Belgische Vereniging Nefrologie). Next, we have made recommendations for nephrolo-
gists to screen for Fabry disease in Chronic Kidney Disease. In collaboration with European 
Fabry experts, we now recommend to screen for Fabry disease in patients with unexplained 
Chronic Kidney Disease, which is defined as persistent albuminuria/proteinuria or an eGFR 
<90 ml/min/1.73m². In males we recommend to screen under the age of 50, as the goal is 
the detection of classical Fabry disease and not that of the attenuated phenotypes. This has 
been published as a “European Best Practice Guideline (ERBP)” (Chapter 4). 
We should, however, remain cautious and critical. It is clear that in many of the cases 
detected in the screening studies, the mutation is associated with an atypical or attenuated 
phenotype and natural history and effects of treatment will be anything but predictable. 
In Flanders, the GLA p.Ala143Thr (c.427G>A) mutation seems to have a high prevalence. 
This is also the case in Austria, as 6 of the 9 cases of Fabry disease detected in a newborn 
screening [1] had this mutation. This mutation was up to now labelled as “associated with 
an attenuated phenotype”, so we studied it in 41 patients among our index cases and their 
families and in cases described in literature and cases registered in the Fabry Outcome Sur-
vey (Chapter 3). This mutation indeed seems to be associated with a low or absent α-Gal A 
activity but we found little convincing evidence that this mutation is disease-causing, as 
biopsies of kidney, heart and skin could not show typical Fabry pathology. The morbidity in 
our patients with this “mutation” (chronic kidney disease and left ventricular hypertrophy) 
could not directly be attributed to Fabry disease, and could be the result of ascertainment 
bias. This mutation was however more prevalent in our high risk population (0.33 %) com-
pared to a general population screening in Austria (0.026 %) [1], so this mutation might be 
one among other contributors to our patients morbidity. We plan to set up a database on 
all patients with p.Ala143Thr (c.427G>A) in order to prospectively study its natural history 
(is there progressive Gb-3 deposition, and organ damage as a consequence?) and the effect 
of enzyme replacement and other therapies, so that in the future, we can make evidence-
based recommendations. 
During the progress of our studies, we optimised our screening methods. The method 
we initially used for screening in males and females was the determination of α-Gal A activ-
ity using a blood spot test. This test using filter paper was described by Chamoles et al. [2] 
and validated in our laboratory setting using blood samples from non-nephrology, non-
ICU, non-hematology and non-pediatric patients. Patients with a confirmed α-Gal A activity 
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below the sixth percentile then entered the second level of a two-tier approach, which was 
mutation analysis. α-Gal A activity measurement is very sensitive in males, but proves not 
to be sensitive in females [3], hence we decided to use GLA mutation analysis for the female 
patients in our subsequent study on the screening for Fabry disease in patients with left 
ventricular hypertrophy [4]. Specificity of α-Gal A activity measurement is low, as we had 
up to 3% (false) positives even with correct internal validation with α-Gal B (data not pub-
lished); in case of low α-Gal A activity, the diagnosis of Fabry disease should be confirmed 
with a repeated measurement of α-Gal A activity (in males) and/or mutation analysis. 
We further evaluated renal outcomes and treatment options by means of a systematic 
literature search. We assessed data on enzyme replacement therapy and survival on renal 
replacement therapy (dialysis and transplantation). The result of this systematic search is 
part of the paper for ERBP mentioned above (Chapter 4). We conclude that only very few 
hard data support a significant effect of enzyme replacement therapy. Only five small ran-
domized controlled trials (RCTs) are available. Significant effects concern surrogate end-
points, such as the decrease of plasma Gb-3 levels and tissue depositions. In these trials, 
the effects on morbidity and mortality was statistically not significant and more specifically, 
these studies show no evidence for a clinical benefit of the use of agalsidase alfa or beta 
to treat Fabry nephropathy. Observational trials suggest that, for the renal aspect of Fabry 
disease, treatment is at best only effective in Chronic Kidney Disease stage 1 or 2, before the 
deterioration of renal function or onset of overt proteinuria, as it does not reduce proteinu-
ria per se. Once proteinuria (>1 g/day) or CKD stage 3 (eGFR < 60 mL/min/1.73m2) develops, 
there are no data supporting a potential protective effect of ERT. Taking this and the very 
high cost (> 200.000 euro/year) into account, in our paper for ERBP, we recommend starting 
ERT in the context of a clinical trial, interventional or observational. As we need more knowl-
edge, we conclude that it is necessary to enter all data in a central, not-industry dependent 
registry preferably at a European level. 
Survival of Fabry patients on hemodialysis is poor, with a reported three-year survival of 
60-63 %, which is lower than that of non-diabetic matched controls. There is no proof of an 
improved survival in renal replacement therapy patients on enzyme replacement therapy. 
Renal replacement therapy can serve as a bridge to transplantation, which has shown ac-
ceptable survival at 10 years compared to matched controls.
Perspectives
Cardiovascular involvement contributes substantially to disease-related morbidity and 
mortality in Fabry disease [5]. Various cardiac symptoms including dyspnea, chest pain, pal-
pitations and syncope are reported appearing in 60% of Fabry patients [6]. Pathology stud-
ies have shown that next to myocardial hypertrophy, fibrosis and scarring of the left ven-
tricular wall is important [7]. Fifty percent of male Fabry patients had hyper-enhancement 
of the myocardium, suggestive for fibrosis. Additionally it is known that Gb-3 deposition can 
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be found in the specific cardiac conduction cells. Both predispose to ventricular arrhythmia 
[5]. The prevalence of symptomatic arrhythmia and the clinical importance of arrhythmia in 
patients with Fabry disease is largely unknown but may contribute to the occurrence of syn-
cope (3,2% in [5]) and sudden cardiac death. Additionally it is well known that a substantial 
number of patients (especially males) develop severe bradycardia and chronotropic incom-
petence. Some of these patients could be treated with a permanent pacemaker/defibrilla-
tor. A significant number of Fabry patients have symptoms of congestive heart failure (11% 
in males in [5]). Some of these patients could be treated with resynchronization therapy 
using a biventricular pacemaker. 
Indeed, in a screening study for Fabry disease in patients with left ventricular hypertro-
phy, 3 out of 4 patients detected had a permanent pacemaker [8]. In another screening 
study, 1 in 7 patients had a permanent pacemaker [9]. In a screening study for Fabry disease 
in kidney transplant recipients, 1 of 2 patients had a pacemaker for atrio-ventricular block 
[10].
In a study of 78 Fabry patients (43 men), 7 men (10.6%) had permanent pacemakers im-
planted for complete heart block (n = 1), symptomatic bradycardia (n = 3), LV outflow tract 
gradient reduction (n = 1), and complete heart block after alcohol septal ablation (n = 1). 
One received a biventricular device and defibrillator for heart failure and symptomatic ven-
tricular hypertrophy [6]. In a large study, 6 in 124 (4.8%) untreated male Fabry patients had a 
permanent pacemaker [5]. In a study of 279 males with Fabry disease from Europe, Canada 
and the USA, 9 patients (3%) had a permanent pacemaker.
In this reasoning, the pacemaker population is a unique high-risk population, which has 
up to now not been studied for Fabry disease. 
In a new study, we would like to screen systematically for Fabry disease in male patients 
with a permanent pacemaker or defibrillator in secondary and tertiary care hospitals in Bel-
gium. A cohort of 500 men with a permanent pacemaker or defibrillator will be screened 
with a blood spot test for α-Gal A deficiency. Inclusion criteria will be age ≥ 30 years and < 
75 years, as patients younger than 30 years with a permanent pacemaker are less likely to 
have Fabry disease. Most of them will have an atrio-ventricular block secondary to a con-
genital AV block, cardiac surgery for the correction of a congenital heart disease, or have a 
pacemaker/defibrillator for the treatment of long QT syndrome. While many pacemaker pa-
tients age 75 or older present with age-dependent fibrosis, patients in the fifth or sixth dec-
ade of their life are still likely to have Fabry disease, and more specifically a cardiac variant. 
Patients with proven prior myocardial infarction, defined with ECG, will be excluded from 
the screening, as heart disease secondary to ischemia is unlikely in Fabry disease. Patients 
will be asked to answer questions oriented to the signs and symptoms of Fabry disease. The 
questionnaire used in this study is based on the “FabryScan”, a screening tool studied and 
validated for detection of Fabry disease in patients with pain [11]. Additional questions that 
can be helpful in detecting patients that have a higher pre-test probability for Fabry were 
added. Such a questionnaire could be an uninvasive tool for screening for Fabry disease; 
comparable to the questionnaire we developed for boys and adolescents (Appendix).
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As already mentioned, a second project concerns the GLA p.Ala143Thr (c. 427G>A). As 
we have doubts about the pathogenicity of this genetic alteration, we want to do further 
research on the impact on every organ system and the possible benefit of treatment and 
counselling. For this we plan to build a database on these patients. Next, with the work on 
GLA p.Ala143Thr, we plan to take part in the “Hamlet study”, designed by the researchers of 
the Academic Medical Centre (Amsterdam, The Nederlands) which was designed for “Val-
orisation of clinical and laboratory assessments for improved diagnosis of Fabry disease”. 
Finally, this thesis can be considered as a part of the “Rare Diseases Project” at the Ghent 
University Hospital. 
Rare diseases are live threatening or chronically debilitating diseases – mostly inherited 
– that affect so few people that special efforts are needed for diagnosis and treatment. In 
EU countries, any disease affecting fewer than 5 people in 10 000 is considered rare. It is es-
timated that today in the EU, 5-8000 distinct rare diseases affect 6-8% of the population or 
between 27 and 36 million people (For reference; http://ec.europa.eu/health/rare_diseases/
policy/index_en.htm). Signs and symptoms of rare diseases can be aspecific but occur at an 
unusual young age or with an unusual severity. In case of Fabry disease, this is stroke, kidney 
failure and premature death. Fabry disease is inherited a special X linked manner, causing 
disease in all male and in most female patients. Some rare diseases can be treated if timely 
diagnosed, but this is the problem, as they are under-ascertained as a consequence of their 
rarity. As we have demonstrated in this thesis, there is a long period between emergence 
of the first symptoms and the appropriate diagnosis, which involves a risky delay as well 
as wrong diagnosis with inaccurate treatments. Referral to qualified specialists is often de-
layed, and even if not so, there is a lack of evidence-based therapy. As rare diseases are often 
systemic diseases, treatment in a multidisciplinary team is required, and many issues next 
to medical ones have to be covered, including psychological, dietary, social and financial.
Awareness of these aspects is important and has become an important subject of regu-
lation at the level of the European Union and the Belgian government. The “Rare diseases 
project” has been set up at the Ghent University Hospital to facilitate this work. I hope in the 
future, I will be able to contribute to this exciting work on rare diseases.
Chapter 5
130
References
1. Mechtler, T. P. et al. Neonatal screening for lysosomal storage disorders: feasibility and incidence from a 
nationwide study in Austria. The Lancet 379, 335–341 (2012).
2. Chamoles, N. A., Blanco, M. & Gaggioli, D. Fabry disease: enzymatic diagnosis in dried blood spots on filter 
paper. Clin. Chim. Acta 308, 195–196 (2001).
3. Linthorst, G. E., Vedder, A. C., Aerts, J. M. F. G. & Hollak, C. E. M. Screening for Fabry disease using whole 
blood spots fails to identify one-third of female carriers. Clinica Chimica Acta 353, 201–203 (2005).
4. Terryn, W. et al. Prevalence of Fabry disease in a predominantly hypertensive population with left ventricu-
lar hypertrophy. Int. J. Cardiol. (2012).
5. Linhart, A. et al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry 
outcome survey. European Heart Journal 28, 1228–1235 (2007).
6. Shah, J. S. et al. Prevalence and Clinical Significance of Cardiac Arrhythmia in Anderson-Fabry Disease. Am. 
J. Cardiol. 96, 842–846 (2005).
7. Sheppard, M. N. The heart in Fabry’s disease. Cardiovascular Pathology 20, 8–14 (2011).
8. Hagege, A. A. et al. Screening patients with hypertrophic cardiomyopathy for Fabry disease using a filter-
paper test: the FOCUS study. Heart 97, 131–136 (2010).
9. Elliott, P. et al. Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the 
European Anderson-Fabry Disease Survey. Heart 97, 1957–1960 (2011).
10. Kleinert, J. et al. Anderson-Fabry disease: a case-finding study among male kidney transplant recipients in 
Austria. Transplant International 22, 287–292 (2009).
11. Arning, K. et al. FabryScan: a screening tool for early detection of Fabry disease. J. Neurol. (2012).
Population Screening
Problems associated with the detection 
of atypical or unknown variants and 
presentation of a possible solution
Appendix
Appendix
132
The strategy used in Chapter 2 for case finding is the screening of high-risk 
groups. In order to detect patients at an early stage of the disease, the next step 
would be to screen in the population at a young age. This was performed in new-
borns in Italy, Taiwan and Austria. It resulted in the detection of atypical Fabry 
disease with an attenuated phenotype, what brings along ethical problems, as 
many of these patients will remain completely asymptomatic for many decades. 
In order to overcome this problem, we designed a strategy to screen for sympto-
matic boys and adolescents. 
Screening of high-risk groups (hemodialysis patients, kidney transplant recipients, patients with left ventricular hypertrophy and cryptogenic stroke) have shown that Fabry disease is more frequent and has a much broader phenotypical spectrum than 
was previously assumed 1. Later-onset cardiac and renal variants of Fabry disease have been 
detected mainly as a result of these studies 2-4. These patients lack angiokeratoma, acro-
paresthesia, hypohidrosis and corneal opacities, which are classical manifestations of Fabry 
disease. Patients with the cardiac variant typically present in the 5th-8th decades of life with 
left ventricular hypertrophy, arrhythmia and/or heart failure. Patients with the renal variant 
develop proteinuria and later-onset renal failure, typically after the age of 50 3. Next, pa-
tients with cryptogenic stroke have been found to have Fabry disease, lacking classic early-
onset symptoms and signs 5. As a result of our screening studies, we learned that the GLA 
p.Ala143Thr mutation has a high prevalence in the Flemish population. This mutation had 
been associated with an attenuated phenotype presenting as a cardiac or renal variant or 
isolated stroke. We even found a much broader range of expression, where males as well as 
females can be completely asymptomatic or suffer from multi-organ involvement. 
Screening of the general population for α-Gal A deficiency with subsequent mutation 
analysis could be the next step to gain knowledge of the real prevalence of Fabry disease 
and to detect patients at an early stage of the disease, amenable for treatment. The first 
screening ( Table A.1) of this kind was performed in Italy 6, where 37104 male new-borns 
were screened for α-Gal A deficiency. Twelve (1/3100) neonates had deficient α-Gal A and a 
GLA mutation, but only one of these had a mutation causing the classic phenotype. Eleven 
neonates had mutations associated with later-onset phenotypes or a new sequence altera-
tion with an unpredictable phenotype. 
In the Taiwan Chinese population two large new-born screening studies were performed 
7,8. Low α-Gal A activity and a GLA mutation was demonstrated in 45 7 and 75 8 neonates. 
This corresponds with a surprisingly high prevalence of up to 1/1250 in males. In a signifi-
cant proportion of these new-borns, the IVS4 + 919GÆA mutation was demonstrated. This 
is an intronic mutation associated with a cardiac variant 9, which appears to have a low 
penetrance as only 1/3 of the grandfathers with this mutation had significant hypertrophic 
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cardiomyopathy. 
A fourth screening study was recently performed in Austria 10, screening 34736 of new-
borns of both genders for α-Gal A activity. A low α-Gal A activity and a GLA mutation were 
detected in 9 patients, yielding a frequency for Fabry disease of 1 per 3859 births. All babies 
had residual enzyme function, and none had a mutation associated with a classical pheno-
type. 
We can conclude from these screening studies in neonates that mutations associated 
with Fabry disease are even more frequent than was assumed until recently and that it has 
a prevalence of up to 1 in 1250. The major part of these mutations are however not associ-
ated with the classical Fabry phenotype. The finding of a genetic predisposition for a pos-
sible late-onset disease where the treatment effectiveness is unclear can possibly have a 
negative impact on the proband. The long latency between diagnosis and disease possibly 
stigmatises and the affected persons might perceive their health as worse than it is. In these 
cases, it would be difficult to decide on enzyme replacement therapy, as the natural history 
of patients carrying atypical mutations is poorly characterized, effects of enzyme replace-
ment therapy in mild cases have not been studied, and a lifelong treatment is a psychologi-
cal burden for the patient and a financial one for both the individual and the society with 
on top of that uncertain results. As a consequence, in a paper with recommendations from 
the European Renal Association, we do not recommend screening for Fabry disease in the 
general population. 
Within this reasoning, in order to detect patients with classic Fabry disease at a sympto-
matic but early stage of the disease, where enzyme replacement therapy could still have im-
portant benefits, we developed a strategy for the screening of symptomatic boys between 
the ages of 6 and 18 years using a questionnaire asking for classical Fabry symptoms (Table 
A.2). This questionnaire was developed using data from the Fabry Registry on the symptoms 
presenting in pediatric Fabry disease. Our hypothesis was that the negative predictive value 
for classical Fabry disease would be high, though this has not been validated. A case-control 
study in boys and adolescents aged 6-18 years would have to be performed first. In case of 
a “negative” questionnaire, classical Fabry disease could be excluded. If the answers to this 
questionnaire were scored “positive”, the next tier of this project would have been screening 
with dried blood spots for α-Gal A deficiency, and if positive, in a third tier, mutation analy-
Table A.1. Newborn screening for Fabry Disease.
Screened (n) GLA mutations (n) Classic FD (n) Later onset or unknown phenotype (n) Reference, region
37104 12 (1/3100 males) 1 11 (3/11 is A143T) Spada 6, Italy
110027 45 (1/1368 males) 1 (“mild classic”) 44 (1/44 is A143T) Lin 7, Taiwan
171977 75 (1/1250 males) 4 (predicted) 71 Hwu 8, Taiwan
34736 9 0 9 (6/9 is A143T) Mechtler 10, Austria
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Table A .2. Questionnaire.
Major questions
I am having pain in the hands, feet, fingers, toes, eg tingling pain, burning sensation
I can do no great efforts or sports
I sweat very little
I endure no heat
I have little thickened red or purple spots on the skin
I have relatives with kidney disease, or who are in dialysis or who have a kidney transplant
My kidneys are not working normally
I have a decreased hearing
I often have tinnitus
There is protein in my urine
My ophthalmologist saw something unusual in my eyes
I have a family member with a heart problem at young age
I have a family member with stroke at a young age 
Minor questions
I regularly have diarrhea and abdominal pains
I often feel bloated after my dinner
I have an irregular heartbeat or palpitations
I am abnormally tired 
I sometimes have fever without obvious cause
I do not feel as healthy as my classmates
I often have headaches
sis. In our opinion, this way of screening could give a good estimate of the true prevalence 
of classic Fabry disease in the Flemish population, without the problematic detection of the 
much more frequent mutations associated with attenuated Fabry disease.
In conclusion, screening for Fabry disease in high-risk groups and in new-borns has 
widened the phenotypical spectrum and has proven that Fabry disease is more frequent 
than was previously assumed. The bulk of the patients with GLA mutations detected in the 
screening studies are however associated with attenuated phenotypes. The detection and 
treatment of these patients at an early age has no proven benefit and could even be harm-
ful. As a result, newborn screening for Fabry disease cannot be recommended. The strategy 
we designed to detect young symptomatic boys and adolescents however could be useful. 
Population Screening: Atypical or Unknown Variants
135
References
1. Linthorst, G. E. et al. Screening for Fabry disease in high-risk populations: a systematic review. J. Med. Genet. 
47, 217–222 (2010).
2. Nakao, S. et al. An Atypical Variant of Fabry’s Disease in Men with Left Ventricular Hypertrophy. N. Engl. J. 
Med. 333, 288–293 (1995).
3. Nakao, S. et al. Fabry disease: Detection of undiagnosed hemodialysis patients and identification of a ‘renal 
variant’ phenotype1. Kidney Int 64, 801–807 (2003).
4. Scheidt, W. V. et al. An Atypical Variant of Fabry’s Disease with Manifestations Confined to the Myocardium. 
N. Engl. J. Med. 324, 395–399 (1991).
5. Gregoire, S. M. et al. Posterior circulation strokes without systemic involvement as the presenting feature 
of Fabry disease. Journal of Neurology, Neurosurgery & Psychiatry 80, 1414–1416 (2009).
6. Spada, M. et al. High Incidence of Later-Onset Fabry Disease Revealed by Newborn Screening*. The Ameri-
can Journal of Human Genetics 79, 31–40 (2006).
7. Lin, H. Y. et al. High Incidence of the Cardiac Variant of Fabry Disease Revealed by Newborn Screening in 
the Taiwan Chinese Population. Circulation: Cardiovascular Genetics 2, 450–456 (2009).
8. Hwu, W.-L. et al. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset 
GLA mutation c.936+919G>A (IVS4+919G>A). Hum. Mutat. 30, 1397–1405 (2009).
9. Ishii, S., Nakao, S., Minamikawa-Tachino, R., Desnick, R. J. & Fan, J.-Q. Alternative Splicing in the 
α-Galactosidase A Gene: Increased Exon Inclusion Results in the Fabry Cardiac Phenotype. The American 
Journal of Human Genetics 70, 994–1002 (2002).
10. Mechtler, T. P. et al. Neonatal screening for lysosomal storage disorders: feasibility and incidence from a 
nationwide study in Austria. The Lancet 379, 335–341 (2012).

Summary
Fabry disease is a rare disease caused by a mutation in the GLA gene, located on the X-chromosome, which encodes for alpha-Galactosidase A. This lysoso-mal enzyme plays a role in the degradation of certain glycosphingolipids, and 
deficiency leads to accumulation of globotriaosylceramide in the lysosomes of most 
cells of the body.
In its classical form, from the age of 3 to 10 years, symptoms arise such as acro-
paresthesias, hypohidrosis, heat intolerance and abdominal discomfort. More than 
half of the patients have angiokeratomas; small purplish elevations on the skin of the 
genitals, lumbosacral region and the thorax, which may increase with age.  Proteinu-
ria occurs in adulthood and frequently evolves to renal failure. There is a significantly 
increased incidence of ischemic stroke from the fourth and fifth decade and progres-
sive left ventricular hypertrophy that can lead to rhythm and conduction disorders, 
heart failure and early death.
Fabry disease is very rare, with an estimated prevalence of 1/117,000. This preva-
lence is however an underestimation as the diagnosis is often missed. Rare diseases 
are not well known, and the symptoms are often aspecific. The signs and symptoms 
which have to be attributed to Fabry disease are often erroneously explained by 
the presence of more frequent co-morbidities such as arterial hypertension, vascular 
disease and diabetes mellitus which would explain the presence of left ventricular 
hypertrophy, stroke and proteinuria, preventing the clinician to think of rare meta-
bolic disorders.
For these reasons, from the year 2000, researchers have been prompted to set up 
screening studies for Fabry disease in high-risk populations. The studies performed 
for this thesis have shown that the prevalence of Fabry disease is much higher than 
was previously assumed. In addition it became clear that the phenotype exhibits a 
very wide variation both in males and females. We have screened in haemodialysis 
patients, renal transplant recipients and patients with left ventricular hypertrophy. 
Among the 2135 patients screened, we found 9 cases, of which only 1 had been 
previously diagnosed. With these patients and with the identification of Fabry pa-
tients in the families of these index cases, we showed that the prevalence in Flan-
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ders is much higher than assumed. A specific mutation, GLA p.Ala143Thr, proved to be very 
prevalent and occurred in 7 out of 9 index cases. This mutation was also quite prevalent in 
a population study in Austria. Notwithstanding this exonic mutation was associated with 
a decreased activity of alpha-Galactosidase A and in literature is considered to be patho-
genic, we found conflicting data. Study of clinical and biopsy data from 41 adults with this 
mutation showed that there is no direct causal link between the morbidity attributed to 
Fabry disease on one hand and the mutation or enzyme deficiency on the other hand. The 
association of this mutation with renal failure or left ventricular hypertrophy could thus be 
based on a selection bias generated by screening of high-risk patients. We conclude from 
this that the diagnosis of Fabry disease requires more than the co-existence of a mutation, 
low enzyme activity and certain signs and symptoms and stresses the importance op bi-
opsies. The prevalence of GLA p.Ala143Thr in our high-risk groups is, on the other hand, 
significantly higher than the prevalence in Austrian newborns, so a possible pathogenic role 
is certainly a possibility.
 These findings obviously have an important impact on counselling and treatment of 
patients and their families. The guidelines regarding enzyme replacement therapy, which 
can be applied to patients with a classical phenotype, are not valid for these atypical cases. 
Like in Flanders, screening studies throughout the world in high-risk populations and in 
newborns showed that the majority of the index cases have a genetic alteration in the GLA 
gene, which is associated with an unknown or attenuated phenotype. We do not know how 
to counsel and treat these patients. Because of this lack of knowledge we think that screen-
ing for GLA mutations in newborns is not indicated. Screening of high-risk groups however 
seems to be a good tool for case finding, as some kind of screening is probably the only 
way to find Fabry patients. In this context, we are planning a screening study in patients 
with a permanent pacemaker or internal defibrillator, an up to present unexplored high-risk 
population. 
Screening symptomatic boys seems worthwhile, as this gives the opportunity to diag-
nose classical Fabry disease at an early stage of the disease. For this purpose, we developed 
a strategy, involving a questionnaire concerning classical Fabry signs and symptoms (e.g. 
acroparesthesias, hypohydrosis, heat intolerance, abdominal symptoms). If this question-
naire is scored as “positive”, the diagnosis will be confirmed by measurement of alpha-Ga-
lactosidase A activity and GLA mutation analysis. First, this approach has the advantage that 
it aims at symptomatic boys with classical Fabry disease, where treatment and support is 
evidence-based. Secondly, this diagnostic approach using a questionnaire is also very low 
cost. However, this questionnaire should be further investigated for sensitivity, specificity 
and validity.
Most rare diseases are progressive and life threatening. Their low prevalence requires 
not only a special approach for diagnosis, but also special attention regarding treatment. 
The development of guidelines for nephrologists seemed a logical and important goal. A 
systematic literature review and consultation with European Fabry experts followed by peer 
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tients with Chronic Kidney Disease. This is published within the framework of the “European 
Renal Best Practice” (ERBP) Guidelines, an organ of the “European Renal Association” (ERA). 
We recommend screening for Fabry disease in males with chronic kidney disease with no 
clear aetiology under the age of 50. We do not recommend screening in older males since 
we focus on the classical forms of Fabry disease and mortality is very high in classical Fabry 
disease in males after the age of 50. In females, we propose no age limit, as the classical 
phenotype can become apparent at an older age. In males, the measurement of the activ-
ity of alpha-Galactosidase A is preferred, as this test is very sensitive, specific and inexpen-
sive. In females, mutation analysis is necessary as there can be residual enzyme activity in 
a significant part of the patients. From a systematic literature research, we conclude that 
there is little evidence for enzyme replacement therapy for nephrological reasons, and if 
therapy is started, it must be done before significant proteinuria occurs and before cre-
atinine clearance falls below 60 ml/min/1.73 m2. All patient data on enzyme replacement 
therapy should be collected in a central, possibly European, database, as the evidence for 
this expensive treatment has to further studied.
In conclusion, we argue that the prevalence of both the classical and attenuated forms of Fabry disease is underestimated and a special approach for the diagnosis includ-ing the screening in high-risk populations is necessary. The attenuated forms, however, 
have a very broad phenotype and no clear genotype / phenotype correlation. This applies 
in particular to the GLA p.Ala143Thr mutation, which is very prevalent in Flanders and has 
important implications for the treatment and counselling of these patients. Given the fact 
that there is little evidence for a general beneficial effect of enzyme replacement therapy, 
especially in atypical disease, further study is warranted. 

Samenvatting
De ziekte van Fabry is een zeldzame ziekte veroorzaakt door een mutatie in het GLA gen, gelegen op het X-chromosoom, dat codeert voor alfa-Ga-lactosidase A. Dit lysosomaal enzyme speelt een rol in de degradatie van 
bepaalde glycospingolipiden, en deficiëntie leidt tot stapeling van onder andere 
globotriaosylceramide in de lysosomen van de meeste cellen in het lichaam.
In de klassieke vorm ontstaan re eds vanaf de leeftijd van 3 tot 10 jaar symptomen 
zoals acroparesthesieën, hypohidrosis, warmte-intolerantie en abdominale klach-
ten. Meer dan de helft van de patiënten heeft angiokeratomen, kleine paarse verhe-
venheden op de huid van de genitalia, lumbosacrale regio en de thorax, die met de 
leeftijd kunnen toenemen. Op volwassen leeftijd ontstaat proteïnurie, wat frequent 
evolueert naar nierfalen. Er is een sterk toegenomen incidentie van ischemische ce-
rebrovasculaire accidenten vanaf de vierde en vijfde decade en progressieve linker 
ventrikel hypertrofie die in een eindstadium kan leiden tot ritme- en geleidings-
stoornissen, hartfalen en vroege dood. 
De ziekte van Fabry is erg zeldzaam, met een geschatte prevalentie van 1/117000. 
De prevalentie wordt echter onderschat door het feit dat de diagnose dikwijls wordt 
gemist. Zeldzame ziektes zijn op zich slecht bekend, en de symptomen zijn dikwijls 
niet specifiek, zodat clinici de diagnose niet makkelijk stellen. Daarbij kunnen de aan 
de ziekte van Fabry toe te schrijven tekenen en symptomen dikwijls verkeerdelijk 
worden verklaard door de aanwezigheid van veel frequentere co-morbiditeit zoals 
arteriële hypertensie, vaatlijden en diabetes mellitus die dan respectievelijk linker 
ventrikelhypertrofie, CVA en proteïnurie zouden verklaren, zodat men niet denkt 
aan zeldzame metabole aandoeningen. 
Vanaf het jaar 2000 heeft dit onderzoekers gedreven om screeningsstudies op te 
zetten naar de ziekte van Fabry in populaties met een verhoogd risico. Deze studies, 
waar het onderzoek uitgevoerd in het kader van deze thesis toe behoort, hebben 
aangetoond dat de prevalentie van de ziekte van Fabry veel hoger is dan vroeger 
werd aangenomen. Daarnaast, en dit is minstens even belangrijk, werd duidelijk dat 
het fenotype een zeer brede variatie vertoont, zowel bij mannen als bij vrouwen. 
Wij hebben gescreend bij hemodialysepatiënten, niertransplantpatiënten, en pa-
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tiënten met linker ventrikel hypertrofie. Onder de 2135 gescreende patiënten vonden wij 
9 gevallen, waarvan slechts 1 voordien reeds was gediagnosticeerd. Mede door de iden-
tificatie van Fabry patiënten in de families van deze index-casussen werd duidelijk dat de 
prevalentie in Vlaanderen veel hoger was dan vroeger werd aangenomen. Eén bepaalde 
mutatie, GLA p.Ala143Thr, bleek erg prevalent te zijn en kwam voor bij 7 van de 9 index-
gevallen. Deze mutatie bleek ook vrij prevalent in een bevolkingsstudie in Oostenrijk. Niet-
tegenstaande deze exonische mutatie geassocieerd is met een verminderde activiteit van 
alfa-Galactosidase A en in de literatuur beschouwd wordt als “pathogeen” kregen we twij-
fels over zijn pathogeniciteit. Studie van klinische en biopsiegegevens van 41 volwassenen 
met deze mutatie toonde aan dat er geen direct oorzakelijk verband bestaat tussen de aan 
de ziekte van Fabry geattribueerde morbiditeit enerzijds en de mutatie/enzymdeficiëntie. 
De associatie van deze mutatie met nierfalen of linker ventrikelhypertrofie zou aldus kun-
nen berusten op een selectiebias gegenereerd door screening van hoog-risicopatiënten. 
We besluiten hieruit dat het stellen van de diagnose van de ziekte van Fabry meer vereist 
dan de aanwezigheid van een mutatie, een lage enzymactiviteit en bepaalde tekenen en 
symptomen, en benadrukt het belang van biopsies. De prevalentie van GLA p.Ala143Thr in 
onze hoog-risicogroepen is daartegen wel duidelijk hoger dan de prevalentie bij Oosten-
rijkse pasgeborenen, zodat een eventueel pathogene rol zeker nog verder onderzoek ver-
dient. Deze bevindingen hebben uiteraard ook een belangrijke impact op de begeleiding 
en behandeling van deze patiënten en hun familie. De richtlijnen voor enzymsubstitutie-
therapie die gelden voor patiënten met een klassiek fenotype zijn in dit geval niet geldig. 
Ook in screeningsstudies uitgevoerd buiten Vlaanderen bij andere risicogroepen en bij 
pasgeboren bleek het grootste deel van de patiënten een genetische alteratie in het GLA 
gen te hebben dat ofwel een nog onbekend effect heeft op het fenotype, ofwel gecorre-
leerd is met een geattenueerd fenotype. Ook daar is het nog onduidelijk hoe we deze pati-
enten zullen moeten begeleiden. Omwille van dit gebrek aan kennis is het voor ons dan ook 
alvast duidelijk dat screenen naar GLA mutaties bij pasgeborenen niet aangewezen is. Het 
screenen van de reeds gekende hoog risicogroepen lijkt echter wel een goed middel voor 
case-finding gezien het feit dat één of andere vorm van screening vermoedelijk de enige 
methode is om Fabry patiënten te vinden. In dit kader plannen we ook een screeningsstu-
die bij patiënten met een permanente pacemaker of interne defibrillator, een tot heden nog 
niet onderzochte hoog risicopopulatie. 
Screening naar de klassieke vorm van de ziekte van Fabry bij symptomatische jongens 
lijkt ons ook zinvol gezien we op die manier klassieke ziekte van Fabry in een vroeg stadium 
zouden detecteren. Hiervoor hebben we een strategie ontwikkeld, waarbij eerst een vra-
genlijst wordt afgenomen naar klassieke symptomen van de ziekte van Fabry (o.a. acropa-
resthesieën, hypohydrosis, warmte-intolerantie, abdominale symptomen). Indien deze 
vragenlijst “positief” wordt gescoord, wordt de diagnose bevestigd door meting van alfa-
Galactosidase A activiteit en mutatie-analyse. Deze aanpak heeft als voordeel dat men zich 
met een vragenlijst richt op symptomatische jongens, waar de behandeling en begeleiding 
evident en nuttig is. Anderzijds is diagnostische aanpak waar men eerst screent met een 
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vragenlijst ook zeer goedkoop. Wel dient deze vragenlijst nog verder onderzocht worden 
op gevoeligheid, specificiteit en validiteit. 
De meeste zeldzame ziekten zijn progressief en levensbedreigend. Hun lage prevalentie 
eist niet enkel een speciale aanpak om tot de diagnose te komen, maar er is ook speciale 
aandacht nodig met betrekking tot hun behandeling. Hiervoor richtlijnen opstellen was 
dan ook een logisch en belangrijk doel. Een systematische literatuurstudie en overleg met 
Europese Fabry experten gevolgd door peer review heeft geresulteerd in richtlijnen voor de 
diagnose en behandeling van de ziekte van Fabry bij patiënten met chronisch nierlijden. Dit 
wordt gepubliceerd binnen het kader van de “European Renal Best Practice “ (ERBP) Guide-
lines, een orgaan van de “European Renal Association”. We raden aan om te screenen naar 
de ziekte van Fabry bij mannen met chronisch nierlijden zonder duidelijke etiologie onder 
de leeftijd van 50 jaar. We raden niet aan te screenen bij ouderen gezien we ons richten op 
de klassieke vormen de mortaliteit bij mannelijke patiënten boven de leeftijd van 50 jaar 
zeer hoog is. Bij vrouwen houden we geen leeftijdslimiet, gezien het fenotype bij vrouwen 
extreem variabel kan zijn, en een mutatie die geassocieerd is met een klassiek fenotype 
zich ook op hogere leeftijd kan uiten. Bij mannen is de meting van de activiteit van alfa-
Galactosidase A te verkiezen, gezien deze test zeer gevoelig en goedkoop is. Bij vrouwen is 
mutatie-analyse noodzakelijk. We besluiten dat er weinig evidentie bestaat voor enzymsub-
stitutietherapie omwille van nefrologische redenen, en indien therapie gestart wordt, moet 
dit gebeuren vooraleer er belangrijke proteïnurie ontstaat en vooraleer de creatinineklaring 
zakt onder 60 ml/min/1.73 m2. Alle patiëntengegevens betreffende enzymsubstitutiethera-
pie zouden in een centrale, eventueel Europese, databank moeten verzameld worden om 
de evidentie voor deze dure behandeling te onderzoeken. 
Tot besluit stellen we dat de prevalentie van zowel de klassieke als geattenueerde vormen van de ziekte van Fabry onderschat wordt en een speciale benadering voor de diagnostiek onder andere via screening in hoog-risicopopulaties nood-
zakelijk is. De geattenueerde vormen hebben echter een zeer breed fenotype en geen dui-
delijke genotype/fenotype correlatie. Dit geldt in het bijzonder voor de GLA p.Ala143Thr 
mutatie die in Vlaanderen erg prevalent is. Dit heeft belangrijke consequenties voor de be-
handeling en begeleiding van deze patiënten. Gezien er ook voor de klassieke vormen van 
de ziekte van Fabry onvoldoende evidentie is voor een te veralgemenen gunstig effect van 
de (extreem dure) enzymsubstitutietherapie is verder onderzoek van groot belang. 

Résumé
La maladie de Fabry est une maladie rare secondaire à une mutation dans le gène GLA, liée au chromosome X, qui code pour alfa-Galactosidase A. Cet enzyme lysosomale joue un rôle dans la dégradation de certaines 
glycosphingolipides, et la carence entraîne une accumulation de globotriaosylcé-
ramide, notamment dans les lysosomes de la plupart des cellules de l›organisme.
Dans la forme classique, dès l›âge de 3 à 10 années, il y a des symptômes tels que 
des acroparesthesies, hypohidrose, intolérance à la chaleur, et des troubles abdo-
minales. Plus de la moitié des patients ont des angiokératomes, qui sont de petites 
élévations mauves su r la peau des organes génitaux, de la région lombo-sacrée et 
le thorax, ce qui peut augmenter avec l›âge. Une protéinurie survient à l›âge adulte, 
qui évolue fréquemment vers l›insuffisance rénale. Il y a une incidence significati-
vement accrue d›accidents vasculaires cérébrales ischémiques dès la quatrième et 
cinquième décennie de la vie et une hypertrophie ventriculaire gauche progressive 
qui, au stade terminal, peut conduire à des troubles de la conduction et du rythme, 
à l›insuffisance cardiaque et à une mort précoce.
La maladie de Fabry est très rare, avec une prévalence estimée à 1/117000. La 
prévalence est sous-estimée, cependant, par le fait que le diagnostic est souvent 
méconnu. Les maladies rares sont assez mal connues, et les symptômes sont sou-
vent aspécifiques, de sorte qu›il n›est pas facile pour les cliniciens de faire le dia-
gnostic. Les signes et symptômes de la maladie de Fabry peuvent souvent à tort 
être expliquées par la présence d›une comorbidité beaucoup plus prévalente telle 
que l›hypertension artérielle, les maladies vasculaires et le diabète sucré. De cette 
manière, l›hypertrophie ventriculaire gauche, l›accident vasculaire cérébral et la pro-
téinurie sont «expliquées» et le clinicien ne pense point au rares troubles métabo-
liques.
A cause de ces raisons, à partir de 2000, les chercheurs ont abordés des études 
de dépistage de la maladie de Fabry chez les populations à haut risque. Ces études, 
dont la recherche effectuée dans le cadre de cette thèse fait partie, ont montré que 
la prévalence de la maladie de Fabry est beaucoup plus élevée qu›on ne le pensait. 
En outre, et tout aussi important, il est devenu clair que le phénotype présente une 
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très grande variation dans les hommes et les femmes.
Nous avons fait des études de dépistage chez les patients hémodialysés, chez les pa-
tients avec une transplantation rénale et chez les patients présentant une hypertrophie 
ventriculaire gauche. Parmi les 2135 patients dépistés, nous avons trouvé 9 cas, dont seu-
lement 1 avait déjà été diagnostiqué auparavant. En raison de l›identification des patients 
Fabry dans les familles de ces cas index, on a montré que la prévalence en Flandre était 
beaucoup plus élevée que prévue. Une mutation spécifique, GLA p.Ala143Thr, s’est avérée 
très répandue et s’est produite dans 7 des 9 cas index. Cette mutation était également assez 
répandue dans une étude de population chez des nouveaux nés en Autriche. Malgré que 
cette mutation exonique soit associée à une diminution de l›activité de l›alfa-Galactosidase 
A et est considéré dans la litérature comme «pathogénique» on avait des doutes sur sa pa-
thogénicité. l›Étude des données cliniques et anatomopathologiques de 41 adultes atteints 
de cette mutation a montré qu›il n›existe pas de lien de causalité direct entre la morbidité 
qui est attribuée a la maladie de Fabry d›une part, et la mutation ou la carence d›enzyme 
d›autre part. L›association de cette mutation avec une insuffisance rénale ou une hypertro-
phie ventriculaire gauche pourrait donc être fondée sur un biais de sélection générée par 
le dépistage des patients à haut risque. Nous en concluons que le diagnostic de la maladie 
de Fabry exige plus que la présence d›une mutation, d›une activité enzymatique diminuée 
et certains signes et symptômes, et nous incite de faire des biopsies. Ces résultats ont évi-
demment un impact important sur la prise en charge de ces patients et de leurs familles. 
Les recommandations sur le traitement des patients avec la maladie de Fabry «classique» ne 
sont pas valides dans les cas «atypiques». Néanmoins, la prévalence de la GLA p.Ala143Thr 
dans nos groupes à haut risque est clairement supérieure à la prévalence chez les nouveaux 
nés autrichiens, donc un rôle pathogène est possible et mérite certainement une enquête 
plus approfondie.
Comme en Flandre, les études de dépistage menées partout au monde dans les groupes 
à haut risque et dans les nouveau-nés ont montrés que la majorité des patients ont une 
altération génétique dans le gène de GLA qui, ou bien est encore inconnue, ou est corrélée 
à un phénotype atténué. En manque de connaissance, la prise en charge de ces patients est 
très difficile. En raison de ce manque de connaissance, le dépistage de mutations GLA des 
nouveau-nés est dans notre opinion inapproprié. En revanche, le dépistage des groupes à 
haut risque semble être un outil indispensable pour le diagnostic. Dans ce contexte, nous 
envisageons une étude de dépistage dans une population jusqu›à présent inexplorée, à 
savoir les patients ayant un stimulateur cardiaque ou un défibrillateur interne permanent.
Le dépistage de la forme classique de la maladie de Fabry chez les garçons symptoma-
tiques nous semble intéressant. Pour cela, nous avons développé une stratégie, impliquant 
un questionnaire sur les symptômes classiques de la maladie de Fabry (par exemple acropa-
resthesies, hypohydrosis, intolérance à la chaleur, symptômes abdominaux). Si ce question-
naire est marqué comme «positif», le diagnostic est confirmé par la mesure de l›activité de 
l›alfa-Galactosidase A et l›analyse mutationnelle. Cette approche a l›avantage de se rendre 
aux garçons symptomatiques, où le traitement est évident. Deuxièmement, l›approche dia-
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gnostique avec un questionnaire est très peu couteuse. Toutefois, ce questionnaire devrait 
être étudié pour sa sensibilité, spécificité et validité.
La plupart des maladies rares sont progressifs et dangereux. Leur prévalence est très 
faible, et il faut non seulement une approche spécifique pour le diagnostic, mais aussi une 
attention particulière en ce qui concerne leur traitement. La conception de lignes direc-
trices pour néphrologues était pour nous un objectif logique et importante. Une revue sys-
tématique de la littérature et la consultation avec des experts européens de Fabry a donné 
lieu à des lignes directrices pour le diagnostic et le traitement de la maladie de Fabry chez 
les patients atteints de néphropathie chronique. Il sera publié dans le cadre de la «European 
Renal Best Practice (ERBP) Guidelines», un organe de l› «European Renal Association». Nous 
recommandons le dépistage de la maladie de Fabry chez les hommes atteints de maladie 
rénale chronique sans étiologie claire sous l›âge de 50 ans. Nous ne recommandons pas 
le dépistage chez les mâles plus âgés puisque nous nous concentrons sur les formes clas-
siques de la maladie de Fabry. Chez les femmes, nous ne retenons aucune limite d›âge, 
étant donné le fait que le phénotype chez les femmes peut être extrêmement variable, et 
une mutation associée à un phénotype classique peut s›exprimer dans la vieillesse. Chez 
les hommes, la mesure de l›activité de l›alfa-Galactosidase A est à privilégier, compte tenu 
que ce test est très sensible et peu coûteux. Chez les femmes, l›analyse de mutation GLA est 
nécessaire. Nous concluons qu’il existe peu de preuves pour l’enzymothérapie substitutive 
pour des raisons néphrologiques, et si le traitement est commencé, il faut le faire avant qu’il 
y ait une protéinurie importante et avant que la clairance de la créatinine soit inférieure à 
60 mL/min/1.73 m2. Toutes les données sur l›enzymothérapie substitutive devraient être 
collectionnées dans un endroit central, peut-être européen, enfin d›apporter des preuves 
scientifiques pour ce traitement cher.
Nous concluons que la prévalence des formes classiques et atténués de la maladie de Fabry est sous-estimée et une approche spécifique pour le diagnostic, y com-pris par le dépistage dans les populations à haut risque, est nécessaire. Les formes 
atténuées cependant, ont un phénotype très variable et il n›y a pas une simple corrélation 
génotype / phénotype. Ceci s›applique en particulier à la mutation GLA p.Ala143Thr qui est 
très répandue en Flandre. Ceci a des implications importantes pour la prise en charge de 
ces patients. Etant donné que la preuve pour un effet bénéfique généralisable de l’enzy-
mothérapie substitutive (qui est très chère) est insuffisante, la recherche restera de grande 
importance. 

Curriculum Vitae
Wim Terryn
Regionaal Hospital Jan Yperman, Ypres, Belgium 
department of nephrology, general internal medicine and infectiology
+3257/ 357181 (phone) +3257468338 (fax)
wim.terryn@iCloud.com
Education
1973-1985  Latin-Sciences, Klein Seminarie, Roeselare, Belgium.
1985-1990  Master in Psychological Sciences, Ghent University, Belgium.
  Great distinction.
1990-1997 Medical Doctor, Ghent University, Belgium. Great distinction. 
1999  Certificate for Acute Medicine. 
2002  Board certificate of Internal Medicine
2003  Board certificate of Nephrology
2003-2004 department of Nephrology, Ghent University Hospital, Belgium
  (Adjunct-Kliniekhoofd)
2004-present - Regional Hospital Ypres, Ieper, Belgium 
     departmen t of Nephrology, General Internal Medicine and Infectiology
     president of the Antibiotic Committee    
     director of the Travel Clinic (WHO certificate for Yellow Fever Vaccination)
  - Ghent University Hospital
     consultant at the department of Sonography
2010- present PhD training program of Doctoral School of Life Sciences and Medicine,   
  Ghent University, Belgium. 
  PhD thesis:  “Screening for Fabry disease: indications, methods and implications.” 
2011  NIH Clinical Research Training course, GCP exam. 
Curriculum Vitae
150
Affiliations
Member of BTS (Belgian Transplantation Society)
Member of ESOT (European Society of Organ Transplantation)
Current projects
Interventional clinical study
Individually Adapted Immunosuppression in de Novo Renal Transplantation Based on Immune 
Function Monitoring: a Prospective Randomized Study (CD4-01) NCT00895206. 
Department of Internal Medicine, division of Nephrology (Prof. dr. Raymond Vanholder)
Clinical working project
 “The rare disease project”,  
Department of General Internal medicine, Infectiology and Psychosomatic Diseases 
(prof. dr. Bruce Poppe, prof. dr. Dirk Vogelaers), Ghent University Hospital
Clinical research project
“Study to verify the frequency of Fabry disease in pacemaker patients, 
a new and unique population.”
Publications
Terryn W, Van Caesbroeck D, “Magnesium and Phosphorus”, Lancet, 352, (9138), 31 October 1998, 1475-1475 
(Letter to the editor). 
Terryn W, Van Caesbroeck D, “Refeeding syndrome met hypofosfatemie en hemolytische anemie”, Tijdschrift 
voor Geneeskunde, 56, nr 13, 2000.
Randon C, Deroose J, Vermassen F, Terryn W, Peeters P, Giri M. “Pancreastransplantatie: state of the art”, Tijd-
schrift voor Geneeskunde, 63, nr 6, 2007.
De Schoenmakere G, Poppe B, Wuyts B, Claes K, Cassiman D, Maes B, Verbeelen D,Vanholder R, Kuypers DR, 
Lameire N, De Paepe A, Terryn W. Two-tier approach for the detection of alpha-galactosidase A deficiency 
in kidney transplant recipients. Nephrol Dial Transplant. 2008 Dec;23(12):4044-8. Epub 2008 Jul 2.
Terryn W, Poppe B, Wuyts B, Claes K, Maes B, Verbeelen D, Vanholder R, De Boeck K, Lameire N, De Paepe A, De 
Schoenmakere G. Two-tier approach for the detection of alpha-galactosidase A deficiency in a predomi-
nantly female haemodialysis population. Nephrol Dial Transplant. 2008 Jan;23(1):294-300. Epub 2007 Sep 5.
Terryn W, Benoit D, Van Loo A, Peeters P, Schepkens H, Cokelaere K, Vanholder R. Goodpasture’s syndrome asso-
ciated with autoimmune thrombotic thrombocytopenic purpura an unusual case. Nephrol Dial Transplant. 
2007 Dec;22(12):3672-3. Epub 2007 Jul 19. 
De Schoenmakere G, De Waele J, Terryn W, Deweweire M, Verstraete A, Hoste E, Rottey S, Lameire N, Colardyn F. 
Phenytoin intoxication in critically ill patients. Am J Kidney Dis. 2005 Jan;45(1):189-92.
Curriculum Vitae
151
Peeters P, Terryn W, Vanholder R, Lameire N. Delayed graft function in renal transplantation. Curr Opin Crit Care. 
2004 Dec;10(6):489-98. Review.
Vanbelleghem H, Terryn W, Van Leuven L, Van Caesbroeck D, Demetter P, Lameire N. A dramatic case of calci-
phylaxis 20 years after kidney transplantation. Nephrol Dial Transplant. 2004 Dec;19(12):3183-5. 
Terryn W, Deschoenmakere G, De Keyser J, Meersseman W, Van Biesen W, Wuyts B, Hemelsoet D, Pascale H, De 
Backer J, De Paepe A, Poppe B, Vanholder R. Prevalence of Fabry disease in a predominantly hypertensive 
population with left ventricular hypertrophy. Int J Cardiol. 2012 Jul 15. [Epub ahead of print] 
Terryn W, Vanholder R, Hemelsoet D, et al. Questioning the Pathogenic Role of the GLA p.Ala143Thr “Mutation” 
in Fabry Disease: Implications for Screening Studies and ERT. JIMD Reports. Volume 8, 2013, pp 101-108.
Terryn W, Cochat P, Froissart R, Ortiz A, Pirson Y, Poppe B, Serra A, Van Biesen W, Vanholder R, Wanner C. Fabry 
nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal 
Best Practice. Nephrol Dial Transplant. 2012 Dec 12. [Epub ahead of print] 
Laute M, Vanholder R, Voet D, Peeters P, Cokelaere K, Deloose S, Terryn W. Safety and sample adequacy of renal 
transplant surveillance biopsies. Acta Clinica Belgica (accepted)
Presentations at international conferences
19/11/2004:  2nd Benelux symposium on lysosomal storage diseases, Waalwijk, Nederland.
  Session; “Improving early diagnosis of LSD patients”, 
  Chairman: Dr. B.J.H.M. Poorthuis, LUMC Leiden.
  Presentation; “Screening of clinical groups.” dr. W. Terryn 
11/5/2012:  Faby Masterclass IV: “Fabry disease: past, present and future”, Berlin, Germany.
  Presentation; “Renal Outcomes”, dr. W. Terryn
Courses
1998  Dialysis Academy (prof Ritz, prof Drüeke, prof Lameire) ,Ghent, Belgium
2000  Dialysis Academy, Heidelberg, Germany
2002  PD (Peritoneal Dialysis) Academy (prof. dr.  Krediet), Amsterdam, The Netherlands
2002  Hesperis-ESOT (European Society of Transplantation) course for transplantation, 
  Cambridge, England
2003  Hesperis-ESOT course for transplantation, Paris, France.
2008 - 2009 Advanced nephrology course, part 1 + 2, the renal association, London, UK.
2009 - 2010 Instituut voor permanente vorming in de Wetenschappen IPVW: 
  cursus statistiek “Basics of Statistical Inference” en “Analysis of Variance”, 
  Ghent University, Belgium. 

Woorden van dank
De tijd dat wetenschap een eenzame en soms wereldvreemde bezigheid was, ligt 
gelukkig ver achter ons. Nieuwe ontwikkelingen en kennis ontstaan via uitwisseling 
en samenwerking. Ook voorliggend werk is een werk van vele mensen. Ik heb de 
kans gekregen om dit werk uit te bouwen dankzij vele ontmoetingen met mijn pro-
motoren, met collega’s en met mensen uit mijn directe omgeving. Mijn dank gaat 
naar elk van hen.
Bedankt prof. Raymond Vanholder , mijn promotor, voor de kritische evaluatie en 
de snelle antwoorden op mijn talrijke mails. De tactvolle en scherpzinnige opmer-
kingen hebben mij veel geleerd, ze hebben deze thesis mee vorm gegeven. 
Twee bijzondere vrienden stonden mee aan de wieg van dit doctoraat: dr. Gert 
Deschoenmakere en prof. Bruce Poppe hebben me van in het begin enthousiast ge-
steund. Gert hielp de screeningsstudies op gang, en toonde mij de weg om de op-
portuniteiten te grijpen. Het is bovendien een grote eer dat mijn vriend Bruce, naar 
wie ik heel erg opkijk, mijn co-promotor wilde zijn.
 Prof. Van Biesen kreeg in een handomdraai een team Europese Fabry-experten 
rond de tafel om te discussiëren. Boeiend en heel leerrijk.
In het concrete onderzoek waren vele mede-onderzoekers en ondersteunende 
collega’s betrokken. In het bijzonder denk ik hierbij aan dr. Dimitri Hemelsoet en dr. 
Birgitte Wuyts, maar ik mag prof. Kathleen Claes, dr. Maria Alvarez, dr. Katrien Van 
Elk, Filip Labeeuw, Katrien Van Geyt en ook de vele artsen die de moeite deden om 
patiënten te includeren voor de screeningsstudies niet vergeten.
In veel klinisch onderzoek is de inzet van de farmaceutische economie onontbeer-
lijk. Dit onderzoek is mee mogelijk gemaakt door de firma’s Genzyme en Shire. De 
vriendelijkheid, het enthousiasme en de ethische houding van hun medewerkers 
hebben mij gesteund in dit werk.
De positieve belangstelling en steun van de collega’s van het Jan Yperman Zie-
kenhuis en het UZ Gent hebben mij gesterkt in dit onderzoek. 
Wetenschap heeft ook te maken met het dagelijks leven. Enkele mensen uit mijn 
dagelijkse omgeving hebben mee gebouwd, gesteund, gelouterd soms ook. Mijn fa-
milie, in het bijzonder Annik en Luc, heeft me veel geleerd over studeren op zich, over 
na-denken en stilstaan, over het hoe en het waarom misschien, maar vooral over 
het leven zelf. Achter al mijn projecten en gedrevenheid schuilt één grote kracht die 
ik krijg van mijn vader, een tachtiger met een jong hart.
Ten slotte dank ik mijn vrouw Mieke en onze fantastische dochters Lou, Aglaja 
en Rilke voor hun warme liefde, hun dagelijkse steun en hun volgehouden geduld. 
Zonder hen zou dit werk nooit geschreven zijn.
Bedankt!
Wim Terryn
Beselare, maart 2013
